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ABSTRACT 
LUONG TIEN NGUYEN: Long Wavelength Fluorescent Reporters for Protein Kinases and 
Design of Light-Activatable Bioagents 
(Under the direction of David S. Lawrence) 
The first part of this dissertation describes the development of wavelength-tunable 
fluorescent reporters for monitoring protein kinase activity. The probing wavelength is 
preprogrammed by using a variety fluorophores which are commercially available. 
Specifically, we develop fluorescent sensors sensing in the far-red and near-IR region and 
use them to monitor endogenous cAMP-dependent protein kinase activity in erythrocyte 
lysates and in erythrocytes. Stabilization of the peptide sensor in erythrocyte lysate is also 
reported. The study provides powerful tools to investigate the roles of protein kinase A 
activity in erythrocyte biochemistry, for example, in Plasmodium Falciparum infection and 
propagation. 
In the second part of the dissertation, we describe the design of light-activatable 
bioagents based on lipidation and membrane sequestration. A lipidated bioagent upon 
binding to cells/organelles’ membrane is biologically inert. A photolabile group placed 
between the lipid and bioagent furnishes a means to release the bioagent from the 
membrane and activate it. The strategy provides a way to fine-tune the presence of an 
“active” bioagent using light. For example, a peptide sensor can be introduced into a 
biological system and remains “silent” until controllably activated with light; a protein can 
be activated or inhibited by the light-triggered release of the corresponding active 
activator or inhibitor that is hidden in the membrane. 
 iv
Additionally, the use of erythrocytes as carriers and protectors of photoactivatable 
peptide therapeutics is also discussed. The study is aim to develop a way to controllably 
deliver active therapeutics to a specific region of the body to increase their potency and 
reduce their toxicity.  
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CHAPTER 1: BACKGROUND AND SIGNIFICANCE 
Fluorescence Techniques and the Optical Windows of Tissue 
Fluorescence Techniques 
Since first reported by Sir John Herschel in 1845 and named by Sir George Stockes 
in 1852, fluorescence has now become a powerful tool in biomedical research.1, 2 The 
techniques provide excellent sensitivity as well as a continuous and nondestructive 
detection with a high degree of spatial and temporal resolution when applied in living 
systems.  
 Small fluorescent molecules (fluorophores) and fluorescent proteins are two 
major classes of fluorescent molecules that are commonly used. For small molecule 
fluorophores, scientists have not only relied on naturally-occurring substances, but also 
developed a huge collection of fluorescent molecules derived from variety of structural 
scaffolds, i.g., coumarin, xanthene, cyanine, oxazine, and so on.3 The excitation and 
emission wavelengths of those fluorophores now cover from 300 nm - 800 nm (Figure 
1.1).4 The discovery of a fluorescent protein in 1962 together with genetic manipulating 
technologies has brought fluorescence to a new level of applicability when the fluorescent 
probes can be generated continuously in situ.5-11 In term of excitation and emission 
wavelength, a number of fluorescent proteins have been reported working at various 
excitation and emission wavelengths, however the selection is somehow limited 
compared to that of small molecule fluorophores due to the strict folding requirement of 
fluorescent proteins.6, 7 
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Based on those fluorescent molecules, scientists have developed numerous 
applications including in, but not limited to, cell and organelle staining, molecular dynamic 
and function sensing, gene expression reporting, enzymatic activity measurements, 
disease markers, tumor surgery, etc.3, 11-17  
Optical Windows of Tissue 
  When a fluorescent technique is used, selection of wavelengths which can provide 
clear images is one of the most important parameters. Signal attenuation and auto-
fluorescence are two major causes of poor images. Typically in tissue imaging, excitation 
photons need to travel through tissue and reach the target fluorescent contrast agent and 
emission photons need to travel the same pathway to reach a detector. During this 
propagation, photons can be absorbed or scattered by tissue’s components. Light 
absorption can be due to selected biomolecules in tissue, such as collagen, elastin, lipids, 
hemoglobin, while scattering can come from cells or intracellular matrix.18, 19 This 
interference is also applied to in vitro assay when strong absorption of assay components 
can eliminate the signal. In addition to tissue scattering and absorption, autofluorescence 
can also severely affect the signal. For example, Frangioni took fluorescent images of a 
sacrificed mouse using three different excitation/emission filter sets: blue/green (λex/λem: 
460 - 500 nm/505 - 560 nm); green/red (525 - 555 nm/590 - 650 nm); and near-infrared 
(NIR) (725 - 775 nm/790 - 830 nm). In the images taken in blue/green and green/red 
regions, significant background from tissue autofluorescense was observed suggesting 
the potential challenge if using fluorescent contrast agents working in those regions. 
However, in the  near IR image, autofluorescence was essentially eliminated.20 This 
observation together with other data suggests an optical window of tissue (600-1000 nm), 
in which the fluorescence signals are least interfered (Figure 1.2).18, 21, 22  
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Protein Kinase and Protein Kinase Activity Probes 
Protein Kinases 
  Protein kinases are enzymes that catalyze the transfer of the γ-phosphoryl group 
from ATP to specific sites in proteins in a process called phosphorylation. In eukaryotes, 
these sites are usually the free hydroxyl groups of serine, threonine, and tyrosine residues 
in proteins. It has been estimated that about 500 genes in human genome encode for 
protein kinases and up to 30% of all cellular proteins contain a phosphate group. Protein 
kinases are involved in every basic cellular process, including metabolism, growth, 
division, differentiation, motility, cellular transport. Numerous studies suggest the roles 
of protein kinases in many human diseases such as cancer, inflammatory diseases, 
neurological disorders, etc.23-26. Protein kinases are currently a major drug target.  
 
Figure 1.2:  Absorbance of various tissue and blood components from 200 nm to 10 µm. 
Reprinted with permission from Pansare, V.; Hejazi, S.; Faenza, W.; 
Prud'homme, R. K., Review of Long-Wavelength Optical and NIR Imaging 
Materials: Contrast Agents, Fluorophores and Multifunctional Nano Carriers.
Chem Mater 2012, 24 (5), 812-827. © 2012 American Chemical Society. 
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  Given the important role of protein kinases in human diseases, it is crucial to be 
able to monitor the activity of a kinase of interest.  To date, a number of protein kinase 
sensors have been developed. The majority of them are fluorescent sensors and can be 
categorized into two major classes: genetically encoded protein based sensors and small 
molecule peptide-based sensors.27 
Protein-Based Kinase Probes 
  The majority of the protein-based kinase probes function through phosphorylation 
induced conformational change leading to Fluorescence Resonance Energy Transfer 
(FRET). Basically, the probes contain a donor fluorescent domain, an acceptor fluorescent 
domain, and a domain of which conformation is phosphorylation sensitive. The 
donor/acceptor pair are selected so that the emission spectrum of the donor domain 
sufficiently overlaps with the excitation spectrum of the acceptor. When phosphorylation 
occurs, the relative orientation between the two are altered, which leads to the change 
in the excitation-emission profile of the pair (Figure 1.3).28 This type of sensors have been 
developed for variety of kinases, such as PKA, Akt, RSK, S6K, ERK, JNK, EGFR/Abl, to name 
a few .27, 29 
  The protein-based probes have both advantages and disadvantages. An advantage 
is that the protein probes can be synthesized continuously in situ thus can be customized 
to provide spatiotemporal information regarding signaling in living cells. Additionally, they 
are usually reversible probes, and thus can provide information about the dynamic 
interplays between the activity of kinases and phosphatases. On the other hand, however, 
the protein probes have limitations in term of signal gain and the flexibility of wavelength 
used. Even after significant effort of optimization, the FRET-based sensors typically only 
give from 10 - 60% and rarely get to 100% signal gain.27, 29 Additionally, the fluorescence 
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bleed-through and limited options of FRET fluorescent protein pairs also lead to 
difficulties when designing and using FRET-based kinase sensors. 
 
Figure 1.3: General design of FRET-based protein kinase sensors. Once phosphorylated by 
a kinase of interest, the phosphopeptide binding domain forms an intramolecular complex 
with the phosphopeptide, giving rise to a distance change between the two flanking 
fluorescent proteins that alters the FRET. 
Reprinted with permission from Ting, A. Y.; Kain, K. H.; Klemke, R. L.; Tsien, R. Y., 
Genetically encoded fluorescent reporters of protein tyrosine kinase activities in 
living cells. Proc Natl Acad Sci U S A 2001, 98 (26), 15003-8. Copyright (2001) 
National Academy of Sciences, U.S.A. 
Peptide-Based Kinase Probes 
  In the last two decades, there has been significant progress in developing 
fluorescent probes for sensing kinase activity based on short peptides. Basically, this type 
of probe contains a fluorophore appended to a short peptide sequence which, upon 
phosphorylation by a kinase of interest, leads to a fluorescence change by different 
mechanisms. These probes can be categorized into groups based on working mechanism: 
chelation induced fluorescent increase, environment sensitive fluorescence, 
phosphorylation disrupting quenching mechanism, or capillary electrophoresis coupled 
with laser induced fluorescence detection. 
 7
 Lawrence and colleagues were the first created a peptide sensor for protein 
kinases based on chelation induced fluorescence increase. Specifically, the probe contains 
a peptide substrate for PKC to which is appended a fluorophore bearing two carboxylate 
groups. Phosphorylation of the peptide substrate generates a M2+ binding site which 
consists of the newly introduced phosphate group and the two carboxylate moieties from 
the fluorophore. The fluorescence signal is gained from phosphorylation followed by 
divalent cation coordination (Figure 1.4).30 
  An analogous approach was exploited by Imperiali and co-workers to develop 
kinase sensors based on the chelation of 8-hydroxy-5-(N,N-dimethylsulfonamido)-2-
methylquinoline (Sox) moiety and phosphate group to Mg2+ (Figure 1.5).31 The probes 
comprise a Sox moiety appended to an optimized peptide substrate for the target kinase. 
Upon phosphorylation and in the presence of Mg2+, the Sox and phosphate groups 
coordinate the divalent magnesium ions leading to fluorescence enhancement. 
Employing this strategy, Imperiali and colleagues have developed sensors targeting a 
number of kinases such as Akt, Abl, ERK1/2, PKA, PKC, p38α, Pim, etc.32, 33 
  Using environmentally sensitive fluorophores is another strategy for making 
peptide-based kinase sensors. For example, Lawrence and co-workers designed a PKC 
probe in which an environmentally sensitive fluorophore is placed on a peptide substrate 
close to the phosphorylation site. Phosphorylation of the peptide changes the 
environment around the fluorophore leading to the fluorescence change (Figure 1.6).34 
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Figure 1.4: Structure of a PKC fluorescent sensor based on chelation induced fluorescence 
change. 
Reprinted with permission from Chen, C. A.; Yeh, R. H.; Lawrence, D. S., Design and 
synthesis of a fluorescent reporter of protein kinase activity. J Am Chem Soc 2002, 
124 (15), 3840-1. Copyright (2002) American Chemical Society. 
 
 
   
Figure 1.5: General design of Sox kinase sensors developed by Imperiali and coworkers. 
Reprinted with permission from Stains, C. I.; Lukovic, E.; Imperiali, B., A p38α-
Selective Chemosensor for use in Unfractionated Cell Lysates. ACS Chem Biol 2010, 
6 (1), 101-105. Copyright (2010) American Chemical Society. 
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Figure 1.6: PKC fluorescent sensor developed by Lawrence and coworkers. Phosphorylation 
of the serine residue which is in proximity of an environmentally sensitive fluorophore 
results in a fluorescence signal. 
Figure adapted from Yeh, R. H.; Yan, X.; Cammer, M.; Bresnick, A. R.; Lawrence, D. 
S., Real time visualization of protein kinase activity in living cells. J Biol Chem 2002, 
277 (13), 11527-32. Copyright the American Society for Biochemistry and 
Molecular Biology. 
  The strategy of using environmentally sensitive fluorophores was further 
developed by Lawrence and co-workers using a phosphopeptide binding domain. The Src 
peptide substrate tagged with an environmentally sensitive fluorophore, following 
phosphorylation, binds to the phosphopeptide binding protein (Lck SH2 domain). The 
change in the environment due to binding event leads to fluorescence signal (Figure 1.7).35   
 
Figure 1.7: An alternative design of kinase fluorescent sensor based on an environmentally 
sensitive fluorophore. Phosphorylation followed by protein binding leads to a fluorescence 
response.   
Reprinted with permission from Wang, Q.; Lawrence, D. S., Phosphorylation-
driven protein-protein interactions: a protein kinase sensing system. J Am Chem 
Soc 2005, 127 (21), 7684-5. Copyright (2005) American Chemical Society. 
  Another type of peptide kinase sensor was developed based on phosphorylation 
induced fluorescence dequenching mechanism. Lawrence et al. designed a Src kinase 
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peptide sensor in which a pyrene is attached to the peptide near the phosphorylated 
tyrosine residue. While the fluorescence of the flurophore is quenched by the tyrosine 
residue, phosphorylation of the residue disrupts the interaction leading to a fluorescence 
increase (Figure 1.8).36, 37 The strategy has been applied to develop tyrosine kinases sensor 
working at long wavelengths for multicolor monitoring experiments.38  
 
Figure 1.8: Tyrosine kinase fluorescent sensor based on a phosphorylation induced 
fluorescence dequenching mechanism developed by Lawrence and coworkers. 
Reprinted with permission from Wang, Q.; Cahill, S. M.; Blumenstein, M.; 
Lawrence, D. S., Self-Reporting Fluorescent Substrates of Protein Tyrosine Kinases. 
J Am Chem Soc 2006, 128 (6), 1808-1809. Copyright (2006) American Chemical 
Society. 
  Alternatively, Sharma and Lawrence reported an elegant design named “Deep 
Quench” technique which provides an excellent fluorescence response upon 
phosphorylation (up to 65 fold fluorescence increase). Basically, the sensor system 
contains a fluorescently labelled peptide substrate and a quencher which can interact and 
quench the peptide fluorescence. Upon phosphorylation, in the presence of a 
phosphoserine recognition domain, the binding of phosphopeptide to the receptor 
disrupts quencher-peptide interaction, thus leading to fluorescence increase (Figure 
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1.9).39 Lawrence and colleagues demonstrated the applicability of  the technique to 
measure the activity of PKA in different mitochondrial sub-compartments.40  
 
Figure 1.9: General design of “Deep Quench” kinase sensor developed by Lawrence and 
colleagues.  
Reprinted with permission from Sharma, V.; Agnes, R. S.; Lawrence, D. S., Deep 
Quench: An Expanded Dynamic Range for Protein Kinase Sensors. J Am Chem Soc 
2007, 129 (10), 2742-2743. Copyright (2007) American Chemical Society. 
  Another kinase activity measurement system based on fluorescent peptides was 
pioneered by Allbritton and coworkers employing capillary electrophoresis with laser 
induced fluorescence detection (CE-LIF). A fluorescently labelled peptide substrate of a 
kinase of interest is introduced into cell lysates or living cells. At various time points, 
aliquots/cells are analyzed by CE-LIF in which the nonphosphorylated peptide and the 
phosphorylated product are separated and quantified. Using this technique, numerous 
peptide-based sensors have been developed, for example for PKA, PKB, PKC, CamKII, 
cdc2K, Src and EGFR.41-44 
  Even though rapidly developed in the last two decades and provides excellent 
fluorescence response upon phosphorylation, peptide-based kinase sensors possess two 
major challenges: cellular delivery and stability inside living cells. Technologies dealing 
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with these two issues are important for further development of the peptide-based 
sensors. 
Spatiotemporal Control and the Creation of Light-Activatable Bioagents 
  In studying of complex biological processes and medical applications, controlling 
the presence as well as the amount of an active species in a spatiotemporal manner is 
crucial. For example, the function of a specific protein in a biological context can be 
revealed by keeping it in an inactive state for a necessary amount of time then quickly 
activating it followed by phenotypic observation. Another example is measuring the 
activity of an enzyme of which the catalytic process is fast. A sensor used to report the 
activity when introduced into the system would be completely processed before the 
system gets equilibrated. It would be beneficial if the sensor is delivered into the system 
in an inert state and quickly converted to active state followed by necessary detection 
when the system is ready. Another circumstance is in medical applications when a drug is 
absolutely beneficial if it is active at only one or a few specific locations rather than the 
whole body. Hence, it is desired to have a “drug” that can circulate in the body in an inert 
form and can be activate at the specific locations in a controlled manner. 
  For that purpose, researchers have been developing photoactivatable agents for 
many years. Based on the characteristic of the activation, those agents can be categorized 
into either reversible or irreversible light-activatable agents. Reversible agents all contain 
groups which can absorbed light and undergo a reversible conformational change while 
irreversible agents typically have one or a few photocleavable groups. Examples of 
reversible light-activatable agents include azobenzene or analogous compounds45-48 and 
genetically encoded light-activatable proteins which have been developed and optimized 
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recently.49 Those reversible agents have found great applications in cellular molecular 
biology.49, 50 
  In contrast to the former group in which the activated agent can turn itself off after 
activation, the irreversible light-activatable agents furnish a way to permanently release 
an active species. These agents usually contain one or a few photocleavable groups.51 
Typically, an essential functional group/groups on the bioagent of interest is/are 
identified and chemically modified with photoremovable group(s). This modification, 
therefore, renders the bioagent functionally inactive. The inactive bioagent is then 
introduced into the biological system and converted from inactive to active form upon 
exposure to light. In some circumstances, however, the photoactivatable bioagents can 
be considered as generated in an indirect manner through photocleavage-induced 
molecular interaction disruption. In those cases, a molecule that contains a photolabile 
group can interact intra- or inter-molecularly and “inhibit” a bioactive molecule. 
Photolysis triggers cleavage of that photolabile group, and thus disrupts the interactions 
which results in the release of the active biomolecule (Figure 1.16). 
  Using both direct and indirect approaches, various photoactivatable bioagents, 
ranging from ions and small molecules to macromolecules such as proteins and 
nucleotides, have been developed.50, 52, 53 The following lists just a few of them. 
  Kaplan, Forbush, and Hoffman were among the first to report the development of 
light activatable ATP utilizing a photocleavable 2-nitrobenzyl moiety and demonstrated 
the ability to activate Na/K-ATPase in ATP-depleted erythrocyte ghosts using light (Figure 
1.10a).54 Hess and colleagues reported the synthesis of light-activatable acetylcholine 
analog (Figure 1.10c)55, glutamate (Figure 1.10b).56 Koh and colleagues synthesized 
photoactivatable estradiol and controlled gene expression with light using this estrogen 
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analog (Figure 1.11a).57 Lawrence and coworkers utilizes a similar approach to gain control 
over gene expression using photoactivatable β-ecdysone (Figure 1.11b).58 
 
 
  Kaplan and Tsien groups at the same time reported the creation of calcium ion 
releaser upon exposed to light (Figure 1.12).59, 60. Ellis-Davies and Kaplan reported a 
construct that selectively binds to calcium with high affinity (80 nM) in the dark. Upon 
 
Figure 1.10: Structures of light-activatable ATP (a), glutamate (b), acetylcholine analog (c), 
and serotonin (d). 
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exposure to UV-irradiation (~350 nm), this binding is eliminated, leading to the release of 
calcium (Figure 1.13).61  
 
Figure 1.12: Light-mediated calcium release designed by Tsien et al. 
Adapted with permission from Adams, S. R.; Kao, J. P. Y.; Grynkiewicz, G.; Minta, 
A.; Tsien, R. Y., Biologically useful chelators that release Ca2+ upon illumination. J 
Am Chem Soc 1988, 110 (10), 3212-3220. Copyright (1988) American Chemical 
Society. 
 
Figure 1.13: Light-mediated calcium release designed by Ellis-Davies and Kaplan. 
Reprinted from Ellis-Davies, G. C.; Kaplan, J. H., Nitrophenyl-EGTA, a photolabile 
chelator that selectively binds Ca2+ with high affinity and releases it rapidly upon 
photolysis. Proc Natl Acad Sci U S A 1994, 91 (1), 187-191. 
  For macromolecules, a variety of photoactivatable peptides, proteins, RNAs, and 
DNA, have been synthesized and used in biology.27, 50, 53, 62. Fay and coworkers reported 
photoactivatable peptide inhibitors of calmodulin and myosin light chain kinase (MLCK).63 
Imperiali and colleagues synthesized a phosphorylated peptide bearing a photolabile 
group on the phosphate moiety (Figure 1.14) and used the peptide to study the global 
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function of phosphopeptide binding protein in cell cycle. The peptide with a photolabile 
group on the phosphate moiety binds poorly to a 14-3-3 protein (Kd ~ 900 µM). Upon the 
removal of the photolabile group with UV light, the peptide tightly binds to the 14-3-3 
protein (Kd of 25 nM), thus depletes the 14-3-3 from binding to endogenous proteins. 
With this technique, Imperiali, Yaffe, and coworkers demonstrated the role of 14-3-3 
binding in various phases of cell cycle and the consequence, e.g., premature cell cycle 
entry, release of G1 cells from interphase arrest, and cells death, when such binding is 
compromised.64 
 
Figure 1.14: Structure of light-activatable phosphopeptide designed by Imperiali and 
coworkers. 
Adapted by permission from Macmillan Publishers Ltd: [Nature Biotechnology], 
Nguyen, A.; Rothman, D. M.; Stehn, J.; Imperiali, B.; Yaffe, M. B., Caged 
phosphopeptides reveal a temporal role for 14-3-3 in G1 arrest and S-phase 
checkpoint function. Nat Biotechnol 2004, 22 (8), 993-1000. Copyright 2004. 
  Lawrence and coworkers applied the light-activatable strategy to kinase peptide 
reporters and demonstrated the applicability of the sensor in studying cellular 
biochemistry (Figure 1.15).65, 66 Additionally, Lawrence et al. reported the design of a light-
deativatable peptide inhibitor to activate  Src protein tyrosine kinase.67 A divalent peptide 
inhibitor was designed to bind to both SH1 and SH2 domains of Src and inhibits the 
enzyme (Figure 1.16). A photolabile moiety was placed in between the two binding motifs 
so that photolysis cuts the peptide in half and restores the kinase activity. 
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Figure 1.16: Design of photocleavable peptide inhibitor to control Src kinase activity
reported by Lawrence and coworkers. 
Li, H.; Hah, J. M.; Lawrence, D. S., Light-mediated liberation of enzymatic 
activity: "small molecule" caged protein equivalents. J Am Chem Soc 2008, 130
(32), 10474-5. Copyright (2008) American Chemical Society. 
 
Figure 1.15: Structure of light-activatable PKC fluorescent sensor reported by Lawrence
et al. 
Adapted with permission from Veldhuyzen, W. F.; Nguyen, Q.; McMaster, G.; 
Lawrence, D. S., A light-activated probe of intracellular protein kinase activity. J 
Am Chem Soc 2003, 125 (44), 13358-9. Copyright (2003) American Chemical 
Society. 
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  For protein, Bayley and coworkers reported the synthesis of light-activatable 
version of c-AMP-dependent protein kinase’s catalytic subunit by chemically targeted   
 modification.68, 69 In the similar strategy and around the same time, Ghosh and coworkers 
reported the construct of a light-activatable cofilin analog and used it to demonstrate 
cofilin’s function in cell migration.70, 71 Imperiali and colleagues reported the synthesis of 
photoactivatable myosin by chemical synthesis and protein ligation and tried to use the 
construct to study the function of myosin inside living cells.72 Lawrence and colleagues 
reported an elegant design of photoactivatable profluorescent PKA which is inactive and 
nonfluorescent before photolysis. Illumination not only activates the enzyme but also 
renders it fluorescent, and thus provides a means to monitor the activation using the 
fluorescence readout.73 In addition to chemically targeted modification, a number of light-
activatable proteins (caspase-3,74, 75 endonuclease,76 β-galactosidase,77 MAP kinase 
kinase (MEK1)78) were synthesized employing technology pioneered by Schultz and 
coworkers, which allows the genetic insertion of unnatural amino acids into protein. For 
polynucleotides, for example, Monroe and colleagues chemically synthesized 
photoactivatable DNAs and demonstrated the ability to induce expression of luciferase 
and GFP in rat skin and HeLa cells, respectively.79 Ando and coworkers synthesized a light-
activatable version of mRNAs of GFP and β-galactosidase and demonstrated the ability to 
drive the expression of the corresponding proteins in zebrafish embryos. The group then 
further synthesized a light-activatable mRNA version of the transcription factor 
Engrailed2a, injected it into the embryos and showed the ability to locally activate, 
express Enggrailed2a, and observe subsequent effects (Figure 1.17).80 
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Figure 1.17: General design, synthesis, and photoactivation of RNA reported by Ando and 
coworkers. 
Reprint with permission from Ando, H.; Furuta, T.; Tsien, R. Y.; Okamoto, H., 
Photo-mediated gene activation using caged RNA/DNA in zebrafish embryos. 
Nat Genet 2001, 28 (4), 317-325. 
  Even though various types of light-activatable biomolecules have been 
synthesized and used in numerous biological studies, the applicability of current strategies 
poses challenges. For example, when interactions between two or more biomolecules 
(i.e., nucleic acid-nucleic acid, protein-protein, nucleic acid-protein interactions) are the 
targets of light-activation designs. There is usually no defined functional group that is 
absolutely essential for the binding. One strategy that has been employed is to block a 
number of functional groups with photocleavable moieties. However, this strategy either 
results in a construct with high “dark background” when few functional groups are 
modified or a construct that is photolysis-demanding when too many photolabile groups 
are incorporated as these need to be removed in order to restore the original interactions.  
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CHAPTER 2: LONG-WAVELENGTH FLUORESCENT REPORTERS FOR PROTEIN KINASES 
Fluorescent techniques have become powerful tools in biomedical research. Their 
in vivo applications, however, reveal an intrinsic limitation brought by tissue opacity. The 
presence of hemoglobin and melanin limits the use of wavelengths below 600 nm 
whereas water interferes with the use of wavelength greater than 1000 nm. The problem 
is exemplified when researchers aim to study biochemistry inside erythrocytes. These 
cells, unlike other mammalian cells, contain a high percentage of hemoglobin (about 97% 
by dry weight). The strong absorption of hemoglobin from UV to 600 nm makes it difficult 
to monitor subcellular biochemical processes in this region (Figure 2.1).  
Among numerous proteins associated with erythrocytes, we were specifically 
interested in cAMP-dependent protein kinase (PKA) since it plays a central role in 
erythrocyte behavior and the life cycle of the malarial parasite Plasmodium Falciparum. 
For example, it is of great benefit to be able to quickly profile the PKA activity in 
 
Figure 2.1: Relative wavelength absorbances of erythrocyte lysate and fluorophore-Aoc-
GRTGRRFSY-amide peptides. 
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erythrocytes during Plasmodium Falciparum infection and determine the roles of PKA-
induced phosphorylation during the infection and propagation of Plasmodium 
Falciparum. While a number of fluorescent sensors for protein kinases have been 
developed, none are compatible with the optical challenges associated with erythrocytes. 
In this chapter, we describe an approach which takes advantage of the commercial 
availability of various fluorophores to create wavelength-tunable protein kinase sensors. 
Especially, we report the development of far-red and near-IR fluorescent sensors for 
protein kinases and demonstrate the applicability of these sensors to monitor 
endogenous PKA activity in erythrocyte lysates and in erythrocytes when using a light-
activatable reporter. 
Results and Discussion 
Design and Synthesis 
Sharma et al. previously reported a strategy for creating fluorescent sensor for 
kinases based on a phosphorylation-induced dequenching mechanism. The strategy, 
however, requires the presence of a phosphopeptide binding protein, 14-3-3τ, which only 
binds tightly to phosphopeptides and sequesters them from interacting with quenchers 
(Figure 1.9).39 However, Dr. Melanie Priestman found that, despite the lack of the 
phosphopeptide binding protein, modest fluorescent increases are observed when PKA is 
added to the assay mixture containing fluorescently labeled peptide, quencher, ATP, and 
MgCl2. We hypothesized that, upon phosphorylation by PKA, the newly introduced 
negatively charged phosphate group serves as a molecular trigger that drives the release 
of the fluorescent quenchers. Therefore, we pursued a screening approach to take 
advantage of the commercial availability of far-red/near-IR fluorophores and create 
tunable fluorescent sensors for protein kinase activity. 
 22
Our initial efforts focused on two serine-containing positively charged peptides, 
Aoc-GRTGRRFSY-amide and KRRRLASLAA-amide, which are known to be phosphorylated 
by PKA.81 Fluorophores were appended to the N termini of both peptides. The amino 
octanoyl (Aoc) moiety was used as a spacer in one of these to reduce any potential 
unfavorable steric effect of the large fluorophores on phosphorylation process. The 
strategy is outlined in Figure 2.2. 
 
 We examined a total of fourteen fluorophores that encompass a nearly 250 nm 
wavelength range throughout the red/far-red region (λex = 494 - 727 nm, λem = 530 - 752 
nm). The structures of these fluorophores were selected from different scaffolds (Figure 
2.3). Fluorophores were coupled to the peptide on resin, cleaved by TFA, and then purified 
by RF-HPLC (Table 2.1). 
Figure 2.2: General strategy for the protein kinase catalyzed dequenching of fluorescent 
kinase substrates. A positively charged fluorescent kinase substrate is quenched upon 
exposure to a negatively charged quencher dye (Q). Kinase-catalyzed phosphorylation 
releases Q as a result of favorable intramolecular electrostatic interactions between the 
newly introduced phosphate and positively charged substrate residues. 
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Figure 2.3: Structures and excitation - emission wavelengths of fluorophores. 
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Table 2.1: Peptide ESI+ mass data.
 
Peptide Molecular formula 
Calculated 
mass Found (ESI+, m/z) 
5Fam-KRRRLASLAA C69H102N21O17- 1496.78 
750.0 ([M + 3 H]2+), 500.4 ([M + 4 
H]3+), 375.6 ([M + 5 H]4+) 
Cy3-KRRRLASLAA C78H128N23O12+ 1579.01 
527.2 ([M + 2 H]3+), 395.7 ([M + 3 
H]4+) 
5Tam-KRRRLASLAA C73H113N23O15 1551.88 
777.1 ([M + 2 H]2+), 518.5 ([M + 3 
H]3+), 389.2 ([M + 4 H]4+) 
Atto610-KRRRLASLAA C73H122N23O12+ 1512.96 
757.2 ([M + H]2+), 505.2 (M + 2 H]3+), 
379.1 ([M + 3 H]4+) 
Atto620-KRRRLASLAA unknown unknown 817.9 ([M + 2 H]
2+), 545.6 ([M + 3 
H]3+), 409.5 ([M + 4 H]4+) 
Red630-KRRRLASLAA C84H137N23O16S 1756.03 
879.6 ([M + 2 H]2+), 586.5 ([M + 3 
H]3+), 440.2 ([M + 4 H]4+) 
Atto635-KRRRLASLAA C76H126N23O12+ 1553.00 
777.0 ([M + H]2+), 518.5 ([M + 2 
H]3+), 389.1 ([M + 3 H]4+) 
Cy5-KRRRLASLAA C80H130N23O12+ 1605.03 
803.1 ([M + H]2+), 535.8 ([M + 2 
H]3+), 402.2 ([M + 3 H]4+), 321.9 ([M 
+ 4 H]5+) 
Atto655-KRRRLASLAA C75H124N24O16S 1648.93 
825.4 ([M + 2 H]2+), 550.9 ([M + 3 
H]3+), 413.4 ([M + 4 H]4+) 
Atto680-KRRRLASLAA C75H122N24O16S 1646.92 
824.6 ([M + 2 H]2+), 550.2 ([M + 3 
H]3+), 412.9 ([M + 4 H]4+) 
Red681-KRRRLASLAA C84H136N23O19S2- 1834.98 
919.2 ([M + 3 H]2+), 613.2 ([M + 4 
H]3+), 460.1 ([M + 5 H]4+) 
NIR700-KRRRLASLAA C87H135N23O16S 1790.02 
896.3 ([M + 2 H]2+), 597.9 ([M + 3 
H]3+), 448.7 ([M + 4 H]4+) 
NIR730-KRRRLASLAA C86H139N23O16S 1782.05 
892.2 ([M + 2 H]2+), 595.3 ([M + 3 
H]3+), 446.7 ([M + 4 H]4+) 
5Fam-Aoc-GRTGRRFSY C76H99N20O19- 1595.74 
799.7 ([M + 3 H]2+), 533.5 ([M + 4 
H]3+), 400.3 ([M + 5 H]4+) 
5Tam-Aoc-GRTGRRFSY C80H110N22O17 1650.84 
826.7 ([M + 2 H]2+), 551.5 ([M + 3 
H]3+), 413.8 ([M + 4 H]4+) 
Atto620-Aoc-GRTGRRFSY unknown unknown 867.3 ([M + 2 H]
2+), 578.6 ([M + 3 
H]3+), 434.1 ([M + 4 H]4+) 
Atto633-Aoc-GRTGRRFSY C90H130N23O15+ 1773.01 
887.1 ([M + H]2+), 591.9 ([M + 2 
H]3+),444.2 ([M + 3 H]4+) 
Red681-Aoc-GRTGRRFSY C91H133N22O21S2- 1933.95 
1291.4 ([2 M + 5 H]3+), 968.6 ([M + 3 
H]2+), 646.2 ([M + 4 H]3+) 
Atto633-Aoc-
GRTGRRF(DMNB)SY C99H139N24O19
+ 1968.06 984.6 ([M + H]
2+), 656.9 ([M + 2 
H]3+), 493.0 ([M + 3 H]4+) 
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Screening Dye Library 
  The fluorescence increase induced by phosphorylation in the presence of a library 
of forty eight dyes (Table 2.2) was investigated. To ensure the coverage of all potential 
peptide-quencher hits, initial screening was carried out in Tris-HCl buffer (25 mM, pH 7.5) 
at peptide concentration of 2.5 µM and 5 µM; and quencher concentration varied from 5 
µM to 60 µM. Upon the addition of PKA to the solution of fluorescently quenched peptide 
(Tris-HCl buffer containing peptide, quencher, MgCl2, and ATP), fluorescence dequenching 
ranging from modest to dramatic was observed (Table 2.3, Figure 2.4-2.6). 
  
Table 2.2: Dye library. 
A B C D
1 Acid Green 27 Ethyl Orange Aniline Blue WS Naphthol Blue Black
2 Acid Blue 40 Methylene Blue Azure A Methylthymol Blue
3 Evans Blue Brilliant Blue R Azure B bromide Methyl Violet
4 Acid Alizarin Violet N Eriochrome Black T Basic Fuchsin Ponceau S
5 Acid Blue 80 Alizarin Red Bismark Brown Y Rose Bengal
6 N,N-dimethylnitrosoaniline Malachite Green Oxalate Brilliant Yellow Rosolic Acid
7 Cresol Red Phenolphthalein Bromocresol Purple Safranin O
8 Phenol Red Carminic Acid Chlorazol Black E Tartrazine
9 Methyl Orange Nuclear Fast Red Chlorophenol Red Trypan Blue
10 Bromophenol Blue Acid Fuchsin Chrysoidine Y Acid Green 25
11 Xylene Cyanol FF Acridine Orange Erythrosin Acid Blue 129
12 Disperse Yellow 3 Acridine Yellow G Ethyl Violet Acid Red 27
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Table 2.3: The PKA-catalyzed fluorescence increase of the fluorophore-substituted 
peptides in buffer Tris-HCl pH 7.5 (25 mM), MgCl2 (1 mM) containing various quenchers.
Fluorescence monitored in a plate reader at maximum wavelengths of the fluorohores
except (**) were done in a spectrofluorometer. 
 
Peptide (2.5 μM) Quencher (μM) Fluorescence fold increase
5Fam-KRRRLASLAA Acid green 27 (30) 3.7 ± 0.8
Cy3-KRRRLASLAA Bromophenol blue (20) 5.1 ± 0.1
5Tam-KRRRLASLAA Acid blue 80 (15) 24.5 ± 1.4
Atto610-KRRRLASLAA Bromophenol blue (35) 5.5 ± 0.2
Atto620-KRRRLASLAA Acid blue 80 (7.5) 21.9 ± 0.5
Red630-KRRRLASLAA Bromophenol blue (30) 4.0 ± 0.5
Atto635-KRRRLASLAA Bromophenol blue (35) 4.2 ± 0.2
Cy5-KRRRLASLAA* Bromophenol blue (20) 5.8 ± 0.2
Atto655-KRRRLASLAA Acid blue 80 (10) 16.7 ± 0.5
Atto680-KRRRLASLAA Acid blue 80 (15) 22.5 ± 2.7
Red681-KRRRLASLAA Acid blue 80 (5) 13.8 ± 0.7
NIR700-KRRRLASLAA** Bromocresol purple (80) 2.7 ± 0.1
NIR730-KRRRLASLAA** Bromocresol purple (80) 2.6 ± 0.2
5Fam-Aoc-GRTGRRFSY Acid green 27 (30) 21.2 ± 0.4
5Tam-Aoc-GRTGRRFSY Acid blue 80 (15) 100 ± 27
Atto620-Aoc-GRTGRRFSY Acid blue 80 (7.5) 31.4 ± 1.0
Atto633-Aoc-GRTGRRFSY Acid blue 80 (5) 30.9 ± 4.9
Red681-Aoc-GRTGRRFSY Acid blue 80 (5) 11.2 ± 0.6
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Figure 2.4: PKA-catalyzed fluorescence dequenching. (a) 5Fam-KRRRLASLAA-amide (2.5 
μM) with Acid Green 27 (30 μM), (b) Cy3-KRRRLASLAA-amide (2.5 μM) with Bromophenol
Blue (20 μM), (c) 5Tam-KRRRLASLAA-amide (2.5 μM) with Acid Blue 80 (15 μM), (d) 
Atto610-KRRRLASLAA-amide (2.5 μM) with Bromophenol Blue (35 µM), (e) Atto620-
KRRRLASLAA-amide (2.5 µM) with Acid Blue 80 (7.5 μM), (f) Red630-KRRRLASLAA-amide
(2.5 μM) with Bromophenol Blue (30 μM). PKA (10 nM) was added to buffer (200 µL),
containing Tris-HCl pH 7.5 (25 mM), MgCl2 (1 mM), ATP (1 mM), peptide, and quencher.
Fluorescence change was followed in a plate reader.  
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Figure 2.5: PKA-catalyzed fluorescence dequenching (continued). (a) Atto635-KRRRLASLAA-
amide (2.5 μM) with Bromophenol Blue (35 μM), (b) Cy5-KRRRLASLAA-amide (2.5 µM) with 
Bromophenol Blue (20 μM), (c) Atto655-KRRRLASLAA-amide (2.5 μM) with Acid Blue 80 (10 
μM), (d) Atto680-KRRRLASLAA-amide (2.5 μM) with Acid Blue 80 (15 μM), (e) Red681-
KRRRLASLAA-amide (2.5 μM) with Acid Blue 80 (5 μM), (f) NIR700-KRRRLASLAA-amide with 
Bromocresol Purple (80 μM). PKA (10 nM) was added to buffer (200 µL), containing Tris-
HCl pH 7.5 (25 mM), MgCl2 (1 mM), ATP (1 mM), peptide, and quencher. Fluorescence 
change was followed in a spectroflurometer (b, f) or in a plate reader for all others.  
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Figure 2.6:  PKA catalyzed fluorescence dequenching (continued). (a) NIR730-KRRRLASLAA-
amide with Bromocresol Purple (80 μM), (b) 5Fam-Aoc-GRTGRRFSY-amide (2.5 μM) with 
Acid Green 27 (30 μM), (c) 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM) with Acid Blue 80 (15 
μM), (d) Atto620-Aoc-GRTGRRFSY-amide (2.5 μM) with Acid Blue 80 (7.5 μM), (e) Red681-
Aoc-GRTGRRFSY (2.5 μM) with Acid Blue 80 (5 μM), (f) Atto633-Aoc-GRTGRRFSY-amide 
(2.5 μM) with Acid Blue 80 (5 μM). PKA (10 nM) was added to buffer (200 µL), containing 
Tris-HCl pH 7.5 (25 mM), MgCl2 (1 mM), ATP (1 mM), peptide, and quencher. Fluorescence 
was followed in a spectroflurometer (a) or in a plate reader for all others. 
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Fluorescent Fold Change and Fluorescent Recovery 
  We investigated the PKA-catalyzed fluorescence fold change and fluorescence 
recovery of the best reporters at a fixed concentration of peptide and varied 
concentrations of quencher. The fluorescence recovery is calculated by dividing 
fluorescence increase induced by phosphorylation by fluorescence before the addition of 
quencher. Examples are shown in Figure 2.7. At the fixed peptide concentration of 2.5 
µM, the fluorescent fold change tends to approach maximal value while the fluorescence 
recovery tends to reduce as the quencher concentration increases (Figure 2.7). 
Figure 2.7: Dependence of fluorescence fold change and fluorescence recovery on the
concentration of quencher. (a, b) Atto680-KRRRLASLAA amide; (c, d) Red681-
KRRRLASLAA-amide. Data was acquired in a spectroflurometer. 
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Peptide Quencher Binding Investigation 
We investigated the dependency of fluorescence fold change and fluorescence 
recovery at various peptide and quencher concentrations. Variations of the fluorescence 
response were observed when the peptide concentration was varied and the quencher 
concentration was fixed or when the peptide concentration was varied and the 
quencher/peptide concentration ratio was fixed. For example, for 5Tam-KRRRLASLAA-
amide and quencher Acid Blue 80, at 100 nM of peptide exhibits little or no fluorescence 
increase at either quencher/peptide concentration ratio of 6 or quencher concentration 
of 15 µM. Since Job plot analyses of several quencher/fluorophore-peptide pairs reveals 
no defined binding stoichiometry, we reasoned that there might be complexity in the 
interaction of the peptide/quencher pairs (Figure 2.8). A good explanation would be the 
formation of quencher/fluorophore-peptide aggregates and phosphorylation of the 
peptide disrupts aggregate formation, resulting in the fluorescence increase. Dynamic 
light scattering (DLS) experiments were carried out but we were unable to confirm any 
high-molecular-weight aggregate formation (Figure 2.9). We, however, note that the 
concentration of peptide and quencher used in DLS experiments were in µM range. 
Aggregates, if formed, might be too dilute to be detected by the DLS equipment. 
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Figure 2.8: Job plot of complex formation of 5Tam-KRRRLASLAA-amide with acid blue 80 
(a), 5Tamra-Aoc-GRTGRRFSY-amide with Acid Blue 80 (b) and 5Tam-Aoc-GRTGRRFSY with 
Evans Blue (c). The peptide and quencher [total concentration of peptide and quencher 
was 10 µM in (a) and 5 µMin (b, c)] were added to buffer (200 µL) containing Tris-HCl pH 
7.5 (25 mM), MgCl2 (1 mM), and ATP (1 mM) in (a) or Tris-HCl pH 7.5 (25 mM), MgCl2 (1 
mM), ATP (1 mM), and NaCl (150 mM) in (b, c). Mixtures were incubated at room 
temperature for 10 min before the absorbance measurements. 
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Initial Phosphorylation Rate and Kinase Inhibitor IC50 Determination 
We investigated the feasibility of using our reporters to detect phosphorylation at 
different wavelengths. We first used five reporters (5Fam: λex - λem = 494 nm - 530 nm, 
5Tam: 550 nm - 587 nm, Atto620: 620 nm - 645 nm, Atto680: 685 nm - 705 nm, and 
Red681: 685 nm - 715 nm) to determine the initial phosphorylation rates based on the 
assumption that the formation of the phosphopeptides is linear with respect to 
fluorescence increase. A standard value was acquired employing 5Fam-KRRRLASLAA-
amide peptide and capillary electrophoresis with laser induced fluorescence detection 
Figure 2.9: Dynamic light scattering analysis did not reveal detectable aggregate
formation. Correlation function of 5Tam-Aoc-GRTGRRFSY-amide (1 µM) solution (a), 
Evans Blue (2 µM) solution (b), and 5Tam-Aoc-GRTGRRFSY-amide (1 µM) + Evans Blue (2 
µM) solution. 
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(CE-LIF). As shown in the Table 2.4, the obtained values from various peptide/quencher 
pairs are comparable to the standard value obtained by capillary electrophoresis. 
In addition to the initial rate determination, we further investigated the ability of 
our reporters for determining the IC50 of kinase inhibitors. H9 and H89 were selected as 
examples of PKA inhibitors since their IC50 values for PKA have been well documented in 
literatures. As shown in Figure 2.10, IC50 value of H9 and H89 determined by various 
reporters are comparable to the values reported in literatures.82 The assay is flexible in 
term of excitation and emission wavelengths since they can be selected if desired from 
λex: 494 nm - 730 nm and λem: 530 nm - 750 nm. 
Effect of High Salt Concentration on the Fluorescence Response 
  We hypothesized that this electrostatic interaction prevents the quencher from 
interacting with the peptide which results in the observed fluorescence increase. This 
electrostatic interaction, therefore, is likely affected by ionic strength of the assay buffer. 
We set out to investigate the interference of the fluorescence response under low and 
high salt concentration. As expected, the addition of NaCl reduces quenching efficiency of 
all quenchers investigated (Table 2.5, 2.6). The fluorescence fold increase, in most of the 
cases, is also reduced when 150 mM NaCl is introduced into the buffer. To our surprise, 
however, in some instances, the fluorescence fold increase is enhanced in the presence 
of 150 mM NaCl compared to that in the absence of the salt (5Tam-Aoc-GRTGRRFSY-
amide and Atto633-Aoc-GRTGRRFSY-amide with Evans blue, Atto620-Aoc-GRTGRRFSY-
amide with Acid Blue 80) (Table 2.5, 2.6). This suggests that other types of interactions, in 
addition to electrostatic interaction, might play a role in the quenching and dequenching 
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mechanism; and that the presence of positively charged residues in the peptide sequence 
might not be absolutely required for the fluorescence increase to be observed. 
 
 
 
 
Table 2.4: Initial phosphorylation rate of various peptide/dye quencher pairs. (#) value 
determined by CE-LIF.  
 
Figure 2.10: IC50 curve of H9 and H89 toward PKA. PKA (10 nM) was added to buffer (200 
µL) containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (100 µM), 5Tam-
KRRRLASLAA-amide (5 µM), acid blue 80 (10 µM), and the designated concentration of 
inhibitor H9 or H89 to initiate the phosphorylation. The relative activity was determined
by the slope of the fluorescence change over that of the control without inhibitor. 
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Monitoring PKA Activity in Erythrocyte Lysates 
  As mentioned before, PKA plays important roles in erythrocyte biochemistry and 
the infection of malarial parasite Plasmodium Falciparum. However, the high hemoglobin 
concentration (5 mM) is likely to obscure fluorescence monitoring at wavelengths below 
Table 2.5: Effect of salt on the fluorescence response upon phosphorylation. Peptides (2.5 
μM) and various dye quenchers were incubated under either “no salt” buffer containing 
Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM) or “with salt” buffer containing Tris-
HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), and 150 mM NaCl. The reaction was 
initiated by addition of PKA (10 nM). 
Buffer 
condition Peptide (2.5 μM) Quencher (μM) Fluorescent quenching (%)
Fluorescent fold
increase
No salt 5Fam-Aoc-GRTGRRFSY Acid green 27 (30) 97.2 ± 0.3 18.5 ± 3.4
With salt 5Fam-Aoc-GRTGRRFSY Acid green 27 (30) 97.0 ± 0.1 3.5 ± 0.5
No salt 5Tam-Aoc-GRTGRRFSY Acid Blue 80 (15) 99.8 ± 0.1 103.7 ± 24.4
With salt 5Tam-Aoc-GRTGRRFSY Acid Blue 80 (15) 99.7 ± 0.0 41.0 ± 1.2
No salt Atto620-Aoc-GRTGRRFSY Acid Blue 80 (7.5) 99.1 ± 0.1 16.6 ± 0.8
With salt Atto620-Aoc-GRTGRRFSY Acid Blue 80 (7.5) 98.6 ± 0.0 18.2 ± 0.1
No salt Atto633-Aoc-GRTGRRFSY Acid Blue 80 (5) 99.4 ± 0.3 30.2 ± 9.1
With salt Atto633-Aoc-GRTGRRFSY Acid Blue 80 (5) 98.6 ± 0.2 23.6 ± 3.0
Table 2.6: Effect of salt on the fluorescence response upon phosphorylation of peptides 
with Evans Blue. Peptides (2.5 μM) and Evans Blue (2.5 μM) were incubated under either 
“no salt” buffer containing tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM) or “with 
salt” buffer containing tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), and 150 mM 
NaCl. The reaction was initiated by addition of PKA (10 nM). 
Buffer 
condition Peptide (2.5 μM) Fluorescent quenching (%) Fluorescent fold increase
No salt 5Fam-Aoc-GRTGRRFSY 80.9 ± 1.5 2.9 ± 0.5
With salt 5Fam-Aoc-GRTGRRFSY 62.1 ± 1.1 1.4 ± 0.0
No salt 5Tam-Aoc-GRTGRRFSY 99.8 ± 0.0 20.6 ± 2.9
With salt 5Tam-Aoc-GRTGRRFSY 99.8 ± 0.0 34.6 ± 14.5
No salt Atto633-Aoc-GRTGRRFSY 98.0 ± 0.4 2.0 ± 0.3
With salt Atto633-Aoc-GRTGRRFSY 94.6 ± 1.3 3.0 ± 0.5
 37
600 nm. To confirm the feasibility of using our reporters in erythrocytes, we investigated 
the loss of fluorescence signals from three peptides in erythrocyte lysate: 5Fam-Aoc-
GRTGRRFSY-amide, 5Tam-Aoc-GRTGRRFSY-amide, and Atto633-Aoc-GRTGRRFSY-amide. 
As expected, while 90% of the fluorescence signal is lost for the 5Fam-peptide and 98% 
for the 5Tam-peptide, only 10% of the signal is compromised in the case of the Atto633-
peptide in 10% lysate (Figure 2.11, blue and red). Additionally, the fluorescence signals 
from 5Fam and 5Tam labeled peptides are completely blocked, whereas 50% of the 
original Atto633-peptide signal is still detected in 100% erythrocyte lysate (Figure 2.11, 
blue and green). 
 
  We further investigated the fluorescence response upon phosphorylation of 
5Tam- and Atto633-labeled Aoc-GRTGRRFSY peptides in erythrocyte lysates. When 
phosphorylated in buffer and in the presence of Evan blue, the 5Tam-peptide shows a 
 
Figure 2.11: Relative fluorescence of 5Fam-, 5Tam-, and Atto633 - labeled petides 
(1μM) in the presence of PBS 1X, 10% erythrocyte lysate, and 100% erythrocyte lysate. 
Adapted with permission from Oien, N. P.; Nguyen, L. T.; Jernigan, F. E.; 
Priestman, M. A.; Lawrence, D. S., Long-wavelength fluorescent reporters for 
monitoring protein kinase activity. Angew Chem Int Ed Engl 2014, 53 (15), 
3975-8. 
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greater fluorescence response (34 fold) compared to the response of the Atto633-peptide 
(3 fold) (Table 2.5, 2.6). However, no fluorescence response is detected when the 5Tam-
peptide is phosphorylated in erythrocyte lysates in the presence of Evans Blue while 
profound response is still observed when the Atto633-peptide is used (Figure 2.12). 
 
 
  We also examined the quenching efficiency of quenchers in erythrocyte lysates. 
Quencher Evans Blue is significantly more effective than Acid Blue 80 in term of quenching 
 
Figure 2.12: Reaction progress curve of the PKA-catalyzed phosphorylation of fluorophore-
Aoc-GRTGRRFSY-amide (1 µM) with Evans Blue (2 µM) in 100% erythrocyte lysates where
the fluorophore is Atto633 (black) or 5Tam (red). 
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Figure 2.13: Quenching of Atto633-Aoc-GRTGRRFSY (1 μM) fluorescence by Acid Blue 80 
(circles, EQ50 = 8.1 ± 1.7 μM) and Evans Blue (squares, EQ50 = 0.35 ± 0.03 μM) in the 
presence of 10% erythrocyte lysate. EQ50 is the concentration of quencher at which 
fluorescence is quenched by 50%.  
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Atto633-peptide fluorescence (Figure 2.13). Furthermore, erythrocyte cellular integrity is 
markedly reduced upon exposure to Acid Blue 80 (30 µM), but remains unperturbed in 
the presence of Evans Blue (30 µM). Therefore, further phosphorylation studies were 
performed with the Atto633-peptide and Evans blue quencher. 
Selectively Detect PKA Activity in Erythrocyte Lysate 
  Erythrocytes possess a number of protein kinases.83 Therefore we investigated 
whether the observed fluorescence response is due to endogenous PKA activity. The PKA 
inhibitor H89 blocks the observed fluorescence change with an IC50 of 1.14 ± 0.17 µM in 
10% lysates. The more selective PKA inhibitor KT5720 prevents the phosphorylation-
induced fluorescence response with an IC50 of 1.59 ± 0.36 µM. 
 
Furthermore, PKA was cleared from the erythrocyte lysates by a PKA-specific antibody 
and kinase activity was then assessed. The precleared lysate showed an 80% decrease in 
 
Figure 2.14: Erythrocyte PKA activity (a-b) in lysates, lysates pre-cleared with a control anti-
mouse IgG, and lysates pre-cleared with an antibody against the catalytic subunit of PKA.
Erythrocyte PKA levels (c-d) in lysates (red), lysates pre-cleared with a control anti-mouse 
IgG (green), and lysates pre-cleared with an antibody against the catalytic subunit of PKA
(black). 
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the rate of fluorescence response compared to control lysates. This directly corresponds 
with the amount of PKA removed from the lysate (Figure 2.14). These results confirm that 
the fluorescence response in the lysate is due to PKA activity. 
Light-activatable sensor and the monitoring PKA activity inside erythrocytes 
  After we succeeded in measuring PKA activity in erythrocyte lysates, we 
investigated the Atto633-Aoc-GRTGRRFSY/Evans Blue as a sensor to measure PKA activity 
inside erythrocytes. One of the challenges associated with assessing intracellular 
enzymatic activity in cells is the control of the starting point (t= 0) of the phosphorylation. 
Veldhuyzen demonstrated one strategy to do so by using a light-activatable peptide 
substrate.65 We, therefore, synthesized the light-activatable Fmoc-Ser(DMNB)-OH amino 
acid and incorporated it into the solid phase peptide synthesis to make the light-
activatable version of the Atto633-Aoc-GRTGRRFSY-amide. LC-MS analysis shows that the 
light-activatable peptide analog, Atto633-Aoc-GRTGRRFS(DMNB)Y-amide is efficiently 
converted to Atto633-Aoc-GRTGRRFSY-amide peptide upon irradiation with UV light 
(Figure 2.15). Additionally, PKA cannot phosphorylate the peptide bearing the photolabile 
group in the absence of photolysis. Upon illumination, however, a time-dependent 
fluorescence increase is observed. The fluorescence response of the photochemically 
activated sensor is blocked in the presence of a PKA inhibitor, which further confirms the 
light-activation and subsequent phosphorylation of the sensor (Figure 2.16). 
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Figure 2.15: Photolysis of Atto633-Aoc-GRTGRRFS(DMNB)Y-amide (a) Structure of peptide 
before and after photolysis (b) UV traces at 600 nm of Atto633-Aoc-GRTGRRFS(DMNB)Y-
amide before (grey) and after photolysis (black). (c, d) ESI+ mass data of before and after 
photolysis in (b) respectively. Atto633-Aoc-GRTGRRFS(DMNB)Y-amide (5 µM) in PBS 1x was 
kept in dark or underwent 2 min illumination before analyzed by LC-MS.  LC-MS analytical 
characterizations were run on an Agilent instrument equipped with UV-VIS and 
quadrupole mass detectors using either a Viva C4 column (5 µM, 50 x 2.1 mm) from
Restek. All LC-MS experiments were conducted using H2O-CH3CN solvents with 0.1% 
formic acid. Photolysis was performed using an Oriel 200 W Hg-arc lamp (model 66901) 
equipped with a beam splitter and a UV bandpass 360 ± 50 nm filter (Newport, FSQ-UG1).
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Light-Activation and Monitoring PKA Activity in Erythrocytes 
  The light-activatable peptide and Evans Blue quencher were introduced into 
erythrocytes using hypotonic loading condition. PKA activity in erythrocytes was assessed 
by confocal microscopy. A 405 nm laser was used to convert the DMNB-bearing peptide 
to its phosphorylatable counterpart. Upon photolysis, a rapid fluorescence response is 
observed in the interior of erythrocytes (Figure 2.17). By contrast, no fluorescence 
response is observed when either the intracellular content of the erythrocytes is depleted 
of ATP or the PKA-selective cell-permeable inhibitor KT5720 is included in the media. 
Figure 2.16: Photoactivation of Atto633-Aoc-GRTGRRFS(DMNB)Y-amide. (a) Atto633-Aoc-
GRTGRRFS(DMNB)Y-amide (1 μM) and Evans Blue (2 μM) in PBS 1X in the absence (red) and
presence (black) of illumination (365 nm, 5 min). Protein kinase-catalyzed phosphorylation 
was initiated following illumination by the addition of PKA (10 nM). (b) Atto633-Aoc-
GRTGRRFS(DMNB)Y-amide (1 μM) and Evans Blue (2 μM) in 10% erythrocyte lysate/PBS
buffer upon illumination (365 nm, 5 min) in the absence (black, 5 min) and presence of 
KT5720 (green, 5 μM) and in the absence of illumination (red). Protein kinase-catalyzed 
phosphorylation was initiated by the addition of ATP (1 mM). 
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These results confirm that Atto633-GRTGRRFSY-amide peptide is phosphorylated by PKA 
upon photolysis. 
 
Conclusion 
We have developed a series of red and far-red sensors for protein kinase activity 
by a convenient quenching and dequenching screening approach. The desired wavelength 
of visualization is easily tuned by appending appropriate commercially available 
 
Figure 2.17: Confocal images of Atto633-Aoc-GRTGRRFS(DMNB)Y-amide loaded 
erythrocytes a) before photolysis and b) 300 sec after photolysis of the encircled cell. 
Photolysis was performed with a 50 mW, 405 nm laser (2% power level) in tornado mode
with a dwell time of 20 µs/pixel and 25 frames. Imaging was performed with a 100X 
objective by using 635 nm at 4% laser power. Scale bar: 5 µm. c) Fluorescence fold change 
as a function of time where photolysis at 405 nm is applied at the third time point (filled
circles), in the presence of KT5720 (triangles), and under depleted ATP (open circles). 
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fluorophores. We have demonstrated the applicability of the approach to develop long 
wavelength fluorescent reporters for PKA and illustrated visualization of the protein 
kinase activity in erythrocytes. 
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Materials and Method 
General reagents and solvents were purchased from Fisher or Sigma-Aldrich. 2-(6-
chloro-1H-benzotriazole-1-yl)-1,1,3,3-tetramethylaminium hexafluorophosphate (HCTU), 
5-carboxyfluorescein (5Fam), 5-carboxytetramethylrhodamine (5Tam), Fmoc protected 
amino acids, and NovaSyn TGR resin were purchased from Chempep, Inc (Wellington, FL) 
and NovaBiochem. Fmoc-8-aminooctanoic acid (Fmoc-Aoc-OH) was purchased from 
Advanced Chemtech (Louisville, KY). All fluorophores, other than Cy3 and Cy5, were 
purchased from Sigma-Aldrich as either the free carboxylic acid or as the NHS ester pre-
activated form. Cy3 and Cy5 carboxylic acids were purchased from Lumiprobe. All 
reagents for the synthesis of the 4,5-dimethoxy-2-nitrobenzyl ether of Fmoc-Ser-OH 
[Fmoc-Ser(DMNB)-OH] were purchased from Sigma-Aldrich. The cAMP dependent 
protein kinase (PKA) inhibitors H89 and KT5720 were purchased from Sigma-Aldrich and 
Calbiochem (EMD), respectively. Peripheral red blood cells were purchased from AllCells. 
8-(4-chlorophenylthio) adenosine-3′,5′-cyclic monophosphorothioate (CPT-cAMP), ATP, 
and cAMP were purchased from Sigma-Aldrich. PKA was obtained either from Promega 
(for initial screening of dyes) or Sigma (all other studies). Halt Protease and Phosphotase 
inhibitors were obtained from Thermo Scientific. PKA and IgG antibodies as well as secary 
goat ant-rabbit antibodies were obtained from Abcam. 
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Syntheses 
Synthesis of Fmoc-L-Ser(DMNB)-OH 
 
 
Fmoc-L-Serine allyl ester 
  Water (150 mL) containing N-α-Fmoc-L-serine (10.22 g, 31.2 mmol) and NaHCO3 
(14.36 g, 31.8 mmol) were combined with CH2Cl2 (60 mL) containing 
tricaprylmethylammonium chloride (~11 g) and allyl bromide (16 mL, 184.89 mmol), and 
the suspension was vigorously stirred at room temperature for 24 h. Water (300 mL) was 
added to the reaction mixture, and the suspension was extracted with methylene chloride 
(3 x 200). The combined organics were dried (Na2SO4) and the solvent was removed under 
reduced pressure. The crude residue was purified by silica flash chromatography (65:35 
hexanes:ethyl acetate) to yield Fmoc-L-Serine allyl ester as a white solid: 1H NMR (400 
MHz, CDCl3) δ = 7.77 (d, J = 7.3 Hz, 2 H), 7.62 (br.d., J = 4.6 Hz, 2 H), 7.41 (t, J = 7.5 Hz, 2 
H), 7.32 (t, J = 7.5 Hz, 2 H), 5.92 (tdd, J = 5.6, 11.0, 16.9 Hz, 1 H), 5.84 (d, J = 7.8 Hz, 1 H), 
5.35 (d, J = 17.1 Hz, 1 H), 5.27 (dd, J = 1.1, 10.4 Hz, 1 H), 4.69 (d, J = 5.4 Hz, 2 H), 4.53 - 4.46 
(m, 1 H), 4.46 - 4.37 (m, 2 H), 4.23 (t, J = 7.0 Hz, 1 H), 4.04 (dd, J = 3.1, 11.1 Hz, 1 H), 3.94 
Scheme 2.1: Synthesis of Fmoc-L-Ser(DMNB)-OH. 
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(dd, J = 2.9, 11.2 Hz, 1 H), 2.37 (br. s., 1 H). Exact mass calculated for C21H21NO5 367.14; 
found (ESI+, m/z) 368.1 (M + H)+, 390.1 (M + Na)+. 
DMNB trichloroacetimidate 
  4,5-dimethoxy-2-nitrobenzyl alcohol (8.97 g, 42.08 mmol) and anhydrous K2CO3 
(14.2 g, 102.74 mmol) were stirred in anhydrous CH2Cl2 (120 mL) under N2 atmosphere. 
To the above mixture, trichloroacetonitrile (10 mL, 99.73 mmol) and anhydrous 
triethylamine (6 mL, 43.01 mmol) were added and the reaction mixture stirred at room 
temperature for 24 h. CH2Cl2 (300 mL) was added to the reaction mixture. The organic 
layer was collected and washed with 0.5 N HCl followed by solvent removal. The dried 
crude residue was purified by silica flash chromatography (75:25 hexanes:ethyl acetate) 
to give DMNB trichloroacetimidate: 1H NMR (400 MHz, CDCl3) δ = 8.51 (s, 1 H), 7.75 (s, 1 
H), 7.23 (s, 1 H), 5.78 (s, 2 H), 3.97 (s, 3 H), 3.96 (s, 3 H). Exact mass calculated for 
C11H11Cl3N2O5 355.97; found (ESI+, m/z) 374.9 (M + H3O)+. 
Fmoc-L-Serine(DMNB) allyl ester 
 Fmoc-L-Serine allyl ester (1.74 g, 4.75 mmol) and the DMNB trichloroacetimidate 
(3.22 g, 9.04 mmol) were dissolved in CH2Cl2 (40 mL) and mixed under N2 atmosphere at 
room temperature. To the above solution was slowly added a solution of triflic acid in 
CH2Cl2 (75 µL triflic acid in 5 mL CH2Cl2). The reaction mixture was stirred at room 
temperature for 30 min after the completion of the triflic acid addition. N,N-
diisopropylethylamine (DIPEA, 150 μL) in CH2Cl2 (10 mL) and silica gel were added to the 
reaction mixture and then concentrated under reduced pressure. The crude residue, 
adsorbed on silica, was purified by silica flash chromatography (67:33 hexanes:ethyl 
acetate) to afford Fmoc-Serine(DMNB) allyl ester: 1H NMR (400 MHz, CDCl3) δ= 7.77 (d, J 
= 7.5 Hz, 2 H), 7.72 (s, 1 H), 7.61 (t, J = 6.7 Hz, 2 H), 7.41 (t, J = 7.3 Hz, 2 H), 7.31 (t, J = 6.6 
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Hz, 2 H), 7.18 (s, 1 H), 5.97 - 5.82 (m, 1 H), 5.71 (d, J = 8.4 Hz, 1 H), 5.33 (d, J = 17.1 Hz, 1 
H), 5.23 (d, J = 10.4 Hz, 1 H), 4.98, 4.92 (ABq, JAB = 15.4 Hz, 2 H), 4.71 (d, J = 5.1 Hz, 2 H), 
4.68 - 4.62 (m, 1 H), 4.48, 4.39 (ABXqd, JAB = 10.5 Hz, JAX = 6.8 Hz, JBX = 6.9 Hz, 2 H), 4.24 
(t, J = 7.1 Hz, 1 H), 4.18 - 4.04 (m, 2 H), 3.96 (s, 3 H), 3.95 (s, 3 H), 3.94 - 3.89 (m, 1 H). Exact 
mass calculated for C30H30N2O9 562.20; found (ESI+) 563.2 (M + H)+, 585.2 (M + Na)+. 
Fmoc-L-Serine(DMNB)-OH 
  Fmoc-Serine(DMNB) allyl ester (1.00 g, 1.78 mmol) was dissolved in CHCl3 (40 mL) 
containing acetic acid (21 mL) and N-methylmorpholine (3 mL). To the above solution was 
added Pd(Ph3P)4 (0.97 g, 0.84 mmol). The reaction mixture was stirred for 4 h at room 
temperature and neutralized by the addition of 0.1 N HCl until pH 4 and then the 
suspension was extracted with CH2Cl2 (twice) and ethyl acetate (three times). The organic 
extracts was dried (Na2SO4), and concentrated under reduced pressure. The crude residue 
was purified by silica flash chromatography (CH2Cl2 and then 48:2 CH2Cl2:CH3OH) to yield 
Fmoc-L-Serine(DMNB)-OH: 1H NMR (400 MHz, CDCl3) δ = 7.76 (d, J = 7.6 Hz, 2 H), 7.66 (s, 
1 H), 7.60 (t, J = 5.9 Hz, 2 H), 7.40 (t, J = 7.5 Hz, 2 H), 7.31 (dt, J = 1.2, 6.4 Hz, 2 H), 7.10 (s, 
1 H), 5.69 (d, J = 8.3 Hz, 1 H), 4.97, 4.87 (ABq, JAB = 15.29, 2 H), 4.68 (br.s., 1 H), 4.53 - 4.37 
(m, 2 H), 4.23 (t, J = 6.7 Hz, 1 H), 4.12 (d, J = 9.2 Hz, 1 H), 3.93 (s, 3 H), 3.90 (s, 3 H), 3.89 - 
3.83 (m, 1 H). 1H NMR (400 MHz , acetone-d6)  = 7.86 (d, J = 7.6 Hz, 2 H), 7.73 (dd, J = 3.8, 
7.4 Hz, 2 H), 7.70 (s, 1 H), 7.44 - 7.37 (m, 3 H), 7.35 - 7.28 (m, 2 H), 4.98, 4.92 (ABq, JAB = 
15.7 Hz, 2 H), 4.58 (t, J = 4.5 Hz, 1 H), 4.41 - 4.29 (m, 2 H), 4.28 - 4.21 (m, 1 H), 4.09 (dd, J 
= 4.9, 9.6 Hz, 1 H), 3.98 - 3.94 (m, 1 H), 3.93 (d, 6 H). Exact mass calculated for C27H26N2O9 
522.16; found (ESI+, m/z) 523.2 (M + H)+, 545.1 (M + Na)+. 
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Synthesis of fluorophore-labeled peptides 
  Solid phase peptide synthesis was performed on a Prelude automatic peptide 
synthesizer from Protein Technology using Fmoc protected amino acids (amino acids 3 eq, 
HCTU 2.95 eq, DIPEA 10 eq in DMF, double coupling in 20 and 40 min). The 4,5-dimethoxy-
2-nitrobenzyl (DMNB) modified Ser residue was double-coupled to resin as follows: Fmoc-
Ser(DMNB)-OH (3.2 eq.), HCTU (3 eq.), DIPEA (10 eq.) for 30 min and then Fmoc-
Ser(DMNB)-OH (1.5 eq.), HCTU (1.5 eq.), DIPEA (10 eq.) for 40 min. Fmoc deprotection 
was performed using 25% piperidine in DMF (3 times, 10 min each). Preactivated 
fluorophores were coupled to peptides on resin for 4 h using 1 eq. of the preactivated 
fluorophore, 10 eq. DIPEA, and an excess amount of peptide. Fluorophores with a free 
carboxylic acid moiety were coupled to the peptides on resin for 4 h using 1 eq. of the 
fluorophore, 1.1 eq. of HCTU, 10 eq. DIPEA, and an excess amount peptide. 5Fam was 
coupled to peptides on resin using 1.5 eq. of 5Fam, 1.7 eq. of diisopropylcarbodiimide, 
and 10 eq. of HOBt in DMF for 2 h followed by 30 min treatment with 25% piperidine in 
DMF (2 times). Labeled peptides were cleaved with trifluoroacetic acid 
(TFA):H2O:triisopropylsilane in a ratio of 95:2.5:2.5, and purified by HPLC using H2O:CH3CN 
with 0.1 % TFA. 
Purification and LC-MS Characterization 
  Flash chromatography purification was performed on an Isolera One instrument 
(Biotage) using a silica or C18 column (Biotage). HPLC purifications were performed on a 
Waters HPLC instrument. Peptides were purified using a C18 HPLC (Apollo C18, 5 μm, 250 
x 22 mm column). LC-MS analytical characterizations were run on an Agilent instrument 
equipped with UV-VIS, fluorescence, and quadrupole mass detectors using either a Viva 
C4 column (5 μm, 50 x 2.1 mm) from Restek or a Prevail C18 column (3 μm, 50 x 2.1 mm) 
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from Alltech Associates, Inc. All LC-MS experiments were conducted using H2O-CH3CN 
solvents with 0.1% formic acid. 
Fluorescence Measurements 
  200 μL 96 well plate fluorescence assays were performed using a Molecular 
Devices SpectraMax Gemini EM Dual-Scanning Microplate Spectrofluorometer. Data was 
collected using SoftMax Pro Software. Alternatively, protein kinase activities were 
monitored using a PTI Technologies QuantMaster-40 equipped with cooled PMT housing. 
The data was collected using FelixGX Software. Sensor monitoring studies were 
performed using a plate reader in a 96 well format (200 μL/well) in Tris-HCl (25 mM, pH 
7.5), MgCl2 (1 mM), PKA (10 nM), peptide (1 μM), and quencher. Reactions were initiated 
with the addition of ATP (final concentration of 1 mM). 
Screening of the Dye Library 
  Kinase buffer (200 μL) containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 
mM) and fluorophore-peptide (2.5 or 5 μM) were added to wells of a 96-well plate. Dyes 
(concentration ranging from 5 μM to 60 μM) were then added to each well and the initial 
fluorescence recorded. Phosphorylation was initiated by the addition of PKA (10 nM) into 
each well and fluorescence was monitored over time. Dyes that produced a fluorescent 
increase upon the PKA addition were selected for further confirmation by replication in 
the plate reader or spectrofluorometer. Phosphorylation products were confirmed by LC-
MS. 
Comparison of Kinase Reporter Assay Using Various Salt Concentrations 
  Fluorophore-labeled peptides were added to 200 μL of either “no salt” buffer 
containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM) or “with salt” buffer 
containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), and NaCl (150 mM) 
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followed by incubation (5 min at 30 °C). Various quenchers were then added to the 
solutions followed by incubation (5 min at 30 °C) and the addition of PKA (to 10 nM) to 
initiate phosphorylation. Fluorescence fold change = Ff/Fq, and fluorescent quenching = 
100*(Fi-Fq)/Fi, where Fi, Fq, Ff are the fluorescence of the reaction mixture in the absence 
of quencher, in the presence of quencher, and after the phosphorylation reaction is 
completed, respectively. 
Job Plots 
  Various ratios of peptide (TAMRA-Aoc-GRTGRRFSY) and quencher dye (Acid Blue 
80 or Evans Blue) at a fixed total concentration of peptide and quencher dye (5 μM) were 
added to 200 μL kinase buffer containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 
mM), and NaCl (150 mM). Mixtures were then incubated at room temperature for 10 min 
before the absorbance measurements were taken. 
Dynamic Light Scattering 
  Dynamic light scattering experiments were performed on a DynaPro Plate Reader 
(Wyatt Technology). Buffer (1 mL) containing Tris-HCl pH 7.5 (25 mM), NaCl (150 mM), 
MgCl2 (1 mM), and ATP (1 mM) was added 5Tam-Aoc-GRTGRRFSY-amide (1 µM) or Evans 
Blue (2 µM) or both 5Tam-Aoc-GRTGRRFSY-amide (1 µM) + Evans Blue (2 µM), followed 
by incubation at room temperature for 10 min. The solutions were then centrifuged at 
14,000 g for 10 min. The solutions (100 µL) were then transferred to wells of a 384-well 
plate, followed by light scattering measurement. 
Initial Phosphorylation Rates of Reporter/Quencher Pairs 
  Buffer (200 μL) containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), 
peptide (5 μM), and quencher was added to individual wells of a 96-well plate. The plate 
was incubated at 30 oC for 5 min followed by addition of PKA (2 nM) to initiate 
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phosphorylation. The concentration of the phosphorylated peptide was calculated by the 
formula: [phosphopeptide] (μM) = 5(Ft – Fq)/(Ff – Fq), where Ft is the fluorescence at time 
t, Ff and Fq are the final fluorescence after the addition of PKA and the initial fluorescence, 
respectively. 
Initial Phosphorylation Rate Determined by Capillary Electrophoresis 
  Buffer (200 µL) containing Tris-HCl (25 mM, pH 7.5), MgCl2 (1 mM), ATP (1 mM), 
5Fam-KRRRLASLAA-amide (5 μM), and Acid Green 27 (20 µM) was added PKA (2 nM). At 
different time points, aliquots were quenched with HCl (10 M). Phosphopeptide and 
peptide were then separated by capillary electrophoresis and quantified by fluorescence. 
PKA Activity in Erythrocyte Lysate 
  Peripheral erythrocytes were washed three times in PBS 1X [sodium phosphate 
(8.06 mM), potassium phosphate (1.94 mM), KCl (2.7 mM) and NaCl (137 mM); pH 7.4] by 
centrifuging at 1400 g for 10 min. After each centrifugation the supernatant was removed 
by aspiration and replaced with PBS 1X buffer. After the final wash, erythrocytes were 
suspended to 50% hematocrit levels and lysed in the presence of DTT (20 mM) with 
mechanical shearing. The lysed erythrocytes were then centrifuged at 10,000 rpm for 3 
min and the subsequent supernatant was used for assay measurements. Kinase assays 
were performed in a 200 μL cuvette using a PTI spectrofluorometer. Solutions contained 
PBS with fluorophore labeled peptide (1 μM), MgCl2 (5 mM), Halt protease and 
phosphatase inhibitors (1), and lysed erythrocytes (10%). Reactions were initiated with 
the addition of cAMP and ATP to a final concentration of 1 mM each. 
Fluorescence Signal Loss Study due to Erythrocyte Lysate 
  A two-chambered cuvette (Precision Cells, LT125ES10) was filled with PBS 1X or 
PBS 1X and 10% lysate in one chamber and PBS 1X containing 5Fam-, 5Tam-, or Atto633-
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Aoc-GRTGRRFSY-amide (1 μM) in the sec chamber. The fluorescence spectrum was 
measured for each peptide using their corresponding maximum excitation and emission 
wavelengths. 
Photoactivation of DMNB-bearing Sensor  
  Photolysis of Atto633-Aoc-GRTGRRFS(DMNB)Y-amide was conducted in PBS 1X 
or in PBS containing 10% erythrocyte lysate, DTT (20 mM), and Halt protease and 
phosphatase inhibitors (1X). Photolysis was performed using a Zeiss Colibri 1 LED light 
source (365 nm light at 100% power) for 5 min or using an Oriel Hg arc lamp (426 
mW/cm2) for 2 min. PBS 1X containing Atto633-Aoc-GRTGRRFSY-amide (1 μM), Evans 
Blue (2 μM), and PKA (10 nM) was photolyzed. Following photolysis, activity was 
monitored using fluorescence by the addition of ATP (1 mM) to initiate the 
phosphorylation. 
Kinase Reporter Loading into Erythrocytes 
  Erythrocytes were loaded with peptide and dye quencher via a hypotonic dilution 
method. Briefly, whole peripheral erythrocytes were washed three times in PBS 1X. 
Erythrocytes were then stored overnight at 4 °C to deplete any remaining ATP. Washed 
erythrocytes (50 μL, 50%) were added to a solution containing Atto633-Aoc-
GRTGRRFS(DMNB)Y-amide (1 μM), Evans Blue (2 μM), ATP (5 mM), CPT-cAMP (1 mM), 
Tris-HCl (10 mM, pH 7.5), and Halt protease and phosphatase inhibitor cocktail (1X) to a 
final volume of 500 μL. The solution was incubated on ice (10 min) and turned a 
transparent red. 52.7 μL of 10X buffer [KCl (1.22 M), MgCl2 (180 mM), glucose (100 mM), 
and Tris-HCl (100 mM, pH 7.5)] was then added to the erythrocyte solution, which 
changed from transparent to opaque. At this point erythrocytes were allowed to recover 
at 4 °C for 30 min. 5 μL of DTT (1 M) and 5 μL of Evans Blue (400 μM) were then added to 
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the erythrocyte solution to completely quench fluorescence outside erythrocytes . Several 
studies have demonstrated that, upon resealing, erythrocytes are unable to completely 
reseal the membrane. To prevent loss of smaller molecules (ATP, cAMP, or quencher) the 
erythrocytes were not washed. For microscopy experiments, 7 μL of the final erythrocyte 
solution was placed between two cover slips. Erythrocytes added to the cover slips were 
allowed to rest for 10 min, and subsequently imaged using confocal microscopy. 
Confocal Microscopy 
  All microscopy experiments were performed at room temperature on an Olympus 
FV1000 scanning confocal with an IX81 microscope base. Laser and region of photolysis 
were controlled via Fluoview software. Photolysis was performed using the stimulation 
mode with images collected before and after stimulation. A photolytic dwell time of 20 
μs/pixel in tornado mode was employed for the defined region of interest using 25 frames 
at 405 nm and 2% power level. All imaging was performed with a 100X at 1.9X digital zoom 
objective using 635 nm at 2% laser power and a dwell time of 12 μs/pixel. The Atto633-
peptide, in the absence of dye quencher, was used to generate a photobleaching curve. 
ImageJ software was employed for image analyses. Final fluorescence intensity changes 
of Atto633 were corrected for photobleaching effect by the following equation. 
Ft (corrected) = Ft x fo/ft 
Where Ft are fluorescence values measured at time t, fo and ft are fluorescence values of 
bleaching curve at t = 0 and at t. 
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CHAPTER 3: PEPTIDE STABILIZATION AND KINASE ASSAY BASED ON 
PHOSPHORYLATION-INDUCED PEPTIDE DEGRADATION 
Using small peptides is an appealing approach in developing biosensors given the 
ease of synthesis, modification, and optimization. However, this type of biosensor, with 
the exception of negatively charged peptides, possess a critical drawback in term of 
stability when using in living cells or cell lysates.43, 44, 84 For example, Proctor et al. showed 
that a PKB peptide substrate, 6Fam-GRPRAATFAEG-amide, is 50% degraded after 20 min 
in HeLa cell lysate. Depending on the preparation of cell lysate, this half-life value might 
be significantly shorter. Moreover, in intact LNCap cells, little of the peptide is detected 
at 1.5 min after the microinjection.43 
A tremendous effort has been put into stabilizing small peptides in general, such 
as substitution or cyclization. When applied to peptide therapeutics such as inhibitors, 
agonists and antagonists, those strategies have led to some successes.85 However, in the 
case of peptide enzyme substrates, the task becomes more challenging since the 
requirement of maintaining the ability of the enzyme to process the modified 
substrates.43 In addition to the chemical modification approach, introducing a mixture of 
various protease inhibitors into the studied system is an alternative to prevent 
degradation of the peptide substrates. This approach, however, unfavorably requires a 
large excess of protease inhibitors and protection is not always sufficiently achieved. For 
example, for fluorophore-KRRRLASLAA-amide peptide sensors described in Chapter 2, 
various protease inhibitor cocktails were employed but significant degradation was still 
observed.    
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  As demonstrated in Chapter 2, negatively charged quenchers interact with the 
positively charged peptides; and the phosphorylation of the peptides disrupt those 
interactions. It has also been suggested that the arginine residues in a peptide play an 
important role in the peptide proteolytic instability.43, 44 Those basic residues are further 
away from the phosphorylation site compared to the proteolytic cleavage sites to which 
they are usually adjacent to. Additionally, we found that the presence of negatively 
charged quencher slows down the phosphorylation process of the peptide sensors, 
fluorophore-KRRRLASLAA-amide and fluorohore-Aoc-GRTGRRFSY-amide. Therefore, we 
hypothesized that quenchers-peptide interaction might prevent proteases from 
processing the peptide while still allow the kinase to phosphorylate the substrate. Upon 
phosphorylation, the peptide-quencher interactions are disrupted leading to the 
digestion of the phosphorylated peptide. The complete fragmentation of the peptide is 
expected to result in a significant fluorescence dequenching since all binding sites are 
destroyed. We decided to investigate the possibility of stabilizing the positively charged 
peptides using the negatively charged quenchers and developing fluorescent sensors 
based on phosphorylation-induced peptide destabilization mechanism (Figure 3.1). 
Results and Discussion 
Protection of Peptide 5Tam-Aoc-GRTGRRFYS-amide from Trypsinolysis by Evans Blue 
  We first investigated the hypothesis that binding of a negatively charged quencher 
to the peptide protects the peptide from proteolysis. Since the Evans Blue quencher binds 
tightly to the peptides fluorophore-Aoc-GRTGRRFSY-amide, we examined the stability of 
the peptide 5Tam-Aoc-GRTGRRFSY-amide toward trypsinolysis in the presence and 
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absence of Evans Blue using LC-MS. As expected, the peptide is significantly more stable 
under trypsinolysis condition when Evans Blue (5 µM and 20 µM) is added to the assay 
buffer (Figure 3.2a). No significant peptide protection at 5 µM of Evans Blue and 30 µM 
of peptide (Figure 3.2b) further confirms that the protection is due to the peptide-Evans 
Figure 3.1:  General strategy for the stabilization and phosphorylation induced peptide
degradation leading to dequenching of fluorescent kinase substrates. Negatively charged
quenchers (Q) interact with a positively charged fluorescent kinase substrate. The 
interaction leads to both the quenching of the peptide’s fluorescence and the stabilization
of the peptide against proteolysis. Kinase-catalyzed phosphorylationof the peptide 
disrupts Q-peptide interaction leading to peptide degradation and fluorescence 
dequenching. 
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Blue association since at that high peptide concentration, the majority of the peptide does 
not bind to the quencher, and thus is susceptible to proteolysis.  
 
 
Trypsinolysis of 5Tam-Aoc-GRTGRRFSY-amide and its phosphorylated peptide in the 
presence of Evans blue 
  We next examined if, upon phosphorylated by PKA, the phosphopeptide is more 
susceptible to trypsinolysis in the presence of Evans Blue. Since we noticed that 
degradation of the peptides also disrupts the fluorescence quenching, we used the 
fluorescence readout as an indication of peptide degradation. The peptide 5Tam-Aoc-
GRTGRRFSY-amide and its phosphorylated counterpart were incubated with trypsin in the 
presence of Evans Blue and fluorescence was monitored. The 10 times higher rate of 
fluorescence increase with phosphopeptide compared to that of nonphosphorylated 
peptide suggests that the phosphopeptide is less protected by Evans Blue (Figure 3.3). 
Figure 3.2: Protection of 5Tam-Aoc-GRTGRRFSY-amide 2.5 µM (a) and 30 µM (b) from 
trypsinolysis by Evans Blue. Tris buffer [150 µL total, Tris-HCl (25 mM, pH 7.5)] containing 
peptide 5Tam-Aoc-GRTGRRSFY-amide (2.5 or 30 µM) and Evans blue (5 or 20 µM) was 
preincubated at 37 oC for 5 min, followed the addition of trypsin (5 nM). At various time 
points, reaction aliquots were quenched and analyzed by LC-MS. 
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Screening for Quenchers Which Protect the Peptide but not Phosphorylated Peptide 
from Proteolysis in Erythrocyte Lysate 
  Given the promising results obtained from the 5Tam-peptide/Evans Blue quencher 
pair with PKA and trypsin, we decided to rescreen all quenchers in our library to find 
quenchers which slow or prevent degradation of the unphosphorylated peptide while 
permitting degradation of the phosphorylated peptide. We used erythrocyte lysates, 
which contain endogenous proteases, as the protease model. The lysate was used at 2.4% 
concentration to reduce the inner filter effect of hemoglobin. No protease inhibitors were 
added to the lysate to preserve the protease activity of the lysate, whereas phosphatase 
inhibitors were added to prevent the newly formed phosphorylated peptide from 
dephosphorylation. In the presence of a number of quenchers, little fluorescence change 
is observed with the unphosphorylated peptide, whereas significant fluorescence 
increase is observed with phosphorylated one (Figure 3.4). The acceleration in 
 
Figure 3.3: Degradation of 5Tam-Aoc-GRTGRRFSY-amide and its phosphorylated 
counterpart by trypsin in the presence of Evans Blue. Peptide (2.5 µM), Evans Blue (5 
µM). Fluorescence was followed in a spectrofluorometer, λex - λem = 550 - 587 nm. 
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fluorescence increase of the phosphorylated samples compared to that of 
unphosphorylated ones suggests that the newly introduced phosphate group destabilizes 
the peptide in the lysate, while little fluorescence increase observed in unphosphorylated 
samples suggests that the peptide might be stabilized in the investigated conditions. 
  Among the forty eight quenchers screened, eight were selected for further study 
based on the background fluorescence increase of unphosphorylated samples and the 
difference in the fluorescence increase rate between phosphorylated and 
unphosphorylated samples. Further studies were conducted to eliminate quenchers 
which, upon association with the peptide, prevent the peptide from getting 
phosphorylated by PKA. The 5Tam-peptide was preincubated with a selected quencher 
followed by the addition of erythrocyte lysate. Br-cAMP was added to the buffer to 
activate endogenous PKA. A number of peptide-quencher pairs show significant 
fluorescence increase only when PKA is activated by 8-Br-cAMP (Figure 3.5). The 
fluorescence increase was abolished in the presence of the PKA inhibitor, H89, further 
confirming the phosphorylation induced fluorescence response. 
Stability of 5Tam-peptide in Erythrocyte Lysate in the Presence and Absence of 
Quenchers as Assessed by LC-MS 
  The protection of peptide from proteolysis in erythrocyte lysate by four selected 
quenchers (Acid Green 27, Disperse Yellow 3, Brilliant Blue R, and Acid Blue 129) was 
further confirmed using LC-MS. The peptide 5Tam-Aoc-GRTGRRFSY-amide was incubated 
with erythrocyte lysate in the presence and absence of a listed quencher. At various time 
points, the samples were quenched and analyzed by LC-MS. As demonstrated in Figure 
3.6, in the absence of quencher, the peptide gets degraded quickly in 2.4% erythrocyte 
lysate with a half-life of about 16 min, whereas under the same conditions in the presence  
 61
 
  
Figure 3.4: Degradation difference of phosphorylated and unphosphorylated peptides in
erythrocyte lysate (2.4% lysate in PBS 1X buffer) in the presence of quenchers, Acid Green
27 (18.75 µM) or other dyes (37.5 µM) and peptide (2.5 µM). Fluorescence was followed
in a plate reader. λex - λem = 550 - 587 nm. 
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Figure 3.5: Fluorescence increase induced by phosphorylation-degradation in erythrocyte 
lysate (2.4% lysate in PBS 1X buffer) in the presence of quenchers, Acid Green 27 (18.75
µM) or other dyes (37.5 µM) and peptide (2.5 µM). ATP (1 mM), MgCl2 (1mM) and 
phosphatase inhibitors was added to the lysate. Phosphorylation was initiated by the
addition of 8-Br-cAMP (100 µM). Fluorescence was followed in a plate reader. λex - λem = 
550 - 587 nm. 
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Figure 3.6: Degradation of 5Tam-Aoc-GRTGRRFSY-amide in erythrocyte lysate in the 
absence and presence of Acid Green 27. LC-Fluorescence trace (λex - λem = 550 - 590 nm) 
of peptide 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM) incubated in erythrocyte lysate (2.4%
lysate in PBS 1X buffer) in the absence (a) and presence of Acid Green 27 (18.75 µM) (b).
5Tam-Aoc-GRTGRRYSY-amide remains in the lysate vs time (c). Red: No quencher, black: 
18.75 µM Acid Green 27. 
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of quencher Acid Green 27, more than 85% of the intact peptide is still detected after 120 
min. Similar levels of protection are also observed with the other three quenchers, 
Disperse Yellow 3, Brilliant Blue R, and Acid Blue 129 (Figure 3.6, 3.7). 
 
Phosphorylation-Induced Degradation of the Peptide in the Presence of Quencher as 
Assessed by LC-MS 
  We investigated if phosphorylation destabilizes the peptide in the lysate. The 
peptide was incubated with erythrocyate lysate in the presence of a selected quencher. 
Phosphorylation of the peptide by endogenous PKA was stimulated by the addition of 8-
Br-cAMP and ATP. After 90 min of incubation at the 30 oC, the assays were analyzed by 
LC-MS. The fluorescence traces from LC-MS experiment demonstrate that the peptide, 
upon phosphorylation, was degraded rapidly, whereas the unphosphorylated peptide was 
intact during the time course of the experiments (Figure 3.8, 3.9).  
 
Figure 3.7: Protection of 5Tam-Aoc-GRTGRRFSY-amide against proteolysis in erythrocyte 
lysate by quenchers. LC fluorescence trace of 5Tam-Aoc-GRTGRRFSY-amide incubated 
with erythrocyte lysate (2.4% lysate in PBS 1X buffer) in the absence (30 min incubation) 
and presence of quencher (60 min incubation). Peptide (2.5 µM), quencher (37.5 µM), 30 
oC.   
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Figure 3.8: Phosphorylation-induced degradation of 5Tam-Aoc-GRTGRRFSY-amide in the 
presence of quencher in erythrocyte lysate. The peptide and quencher were incubated 
with erythrocyte lysate with and without the activation of PKA. After 90 min of
incubation, assay samples were analyzed by LC-MS. Fl = Fluorescence. λex - λem = 550 nm 
- 590 nm.  
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Figure 3.9: Phosphorylation-induced degradation of 5Tam-Aoc-GRTGRRFSY-amide in 
the presence of quencher in erythrocyte lysate. The peptide and quencher were 
incubated with erythrocyte lysate with and without the activation of PK. After 90 min 
of incubation, assay samples were analyzed by LC-MS. Fl = Fluorescence. λex - λem = 
550 nm - 590 nm. 
5Tam-Aoc-GRTGRRFSY-amide
-20
180
380
0 2 4 6 8 10 12 14 16 18
Fl
. /
 a
. u
.
With Brilliant Blue R, no ATP, no 8-Br-cAMP
5Tam-Aoc-GRTGRRFSY-amide
P-peptide
-20
80
180
280
0 2 4 6 8 10 12 14 16 18
Fl
. /
 a
. u
.
Time / min
With Brilliant Blue R, ATP, and 8-Br-cAMP
5Tam-Aoc-GRTGRRFSY-amide
-20
80
180
280
380
0 2 4 6 8 10 12 14 16 18
Fl
. /
 a
. u
.
With Disperse Yellow 3, no ATP, no 8-Br-cAMP
5Tam-Aoc-GRTGRRFSY-amide
P-peptide
-20
80
180
280
0 2 4 6 8 10 12 14 16 18
Fl
. /
 a
. u
.
Time / min 
With Disperse Yellow 3, ATP, and 8-Br-cAMP
 67
 
Conclusion 
 We have demonstrated a strategy for creating enhanced fluorescent kinase 
sensors based on phosphorylation and degradation-induced fluorescence dequenching. 
Four developed sensors have been demonstrated to be capable of monitoring PKA activity 
in erythrocyte lysate. Additionally, we have shown a strategy to stabilize a peptide sensor 
in cell lysate without the necessity of adding protease inhibitors. 
  
 
  
 68
Materials and Method 
  General reagents and solvents were purchased from Fisher or Sigma-Aldrich. 8-
bromoadenosine-3′,5′-cyclic monophosphate (8-Br-cAMP), ATP, H89, and phosphatase 
inhibitor cocktail were purchased from Sigma-Aldrich. PKA was obtained from Promega. 
Peptide Synthesis and Purification 
  Peptide synthesis and purification was conducted as described in Chapter 2 
(Materials and Method). 
LC-MS Analysis 
  All LC-MS analyses were performed on an Agilent liquid chromatography 
instrument which is coupled to a fluorescence and a mass detector. An Agilent C18 Eclipse 
4.5 x 150 mm column was used for the separation. Peptide degradation was quantified by 
the area under the curve of the fluorescence traces. 
Protection Peptide 5Tam-Aoc-GRTGRRFYS-amide from Trypsinolysis by Evans Blue 
  Tris buffer [150 µL total, Tris-HCl (25 mM, pH 7.5)] containing peptide 5Tam-Aoc-
GRTGRRSFY-amide (2.5 or 30 µM) and Evans blue (5 or 20 µM) was preincubated at 37 oC 
for 5 min before the addition of trypsin (final 5 nM). At various time points, reaction 
aliquots were quenched with HCl (10 M) and analyzed by LC-MS. 
Trypsinolysis of 5Tam-Aoc-GRTGRRFSY-amide and Its Phosphorylated Counterpart in the 
Presence of Evans Blue 
  A quartz cuvette containing a buffer [200 µL of Tris.HCl (25 mM, pH 7.5)], MgCl2 (1 
mM), ATP (1 mM), and peptide 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM) was added PKA (10 
nM) and incubated at 30 oC. After a 45 min incubation when all the peptide was 
phosphorylated, Evans Blue (5 µM) was added to the cuvette. The mixture was then 
equilibrated for 10 min followed by the addition of trypsin (5 nM). A parallel cuvette, 
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which contained a buffer [200 µL of Tris.HCl (25 mM, pH 7.5)], MgCl2 (1 mM), ATP (1 mM), 
and peptide 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM) was incubated at 30 oC for 45 min 
without the addition of PKA. Evans Blue (5 µM) was then added to the cuvette followed 
by a 10 min equilibrium and a trypsin addition (5 nM). The fluorescence after the trypsin 
addition was monitored in a spectrofluorometer.  
Degradation Screening with Erythrocyte Lysate (Primary Screening) 
  Erythrocyte Lysate Preparation. Erythrocytes were washed three times with 
Gibco® PBS 1X buffer. Packed erythrocytes (625 µL) was then added to H2O [3875 µL 
containing 198 µL phosphatase inhibitor cocktail 100X (product P0044 Sigma-Aldrich)]. 
The mixture was sonicated on ice in a water bath sonicator (5 times, 10 - 20 sec each) or 
by anultrasonic sonicator probe (3 times, 3-5 sec each). Gibco® PBS 10X (500 µL) was then 
added to the sonicated lysate to yield erythrocyte lysate (12% in PBS 1X buffer). 
  Screening. PBS 1X buffer (150 µL), 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), MgCl2 
(1 mM), ATP (1 mM), and PKA (10 nM) were added to 48 wells of a clear-bottom, black, 
96-well plate were added. PBS 1X buffer (150 µL), 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), 
no MgCl2, no ATP, and kinase dilution buffer were added to the other 48 wells. The plate 
was incubated at 30 oC for over 30 min then dyes (25 µM) in the 48-dye library were added 
to each well. Following a 15 min equilibration, the erythrocyte lysate (40 µL) was added 
to each well and the fluorescence monitored (λex - λem: 555 nm - 586 nm). Fluorescence 
increase rates were compared between wells containing phosphorylated peptide and 
unphosphorylated peptide of the same dye. Thirteen promising peptide-dye pairs which 
showed minimal fluorescence increase in the unphosphorylated sample and accelerated 
fluorescence increase in phosphorylated sample were further screened at 37.5 µM dye. 
Evans Blue was further screened at 9.375 µM. 
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Screening the phosphorylation in erythrocyte lysate (Secondary Screening) 
  Among the forty eight dyes in the screened library, eight were selected for further 
phosphorylation screening. An additional dye, Chrysophenine, was also added to the list 
because of its structural similarity to the dye Brilliant Yellow. PBS 1X buffer (150 µL), 
5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), MgCl2 (1 mM), ATP (100 µM), and 8-Br-cAMP (100 
µM) each were added to a 96-well plate. Two sets of control wells # 1: PBS 1X buffer (150 
µL), 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), MgCl2 (1 mM), no ATP, and no 8-Br-cAMP; # 
2: PBS 1X buffer (150 µL), 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), MgCl2 (1 mM), ATP (100 
µM), 8-Br-cAMP (100 µM), and H89 (10 µM)] were prepared in parallel. To each well was 
then added the selected dye (37.5 µM for all dyes, additional screening concentration at 
18.75 µM for Acid Green 27 and Chrysophenine). The plate was then incubated at 30 oC 
for 30 min followed by the addition of erythrocyte lysate (40 µL, 12% lysate). Fluorescence 
increase rates were compared between the assay wells and the two control wells.  
Confirmation of Peptide Stabilization by Quencher in Erythrocyte Lysate by LC-MS 
  Five Eppendorf vials containing PBS 1X buffer (450 µL), the peptide 5Tam-Aoc-
GRTGRRFSY-amide (2.5 µM) were added quenchers or water as a control (18.75 µM for 
Acid Green 27 and 37.5 µM for Disperse Yellow 3, Brilliant Blue R, Acid Blue 129). The vials 
were then preincubated at 30 oC for 5 - 10 min followed by the addition of erythrocyte 
lysate (120 µL, 12% lysate) and further incubation at 30 oC.  At different time points, 
reaction aliquots (100 µL) were quenched with HCl (10 M, 10 µL), then dilluted by MeOH 
(100 µL) and filtered through 3K molecular-weight-cut-off centrifugal filters (Amiconultra-
0.5 mL Centrifugal Filters, 14,000 g, 30 min). After the first round of centrifugation, the 
filters were washed with another solution of MeOH-H2O (200 µL, 50-50 by volume, 14,000 
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g. 30 min). Filtrates were collected and dried under vacuum. The residue were then 
dissolved in DMSO (100 µL), diluted with H2O (100 µL), and analyzed by LC-MS. 
Confirmation the Phosphorylation-Induced Degradation of the Peptide in the Presence 
of Quencher by LC-MS 
  PBS 1X buffer (150 µL) containing the peptide 5Tam-Aoc-GRTGRRFSY-amide (2.5 
µM), MgCl2 (1 mM), ATP (100 µM), and 8-Br-cAMP (100 µM), was added to 4 wells of a 
96-well plate. Two other sets of wells were used for control samples # 1: PBS 1X buffer 
(150 µL), 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), MgCl2 (1 mM), no ATP, and no 8-Br-
cAMP; # 2: PBS 1X buffer (150 µL), the peptide 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM), 
MgCl2 (1 mM), ATP (100 µM), 8-Br-cAMP (100 µM), and H89 (10 µM)]. Quenchers were 
then added to each well (18.75 µM for Acid Green 27 and 37.5 µM for Disperse Yellow 3, 
Brilliant Blue R, and Acid Blue 129) and the plate was preincubated at 30 oC for 10 - 15 
min, followed by the addition of erythrocyte lysate (40 µL, 12% lysate) and fluorescence 
monitoring. At 90 min after the addition of the lysate, reaction mixtures were quenched 
with HCl (20 µL, 10 M), diluted with MeOH (200 µL) and filtered through 3K molecular-
weight-cut-off centrifugal filters (Amiconultra-0.5 mL Centrifugal Filters, 14,000 g, 30 
min). After the first round of centrifugation, the filters were washed with another solution 
of MeOH-H2O (200 µL, 50-50 by volume, 14,000 g. 30 min). Filtrates were collected and 
dried under vacuum. The residue were then dissolved in DMSO and analyzed by LC-MS. 
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CHAPTER 4: MEMBRANE SEQUESTRATION AND THE DESIGN OF LIGHT-ACTIVATABLE 
BIOAGENTS 
 Light-controllable agents have been widely used in drug delivery and chemical 
biology as they provide a unique means to orthogonally manipulate the biological systems 
with a high degree of spatial and temporal resolution. The principles of designing and 
constructing these species are well-defined. Prior to light exposure, the agent is 
biologically/biochemically/chemically inert. Upon light-activation, the active agent is 
rapidly produced and drives the desired process with the high degree of spatiotemporal 
control. One strategy for constructing such light-controllable reagents involves using 
photolabile groups. In this case, a key functional group (e.g. alcohol, amine, carboxylate) 
of the bioactive agents is covalently modified with a photocleavable moiety (e.g. 
nitrobenzyl, phenacyl, coumarin). The modification renders the bioagent inactive until 
photolysis removes the photolabile group and activates the bioagent. However, in a 
number of instances, a key functional group is not well defined or the modification of only 
a single functional group is not sufficient to eliminate biological activity. Modification of a 
phosphorylable hydroxyl group in kinase peptide sensors, for example, is sufficient to 
block its phosphorylation susceptibility but insufficient to protect the peptide from being 
processed by other enzymes (e.g., proteases). Upon entering a biological environment, 
the sensor might be degraded before any light-activation event. With the aim of 
controlling the initiation of phosphorylation and protecting peptide sensors from 
degradation inside living cells, we have developed a strategy to create light-activatable 
bioagents based on the compartmentalized nature of cells and organelles. The light-
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activatable bioagents can be constructed from active agents of which no functional group 
is absolutely essential. Additionally, activation of those bioagents can be attained by a 
single photolytic event. 
Hypothesis 
 Biological membranes are composed of a lipid bilayer decorated by proteins. Cells 
commonly employ hydrophobic moieties, such as fatty acids, terpenes, cholesterol, and 
peptides to direct proteins to membranes. We hypothesize that lipidated bioactive 
species, upon anchoring to the membrane will be embedded within the protein layer, and 
thus hidden from enzymatic species might be prevented from acting on or being acted 
upon by their intracellular targets. Placing a photolabile group between the membrane 
targeting moiety and the bioactive agent provides a way to control the release of the 
bioactive species from the membrane in a light-dependent fashion (Figure 4.1).  
Results and Discussion 
Design of Photolabile Lipid Anchor 
The membrane anchoring linker (C18-bn-COOH) was synthesized with a lipophilic 
C18 alkyl moiety which serves as membrane directing group and a carboxylate 
functionality to which the bioactive active species can be appended (Figure 4.2). The 
 
Figure 4.1: General strategy for lipid pool-anchored light-activatable bioagents. The active 
species (R), when appended to a lipid, is embedded within the densely populated protein
sheath and thus unavailable for interaction with its biological target. Photolysis releases R
from the membrane and thus renders the bioagent active. 
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nitrobenzyl moiety is inserted in between the lipophilic and carboxylate moieties to 
facilitate the release of appended bioactive species from the membrane upon photolysis. 
 
Study of a Lipidated Fluorophore 
For our initial studies, a fluorophore was appended to the C18-bn-COOH and 
membrane association as well as light-triggered membrane-release was investigated. The 
5Tam fluorophore was appended to the side chain of a lysine residue. The fluorophore-
labeled lysine was then appended to the carboxylate moiety of the membrane anchoring 
group to produce C18-bn-K(5Tam) (Figure 4.3). LC-MS data confirmed that photolysis of 
C18-bn-K(5Tam) produces the corresponding lipid-free (5-Tam)-labeled lysine (Figure 
4.4). 
 
 
Figure 4.2: Structure of the photolabile lipid linker C18-bn-COOH. bn denotes the 
photolabile group where the cleavage site is on the n-site and the nitroso by-product goes 
with the moiety on the b-site.    
 
Figure 4.3: Structure of the photolabile lipidated fluorophore C18-bn-K(5Tam) and its 
photolyzed product Suc-K(5Tam). 
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Octanol/water partition experiments revealed that C18-bn-K(5Tam) exclusively 
resides in the octanol phase prior to photolysis and migrates to the aqueous phase after 
photolysis (Figure 4.5a). Studies with biological membrane models showed that C18-bn-
K(5Tam) is completely associated with both mitochondria (Figure 4.5b, 4.6) and 
erythrocyte ghosts (Figure 4.5c). Photolysis subsequently triggers the release of the 
 
Figure 4.4: (a) LC-MS trace of C18-bn-K(5Tam) before (black) and after (red) photolysis. ESI+ 
MS data of peak 1 (b) and peak 2 (c). 90 µL solution containing PBS 1X (45 µL), MeOH (45
µL), DTT (5 mM), and C18-bn-K(5Tam) (4 µM) was photolyzed at 360 nm for 2 min. The 
sample was run on the C4 column after removal of MeOH by vacuum. Pure C18-bn-K(5Tam)
was run as a reference. Absorbance was monitored at 550 nm. Photolyzed product Suc-
K(5Tam) (peak 2): C35H40N5O6+, calculated (M)+ 658.3, found (ESI+, m/z) 658.3 (M)+, 329.6 
(M + H)2+. 
595.9
1190.7
0
25
50
75
100
125
200 400 600 800 1000 1200 1400
Re
la
tiv
e 
in
te
ns
ity
 /
 %
 
m/z
b)
12
-100
0
100
200
300
400
500
0 2 4 6 8 10 12
Ab
so
rb
an
ce
 /
 a
. u
. 
Retention time / min
a)
329.6
658.3
0
25
50
75
100
125
200 400 600 800 1000 1200 1400
Re
la
tiv
e 
in
te
ns
ity
 /
 %
m/z
c)
 76
peptide from the organelles/cells into the aqueous solution (Figure 4.5b, c, ii). Given the 
lipophilic characteristics of C18-bn-K(5Tam), it was surprising that C18-bn-K(5Tam) stays 
exclusively on the outer leaflet of erythrocytes even after hours of incubation at 37 oC. 
This suggests that C18-bn-K(5Tam), upon binding to the outer leaflet of the bilayer 
membrane, was unable to flip to the other side due to the energy barrier associated with 
the transfer of positively charged 5Tam moiety. 
 
Using 2-hydroxypropyl-β-cyclodextrin and buffer tonicity manipulation, we were 
able to load C18-bn-K(5Tam) onto the inner leaflet of erythrocytes. Briefly, C18-bn-
K(5Tam) was dissolved in a solution of 2-hydroxypropyl-β-cyclodextrin (100 mg/mL) 
 
Figure 4.5: Light-dependent distribution studies with C18-bn-K(5Tam). a) Distribution of 
C18-bn-K(5Tam) in octanol (top) and water (bottom) prior to (i) and after (ii) photolysis. 
b) Distribution of C18-bn-K(5Tam) in mitochondria (pellet) and buffer prior to (i) and 
after (ii) photolysis. c) Distribution of C18-bn-K(5Tam) in erythrocytes (pellet) and buffer 
prior to (i) and after (ii) photolysis. 
 
Figure 4.6: Mitochondria stained with C18-bn-K(5Tam) prior to (i) and after (ii) loading of 
C18-bn-K(5Tam). Image acquired with ambient light. 
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followed by the addition of washed erythrocytes. Cold deionized water was added to the 
mixture to reduce the tonicity of the solution and open the erythrocytes’ membranes. 
After adequate equilibrium, the tonicity of the solution was restored to that of PBS 1X to 
seal the erythrocytes. Confocal microscopy confirmed that the lipidated fluorophore C18-
bn-K(5Tam) is retained by the erythrocyte membrane prior to photolysis. By irradiating 
with a UV laser, we demonstrated the ability to selectively photolyze and release the 
 
 
Figure 4.7: Confocal microscopy of erythrocyte ghosts loaded C18-bn-K(5Tam) with and 
without photolysis. (a) Before photolysis, (b) immediately after photolysis, and (c) 8.5 min 
after photolysis. (d) Changes of average fluorescence inside erythrocytes loaded with C18-
bn-K(5Tam) with (red) and without photolysis (black). n = 8 for photolyzed cells, n = 7 for 
non-photolyzed cells. Photolysis was performed with 100 mW, 355 nm laser at the power 
level of 1 mW, tornado mode, dwell time of 10 µs/pixel, and 5 frames. Images were
acquired by excitation at 559 nm and data collected using spectral PMTs set for the 5-Tam 
fluorophore. 
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fluorescent moiety into the interior of erythrocytes (Figure 4.7). However, we noticed that 
it takes more than 5 min after photolysis for the fluorescence to completely migrate to 
erythrocyte interior. Since the photolysis of 2-nitrobenzyl group involves acid/base 
catalyzed steps,86 the delay in fluorescence release might indicate that the photolabile 
group is positioned away from hydrophilic environment.  
Study of Lipidated Protease Substrate 
  We subsequently investigated if bioactive species can be rendered 
biologically/biochemically inert by membrane sequestration and then activated upon 
photolysis-triggered membrane releasing. The FRET-based peptide Ac-K(Tam)--K(Fam) 
was synthesized, which serves as a generic protease substrate. The corresponding 
lipidated derivative C18-bn-K(Tam)--K(Fam), was prepared by acetylating the N-terminal 
of the peptide NH2-K(5Tam)RRRLAALAAK(5Fam)-amide with the lipidated photolabile 
linker C18-bn-COOH (Figure 4.8). 
 
 
Figure 4.8: Structure of the photolabile lipidated protease sensor C18-bn-K(Tam)--
K(Fam), the corresponding light-activated membrane-released derivative Suc-K(Tam)--
K(Fam), and a control non-lipidated sensor Ac-K(Tam)--K(Fam). 
 79
  The fluorescence of 5Fam fluorophore is completely quenched by 5Tam, provides 
the means to monitor substrate proteolysis at the 5Fam emission wavelength (492 nm - 
525 nm). Moreover, the partially quenched 5Tam fluorescence signals the location of the 
peptide (555 nm - 587 nm) both prior to and following photolysis (Figure 4.9). 
 
LC-MS analysis demonstrated the formation of the lipid-free peptide from C18-bn-
K(Tam)--K(Fam) upon photolysis (Figure 4.10). An octanol/water partition study of C18-
bn-K(Tam)—K(Fam) showed that, prior to photolysis, the lipidated peptide resides in  the 
octanol phase and is not susceptible to trypsinolysis even when trypsin is present in the 
aqueous phase. Upon photolysis, the lipid-free protease substrate peptide is released into 
the aqueous phase and processed by trypsin (Figure 4.11). Further investigation with 
mitochondria demonstrated that C18-bn-K(Tam)--K(Fam) is completely associated with 
the mitochondria and protected from trypsinolysis. Subsequent photolysis triggers the 
release of the substrate from the mitochondria and renders it susceptible to trypsin-
 
Figure 4.9: Fluorescence response from trypsin digestion of Ac-K(Tam)--K(Fam). Tris-HCl 
buffer (200 µL, 25 mM pH 7.5) containing MgSO4 (4 mM) and Ac-K(Tam)--K(Fam) (1 µM) 
was incubated at 37 oC for 5 min followed by addition of trypsin (20 nM) and 
fluorescence was scanned over time. Emission scan with 495 nm excitation prior to 
(black) and 20 min after the addition of trypsin (red). Emission scan with 553 nm 
excitation prior to (green) and 20 min after the addition of trypsin (blue). 
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catalyzed proteolysis (Figure 4.12 - 4.14). Furthermore, binding of C18-bn-K(Tam)--
K(Fam) to erythrocyte ghosts prevent it from being digested by trypsin. Photolysis 
releases the substrate from the membrane leading to a rapid proteolysis (Figure 4.15 - 
4.18). 
 
 
 
 
Figure 4.10: (a) LC-MS of C18-bn-K(Tam)--K(Fam) before (black) and after photolysis (red).
ESI+ MS data of peak 1 (b) and peak 2 (c) in (a). PBS 1X (100 µL) containing C18-bn-K(Tam)-
-K(Fam) (4 µM), DTT (5 mM) was photolyzed at 360 nm for 2 min. Sample was run on the 
C4 column. Absorbance was monitored at 550 nm. Photolyzed product Suc-
K(5Tam)RRRLAALAAK(5Fam)-amide (peak 2): C104H140N25O24+, calculated (M)+ 2123.0, 
found (ESI+, m/z) 1062.4 (M + H)2+, 708.3 (M + 2H)3+, 531.5 (M + 3H)4+, 425.5 (M + 4H)5+.
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Figure 4.11: Trypsin cleavage of C18-bn-K(Tam)--K(Fam) distributed in octanol and water 
with and without photolysis as assessed by fluorescence. Samples were excited by 360 nm 
UV light from a Hg-Arc lamp source, images were acquired with X-Nite 525 filter (a) and X-
Nite 590 filter (b). C18-bn-K(Tam)--K(Fam) (4 µM) without photolysis (i) and with photolysis 
(ii) after 2.5 h incubation with trypsin (20 nM) at room temperature. Top layer octanol and
bottom layer PBS 1X. 
 
Figure 4.12: Mitochondria prior to (i) and after (ii) loaded with C18-bn-K(Tam)--K(Fam). 
Images acquired with ambient light. 
 
Figure 4.13: Trypsin cleavage of C18-bn-K(Tam)--K(Fam) loaded on mitochondria with and 
without photolysis as assessed by fluorescence. Samples were excited by 360 nm UV light
from a Hg-Arc lamp source, images were acquired using the X-Nite 590 filter. C18-bn-
K(Tam)--K(Fam) (4 µM) without photolysis and with trypsin (i); with photolysis and no
trypsin (ii); with photolysis and with trypsin (iii) after 40 min incubation at 37 oC. Trypsin 
(10 nM) was used in with trypsin experiments. 
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Figure 4.14: a) Trypsin cleavage of C18-bn-K(Tam)--K(Fam) loaded onto mitochondria in 
the absence and presence of illumination as assessed by fluorescence. Samples were
illuminated with 360 nm UV light from a Hg-Arc lamp source, images were acquired with 
the X-Nite525 filter. i) In the dark with trypsin; ii) with photolysis and no trypsin; and iii)
with photolysis and trypsin after 40 min incubation at 37 oC. b) Relative amount of C18-
bn-K(Tam)--K(Fam) in the supernatant in the absence and presence of mitochondria
(supernatant i with mitochondria), and after a mitochondria wash (supernantant ii with 
mitochondria). c) Relative rate of trypsinolysis of C18-bn-K(Tam)--K(Fam) in the presence 
of mitochondria with and without photolysis compared to that of Ac-K(Tam)--K(Fam) (with 
mitochondria) as determined by fluorescence increase 492 nm - 525 nm. RF = relative 
fluorescence. 
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Figure 4.15: Erythrocyte ghosts prior to (i) and after (ii) loaded with C18-bn-K(Tam)--
K(Fam). Image acquired with ambient light. 
 
 
 
Figure 4.16: Distribution of C18-bn-K(Tam)--K(Fam) in aqueous phase in the presence of 
erythrocyte ghosts. Cold ghost buffer (200 µL) containing C18-bn-K(Tam)--K(Fam) (4 µM) 
and 20% hematocrit was incubated on ice for 30 min followed by centrifugation (5000 g
for 5 min) to give supernatant i. The pellet resuspended in cold ghost buffer (200 µL) was
centrifuged to give supernatant ii. Supernatants were diluted in MeOH (1:1 ratio by v:v)
and the fluorescence (λex - λem = 555 nm - 587 nm) of the solutions were compared to 
corresponding fluorescence of C18-bn-K(Tam)--K(Fam) (4 µM) by the identical dilution.   
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Figure 4.17: Trypsin cleavage of C18-bn-K(Tam)--K(Fam) loaded on erythrocyte ghosts with 
and without photolysis as assessed by fluorescence. Samples were excited by 360 nm UV
light from a Hg-Arc lamp source, images were acquired with the X-Nite 525 filter (a) and X-
Nite 590 filter (b). C18-bn-K(Tam)--K(Fam) (4 µM) without photolysis and with trypsin (i); 
with photolysis and with trypsin (ii) after 45 min incubation at 37 oC. Trypsin (10 nM) was 
used in the trypsin experiments. 
 
Figure 4.18: C18-bn-K(Tam)--K(Fam) (4 µM) with erythrocyte ghosts (20% hematocrit) and 
trypsin (10 nM) in the presence (red) and absence (black) of photolysis (3 min). Ac-K(Tam)-
-K(Fam) (4 µM) with erythrocyte ghosts and trypsin (10 nM) was performed in parallel as
reference (blue). Data from a single experiment (a) and average of three experiments (b).
Trypsin addition indicated by the arrow.  
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Finally, we used the light-activatable sensor, C18-bn-K(Tam)--K(Fam), to assess 
endogenous intracellular proteolytic activity of erythrocytes in a light-dependent fashion. 
The control non-lipidated sensor, Ac-K(Tam)--K(Fam), is rapidly proteolyzed in 
erythrocyte lysates as demonstrated by LC-MS analysis (Figure 4.19). Various 
combinations of protease inhibitors were used to confirm the activity and inhibition of 
endogenous proteases acting on the peptide in erythrocyte lysate (Figure 4.20). 
Subsequently, the lipidated protease sensor, C18-bn-K(Tam)--K(Fam) was loaded into the 
inner leaflet of erythrocytes using 2-hydroxypropyl-β-cyclodextrin and buffer tonicity 
manipulation [see loading of C18-bn-K(5Tam) into erythrocyte]. Confocal images of the 
loaded erythrocytes revealed that the lipidated peptide is localized onto erythrocyte 
membrane as indicated by the 5Tam fluorescence (Figure 4.21b). Photolysis with a UV 
light separates the protease peptide substrate from the membrane anchoring moiety 
leading to the release of the unlipidated peptide into the erythrocyte interior (Figure 
4.21e). By contrast, there is no observable presence of the sensor in the interior of 
unphotolyzed erythrocytes. Additionally, photoactivated cells showing a robust increase 
in 5Fam fluorescence indicates degradation of photolyzed protease sensor in the interior 
of erythrocytes (Figure 4.21a, c). The potent combination of protease inhibitors [(EDTA 
(10 mM), leupeptin (100 µM), and MG-132 (100 µM)] blocking the 5Fam fluorescence 
increase in the interior of erythrocytes further confirms the proteolytic activity inside 
erythrocytes (Figure 4.21c). 
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Figure 4.19: (a) LC-MS analysis of Ac-K(Tam)--K(Fam) before (black) and after (red) 
incubation with erythrocyte lysates. ESI+ MS data of (b) peak before and (c) peak after 
incubation. Ac-K(Tam)--K(Fam) (20 µM) was added to 37 oC-preincubated erythrocyte 
whole lysates (200 µL) and fluorescence (λex 495 nm, λem 525 nm) was monitored in the
plate reader until the fluorescence plateaued. HCl (20 µL, 10 M) and MeOH (160 µL) were
then added to the reaction mixture followed by centrifugation filtration (14,000 g for 30
min) using a 3K cutoff filter (Invitrogen). The collected solution was dried and analyzed by
LC-MS on a C18 column. Absorbance was monitored at 550 nm. Major cleaved product
was Ac-K(5Tam)R-OH: C39H49N8O8+ exact mass calculated 757.4, found (ESI+, m/z) 757.3 
(M)+ and 379.2 (M + H)2+. 
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Figure 4.20: Inhibition of protease activities in erythrocyte lysate by different protease 
inhibitors. Erythrocyte whole lysates were prepared by sonication of PBS 1X-containing 
10% hematocrit. “Loading lysates” were the supernatant containing-materials that 
leaked out of erythrocyte during the loading of C18-bn-K(Tam)--K(Fam) (4 µM). Protease 
activity was determined by the rate of cleavage of the fluorescent sensor Ac-K(Tam)--
K(Fam) (1 µM) monitored at λex - λem = 495 nm - 525 nm. Lysates with or without inhibitors 
were preincubated at 37 oC for 5 min before the addition of Ac-K(Tam)--K(Fam) to start 
the reaction.  
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Figure 4.21: Confocal images of erythrocytes loaded with C18-bn-K(Tam)--K(Fam). (i) 
before photolysis, (ii) immediate after photolysis, (iii) 1.5 min after photolysis, and (iv) 13 
min after photolysis. Photolysis was performed with 100 mW, 355 nm laser at the power
level of 1 mW, tornado mode, dwell time of 10 µs/pixel, and 5 frames. Images were
acquired by excitation at (a) 448 nm (5Fam), (b) 559 nm (5Tam) and data collected using 
spectral PMTs set for the fluorophores. c) Average fluorescence (5Fam) inside photolyzed 
erythrocytes (red; n = 30), unphotolyzed erythrocytes (blue; n = 30), and photolyzed 
erythrocytes in the presence of a protease inhibitor cocktail (black; EDTA (10 mM), 
leupeptin (100 µM), and MG-132 (100 µM); n = 14). d) Relative fluorescence increase rate 
of photolyzed and unphotolyzed cells. e) Line scanning fluorescence profile in 5Tam
wavelengths of an erythrocyte loaded with C18-bn-K(Tam)--K(Fam) before (black) and 13 
min after photolysis (red). 
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Study of Cholesterol-Conjugated Coumarin-Based Protease Substrate 
We also examined the light-dependent behavior of a lipidated coumarin-based 
trypsin sensor, 5Tam-K(Chol)-nb-R-AMC. In this case, the lipid anchor is cholesterol and 
the hydrolysis is followed by the coumarin fluorescence (Figure 4.22). The 5Tam 
fluorophore was appended to signal the membrane binding of the lipidated substrate and 
help in analysis with LC-MS. Photolysis of 5Tam-K(Chol)-R-AMC releases the lipid anchor 
from the coumarin trypsin substrate (Figure 4.23). In analogy to the lipidated protease 
substrate C18-bn-K(Tam)--K(Fam), erythrocyte-bound 5Tam-K(Chol)-nb-R-AMC, is not 
susceptible to trypsinolysis. Upon light-exposure of the 5Tam-K(Chol)-nb-R-AMC loaded 
erythrocyte, the trypsin substrate is released from the membrane and rapidly proteolyzed 
by trypsin as indicated by the increase in fluorescence of at coumarin’s wavelengths (λex - 
λem = 354 nm - 442 nm) (Figure 4.24). 
 
Figure 4.22: The inert trypsin sensor 5Tam-K(Chol)-nb-R-AMC is anchored to erythrocyte 
membranes using cholesterol. Photolysis releases the active sensor X-R-AMC that, upon 
trypsinolysis, release fluorescent coumarin derivative. 
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Figure 4.23: (a) LC-MS trace of 5Tam-K(Chol)-nb-R-AMC before (black) and after (red 
photolysis. ESI+ MS data of pure 5Tam-K(Chol)-nb-R-AMC (peak 1, b) and 5Tam-labelled 
photolyzed product (peak 2, c). PBS 1X (100 µL) containing DTT (5 mM) and 5Tam-K(Chol)-
nb-R-AMC (2.5 µM) was photolyzed at 360 nm for 2 min. The sample was then run on the
C4 column. Pure 5Tam-K(Chol)-nb-R-AMC was run as a reference. Absorbance was 
monitored at 550 nm. 5Tam-labelled photolyzed product (peak 2): C59H80N5O7+, exact 
mass calculated (M)+ 970.6, found (ESI+, m/z) 970.5 (M)+. 
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Study of Lipidated Kinase Substrate 
  In addition to protease substrates, we also investigated the susceptibility of a 
membrane-bound protein kinase substrate to phosphorylation. As described in Chapter 
2, the peptide sequence KRRRLASLAA is efficiently phosphorylated on the serine residue 
by PKA. Since the N-terminal lysine residue is not important for substrate recognition,81 
we prepared a lipidated analogue of this sequence, C12-bn-PKA (Figure 4.25). In a manner 
similar to the lipidated protease substrates, more than 98% of the lipidated PKA substrate 
associates with mitochondria after 1 h on-ice incubation (Figure 4.26a). 2 min of 360 nm 
photolysis releases approximately 50% of the mitochondria-embedded peptide (Figure 
4.26b). Furthermore, the relative PKA-catalyzed phosphorylation rates of C12-bn-PKA in 
Figure 4.24: Study of 5Tam-K(Chol)-nb-R-AMC with trypsin and erythrocyte ghosts. (a) 
Erythrocyte ghosts loaded with 5Tam-K(Chol)-nb-R-AMC (2.5 µM). (b) Digestion of 5Tam-
K(Chol)-nb-R-AMC by trypsin as assessed by fluorescence in the presence of erythrocyte
ghosts and no light (black); in the presence of erythrocyte ghosts and 3 min photolysis at 
360 nm (red). (c) Relative digestion rate of 5Tam-K(Chol)-nb-R-AMC bound erythrocyte 
ghosts in the presence and absence of ligtht. PBS 0.1X (200 µL) containing 5Tam-K(Chol)-
nb-R-AMC (2.5 µM)  and DTT (5 mM) was added erythrocyte ghosts (20% hematocrit) 
followed by incubation at 37 oC for 20 min. The suspension was then kept in dark (-
photolysis) or photolyzed (3 min, 360 nm) (+ photolysis) followed by addition of trypsin
(200 nM). Fluorescence of the reaction mixture was monitored in the plate reader (λex -
λem  = 354 - 442 nm, cut-off 435 nm) at 37 oC. 
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the absence of mitochondria, in the presence of mitochondria, and in the presence of 
mitochondria followed by photolysis were assessed by capillary electrophoresis and 
compared. When C12-bn-PKA is free in solution, it is efficiently phosphorylated by PKA. 
On the contrary, mitochondria-bound lipidated PKA substrate is not susceptible to PKA-
catalyzed phosphorylation. The latter, upon photolysis, generates an active PKA sensor 
that undergoes PKA-dependent phosphorylation at a rate 50% of that displayed by C12-
bn-PKA that is free in solution (Figure 4.26d, e). 
Role of peptide charge, lipid, and biological membrane in binding and protection 
  We also investigated the role of peptide charge in membrane binding and the role 
of membrane itself in rendering bioagents from active to inactive upon its binding. Three 
additional lipidated molecules, 5Tam-EEK(Chol)-nb-R-AMC, 5Tam-K(Stear)-nb-R-AMC, 
and 5Tam-EEK(Stear)-nb-R-AMC, which varies in lipid moiety and total molecular charge, 
were synthesized (Figure 2.27)). Interestingly, 5Tam-K(Chol)-nb-R-AMC binds tightly to 
erythrocyte ghosts whereas 5Tam-EEK(Chol)-nb-R-AMC favorably resides in aqueous 
solution (Figure 4.28a, b). In an analogous pattern, a stearoyl group is sufficient to anchor 
 
Figure 4.25: The structure of lipidated PKA sensor C12-bn-PKA and its photolyzed product, 
Suc-PKA. When anchoring to biological membranes, the lipidated PKA sensor is not 
susceptible to phosphorylation. Upon photolysis, the active sensor Suc-PKA is released 
and phosphorylated by PKA. 
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the 5Tam-K-bn-R-AMC peptide to erythrocyte ghosts whereas this anchor is not enough 
to recruit the peptide analog to erythrocyte ghosts when two negatively charge glutamate 
residues is added to the peptide (Figure 4.28 c, d). 
  Additionally, liposomes are unable to render the lipidated kinase substrate 
resistant to phosphorylation (Figure 4.29). This data is consistent with the hypothesis that 
negatively charge protein layer, which covers the erythrocyte membrane, plays a role in 
binding and rendering the peptides inert toward the corresponding enzymes. It is also 
 
Figure 4.26: Study of lipidated PKA sensor with mitochondria and PKA. (a) Distribution of 
C12-bn-PKA in aqueous phase in the presence of mitochondria. (b) Relative amount of the 
lipidated PKA sensor remaining on mitochondria without and with photolysis as assessed 
by fluorescence. Mitochondria loaded with the lipidated PKA sensor was kept in the dark 
or exposed to 2 min of illumination (360 nm) followed by washings with mito buffer, pellet 
solublization in mito buffer and dilution buffer (1:1 by v:v) and fluorescence measurement 
(λex - λem =  492 - 525 nm). (c) Phosphorylation of lipidated PKA sensor by PKA in the 
presence of mitochondria and no light (black); in the presence of mitochondria and UV 
light (red); and in the absence of both mitochondria and UV light (blue) as assessed by 
capillary electrophoresis. (d) Quantification of experiments in (b, c). 
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interesting to note that C18-bn-K(5Tam) tightly binds to mitochondria and erythrocyte 
membranes, even though it has the same total charge as 5Tam-EEK(Chol)-nb-R-AMC and 
5Tam-EEK(Stear)-nb-R-AMC. This observation together with the delay in the release of 
fluorophore from erythrocyte-bound C18-bn-K(5Tam) upon photolysis (Figure 4.7) 
implies that the photolabile linker is likely inserted in the membrane. 
 
 
 
Figure 4.27: Structures of 5Tam-EEK(Chol)-nb-R-AMC, 5Tam-EEK(Stear)-nb-R-AMC, and 
5Tam-K(Stear)-nb-R-AMC.   
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Figure 4.28: Binding of 5Tam-K(Chol)-nb-R-AMC (a), 5Tam-EEK(Chol)-nb-R-AMC (b), 5Tam-
K(Stear)-nb-R-AMC (c), and 5Tam-EEK(Stear)-nb-R-AMC (d) to erythrocyte ghosts. 
Erythrocyte ghosts (1 mL, 10% hematocrit) in PBS 0.1X (a, b) or PBS 1X (c, d) were added 
to ethanol solution (10 uL) containing a lipidated peptide (final peptide concentration 2.5 
µM). The suspension was then mixed at room temperature for 30 min, followed by 
centrifugation (5000 g / 5 min in a, b, or 2000 g / 2 min in c, d). The pellets were washed 
two more times with PBS buffer (1 mL, 0.1X in a, b and 1 mL, 1X in c, d), and resuspended 
in the buffer before imaging.   
 
Figure 4.29: Phosphorylation of C12-bn-PKA by PKA in the presence and absence of 
liposomes as assessed by capillary electrophoresis. HEPES buffer (100 mM, pH 7.3, 20 µL) 
containing liposomes (total lipid concentration 24 mM) or containing no liposome was 
added C12-bn-PKA (9.5 μM). Mixtures were incubated at 28 oC followed by addition of PKA 
(5 nM). Reaction samples were quenched with HCl at 3 min and analyzed by capillary 
electrophoresis. 
 96
Lipidated Peptides and Cellular Uptake Studies with HeLa Cells  
We also synthesized and investigated the cellular uptake of a lipidated peptide, 
C18-bn-K(5Tam)RRRLAALAA-amide (Figure 4.30). 
 
As expected, upon incubation at 4 oC with HeLa cells, the peptide binds to and 
resides on plasma membrane as endocytotic processes are inhibited at low temperature 
(Figure 4.31a, b). Photolyzed cells showing no observable fluorescence increase in the 
interior of the cell compared to that of unphotolyzed cells suggesting that the peptide 
locates exclusively on the outer leaflet of the plasma membrane (Figure 4.31c, d). 
Incubation of the peptide with HeLa cells at 37 oC results in cells containing punctate 
fluorescence (Figure 4.32a), which shows no clear change in fluorescence pattern upon 
photolysis (Figure 4.32b). The observation suggests that the peptide still resides on the 
membrane’s outer leaflet of lipid vesicles and, upon photolysis, the cleaved peptide is 
trapped inside lipid vesicles. Interestingly, treatment of the cells with an endosomal 
disrupting agent, chloroquine, shows no apparent difference in fluorescence pattern 
before and after photolysis (Figure 4.32c, d). The study needs further investigation. 
 
Figure 4.30: Structure of lipidated fluorescent peptide C18-bn-K(5Tam)RRRLAALAA-amide.
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Figure 4.31: Confocal images of HeLa cells treated with C18-bn-K(5Tam)RRRLAALAA-amide
(500 nM) for 2 h at 4 oC. (a, b) before photolysis, (c, d) after 5 min photolysis with a Hg-
Arc lamp using a 360 nm bandpass filter. (b, d) Confocal images acquired with standard
filter setting for 5Tam fluorophore. HeLa cells were incubated with L-15 media containing 
the peptide, washed, and imaged. 
 
Figure 4.32: HeLa cells treated with C18-bn-K(5Tam)RRRLAALAA-amide (500 nM) at 37 oC 
for 0.5 h in the absence of UV light (a), followed by 5 min photolysis (b). HeLa cells treated 
with C18-bn-K(5Tam)RRRLAALAA-amide (500 nM) and chloroquine (100 µM) at 37 oC for 
1.5 h in the absence of UV light (c), followed by 5 min photolysis (d). Photolysis was 
performed with a Hg-Arc lamp using a 360 nm bandpass filter. Confocal images acquired
with standard filter setting for 5Tam fluorophore. 
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Peptide Deliver Using Doubly Labeled Transmembrane Helical Peptides 
We also investigated delivery and photoactivation of peptides using doubly 
labeled transmembrane helical peptides. Since incubation of lipidated peptides with HeLa 
cells (at 4 oC) and erythrocytes shows no detectable outer-to-inner leaflet flipping of the 
peptide, we hypothesized that a transmembrane helical peptide which has bioagents on 
both termini, upon inserting into membrane, will pull one of the cargos across the 
membrane. The energy gained by the helical formation in the membrane’s hydrophobic 
interior would produce the force to drive the cargo across cell membrane (Figure 4.33). 
Two 25-amino acid peptides were synthesized where the length should be 
sufficient to form transmembrane helices. Lipophilic amino acids, leucine and alanine, are 
two major components of the peptides. Leucine residues are separated by five alanine 
residues to further facilitate helix formation upon membrane insertion. In one of the 
peptides, four terminal alanine residues were replaced by arginine to improve peptide 
solubility in aqueous environment. Additionally, two cysteine residues were appended on 
both termini to allow attaching maleimide containing cargos through maleimide-thiol 
conjugation (Figure 4.34). 
 
Figure 4.33: Transmembrane peptide as a membrane inserting agent. A transmembrane
helical peptide appended a bioactive molecule on both sides, upon insertion into the cell
membrane, evenly distributes the bioactive molecule on both sides of the membrane.
Photolabile linkers placed between the transmembrane peptide and bioactive species 
furnishes a means to control the release of the bioactive molecule in a light-dependent
fashion.  
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  Two doubly labelled transmembrane helical peptides were synthesized, Peptide-
anp-Helix1-anp-Peptide and Peptide-anp-Helix2-anp-Peptide by appending the peptide 
sequence K(5Tam)RRRLAALAA-amide to two 25-amino peptides, Cys-Hex1-Cys and Cys-
Hex2-Cys (Figure 4.34, 4.35). Photolabile linkers (anp) were placed between the 
fluorophore-containing peptide and the transmembrane peptide to furnish a means to 
Figure 4.34: Structures of doubly labeled transmembrane helices.  
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release the peptide from the transmembrane helix in a light-dependent fashion (Figure 
4.34). 
 
 Confocal images of HeLa cells incubated with P-H1-P and P-H2-P shows cells with 
punctate fluorescence (Figure 4.36). Interestingly, photolysis with a 405 laser leads to an 
obvious increase in fluorescence at those spots whereas no detectable fluorescence 
increase was observed in cell’s interior (Figure 4.36, circled region). One explanation is 
based on the presumed self-quenching of the two fluorophores on the peptide. Upon 
endocytosis and subsequent photolysis, the two fluorophores are separated, leading to 
the noticeable fluorescence dequenching. We, however, do not eliminate the possibility 
that the peptides inserts properly and distributes the cargo evenly on both side of cell 
membrane. Photolysis releases half of the labeled peptide into cell interior. The 
brightness of the fluorescence spots as well as the dilution effect once the peptide is 
 
Figure 4.35: LC-MS data of doubly labeled transmembrane peptides P-H1-P (a) and P-H2-P
(b). Left: LC-UV traces, right: ESI+ data of the peak in the left.  
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released into cell’s interior might, however, prevent the signal from being captured by the 
confocal microscope. The study needs further investigation. 
 
Conclusion 
We have developed a strategy for constructing light-activatable bioagents by 
cellular membrane sequestration. An active bioagent appended to a lipid binds to 
cells/organelles’ membrane and is resistant to processing by its biological target. 
Photolysis releases it from the membrane anchor and renders it biologically active. This 
 
Figure 4.36: HeLa cells incubated with P-H1-P (1 µM) before photolysis (a) and after 
photolysis in the circle (b); with P-H2-P (1 µM) before photolysis (c) and after photolysis 
(d). HeLa cells incubated with peptide for 30 min. Photolysis was performed in circled 
region using 405 nm laser, 100 us/pixel, 100 frames turnado mode. Fluorescence confocal 
images were acquired using standard filter setting for 5Tam fluorophore. 
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strategy provides a means to control the release of active biomolecules with a high degree 
of spatiotemporal resolution. The construction, however, needs further investigation in 
term of cellular delivery if the bioagent of interest functions inside cells. The role of 
linker’s length between membrane anchoring moiety and bioagent as well as the nature 
of anchor itself in membrane binding and rendering biomolecules inactive is also in need 
of further examination.     
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Materials and Method 
Reagents were purchase as described before unless noted otherwise.  Fmoc-
Lys(NH3+Cl-)-OH was obtained from Bachem; Fmoc photolabile linker, Fmoc-nb-COOH, 
was acquired from Advanced Chemtech. Protease inhibitors were purchased from Sigma-
Aldrich, Enzo Life Science, and Selleckchem. Mitochondria were ordered from 
Mitoscience. 
Purifications 
  HPLC purifications were run on Waters HPLC instrumentation. Flash 
chromatography purifications were run on an Isolera One instrument (Biotage) using a 
silica or C18 column (Biotage). Lipidated molecules, unless otherwise specified, were 
purified by HPLC on a Viva C4 preparative column (5 µM, 250 x 21.2 mm) from Restek. 
Non-lipidated molecules were either purified by C18 flash chromatography or C18 HPLC 
(Apollo C18, 5 µM, 250 x 22 mm column). LC-MS analytical characterizations were run on 
an Agilent instrument equipped with a UV-VIS, fluorescence, and quadrupole mass 
detectors using either a Viva C4 column (5 µM, 50 x 2.1 mm) from Restek or a Prevail C18 
column (3 µM, 50 x 2.1 mm) from Alltech Associates, Inc. All LC-MS experiments were 
conducted using H2O-CH3CN solvents with 0.1% formic acid. 
Fluorescence Assays 
  Fluorescence assays were performed on 96 or 384-well clear bottom plates on a 
SpectraMAX Gemini EM instrument from Molecular Devices or in a cuvette on a 
spectroflurometer from PTI. 
Capillary Electrophoresis 
  Capillary electrophoresis was performed on a ProteomeLab PA800 system 
equipped with a laser-induced fluorescence (LIF) detector (Beckman Coulter). The LIF was 
 104
excited using a 488 nm argon laser. A fused-silica capillary (30/20 cm total/effective 
length, 30 or 50 µM inner diameter) was used for separation (Polymicro Technologies). 
Capillaries were pretreated with 0.1 M NaOH for 12 h, distilled water for 1 h, 0.1 M HCl 
for 6 h and water for 12 h before installation. The samples were hydrodynamically injected 
and separated at a constant voltage of 15 kV using a separation buffer containing 350 mM 
tris, 175 mM tricine, and 20 mM sodium cholate pH 8.5. Before each run, the capillary was 
rinsed with 1 M NaOH (1 min), distilled water (2 min), and the running buffer for 2 min 
under 20 psi pressure. Data was collected and analyzed using 32 Karat Software (Version 
8.0, Beckman Coulter). 
Octanol - Water Partition Studies 
Partition Studies with C18-bn-K(5Tam) 
  Octanol (300 µL) containing C18-bn-K(5Tam) (4 µM) was mixed with of PBS 1X (300 
µL) containing DTT (5 mM) by pipetting then centrifuged (1000 g for 5 min). An image of 
the tube being excited by the UV light from the top was acquired. The test tube was then 
photolyzed for 30 min with mixing every 5 min followed by centrifugation (1000 g for 5 
min) and reimaging. All images were acquired using the X-Nite 590 filter. 
Partition Study with C18-bn-K(Tam)--K(Fam) 
  Octanol (300 µL) containing C18-bn-K(Tam)--K(Fam) (4 µM) was mixed with 300 
µL of PBS 1X containing DTT (5 mM) by pipetting followed by centrifugation (1000 g for 5 
min). Trypsin (20 nM) was gently added to the aqueous phase. The tube was then 
incubated at room temperature for 2.5 h and imaged. The test tube was then photolyzed 
for 10 min with one time mixing at 5 min. After photolysis, the test tube was centrifuged 
at 1000 g for 5 min and then reimaged. Fluorescence images were acquired using X-Nite 
525 and X-Nite 590 filters while the tube was being excited by the UV light from the top. 
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Studies with Mitochondria 
C18-bn-K(5Tam) and mitochondria 
  Mito buffer: 10 mM Tris 7.5, 0.25 M Sucrose, 0.2 mM EDTA. 
  Mitochondria were washed 3 times with mito buffer and resuspended in mito 
buffer to a concentration of 5.5 mg/mL. A 150 µL cold solution of mito buffer containing 
C18-bn-K(5Tam) was sonicated for 3 min to which 50 µL of washed mitochondria (5.5 
mg/mL) was added. The final concentration of C18-bn-K(5Tam)  was 4 µM. The suspension 
was gently mixed and incubated on ice for 30 min. Mitochondria were pelleted by 
centrifugation at 5000 g for 5 min and imaged under ambient light. The pellet was then 
washed with cold mito buffer (200 µL) and resuspended in cold mito buffer (200 µL) 
containing DTT (5 mM). The fluorescence of the contents was imaged after 5 min of 
centrifugation. The contents were then resuspened followed by photolysis (3 min), 
centrifugation, and reimaging. 
C18-bn-K(Tam)--K(Fam), mitochondria, and trypsin 
  A cold mito buffer solution (150 µL) containing C18-bn-K(Tam)--K(Fam) (4 µM) was 
sonicated for 1 min and then 50 µL of washed mitochondria (5.5 mg/mL) was added. The 
suspension was gently mixed and incubated on ice for 30 min. Mitochondria were pelleted 
by centrifugation at 5000 g for 5 min. The supernatant (named supernatant i) was 
collected. The pellet resuspended in 200 µL cold mito buffer, centrifuged to collect 
supernatant ii, and then resuspended in 200 µL cold mito buffer containing DTT (5 mM). 
100 µL of the above suspension was photolyzed for 3 min. 80 µL of the photolyzed or non-
photolyzed suspension was transferred to a 384-well plate and equilibrated at 37 oC for 5 
min. Trypsin (10 nM) was added and the fluorescence change was monitored (λex 492 nm, 
λem 525 nm). A well containing mito buffer (80 µL), mitochondria (1.375 mg/mL), DTT (5 
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mM), Ac-K(Tam)--K(Fam) (4 µM), and trypsin (10 nM) was prepared as a reference. The 
experiments were performed in triplicate. 
C12-bn-K(5Fam)RRRLASLAA-amide, mitochondria and PKA 
  Dilution buffer: 190 mM Tris 7.5, 0.25 M sucrose, 0.25 mM EDTA, 2% SDS. 
Loading study 
  Washed mitochondria (final concentration of mitochondria 0.917 mg/mL) was 
added to mito buffer containing peptide C12-bn-PKA (9.5 μM, 100 μL total volume) 
followed by incubation  on ice 1 h and centrifugation (5000 g for 10 min) to get mito-
supernatant i and pellet. The pellet was then washed twice with mito buffer (100 µL) to 
get mito-supernatant ii and mito-supernatant iii. The mito-supernatants were then 
diluted with dilution buffer (1:1 by v:v) and the fluorescence of the diluted solution (λex 
492 nm, λem 525 nm) compared to fluorescence of a standard solution of C12-bn-PKA in 
the same final buffer. 
Photorelease assessment 
  The peptide mitochondria pellet loaded with C12-bn-PKA was resuspended in 
DTT-contaning mito buffer (100 μL, 5 mM DTT) and photolyzed for 2 min. After 
centrifugation (5000 g / 10 min) the pellet was washed twice by 100 μL mito buffer and 
then dissolved in 50 μL mito buffer + 50 μL dilution buffer. The dissolved photolyzed 
mitochondria solution (10 μL) was diluted in 35 μL mito buffer + 35 μL dilution buffer and 
the solution’s fluorescence was measured (λex 492 nm, λem 525 nm). A parallel sample 
without photolysis was performed as a reference. 
Phosphorylation studies 
  The [C12-bn-PKA]-loaded mitochondria pellet was suspended in mito buffer (420 
µL) containing DTT (5 mM), ATP (1 mM), and MgCl2 (1 mM). The final concentrations were 
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9.5 µM(peptide) and 0.917 mg/mL (mitochondria). An aliquot (40 µL) was quenched with 
HCl 1M (40 µL) followed by photolysis (2 min) and capillary electrophoresis (CE) analysis. 
The suspension was then photolyzed for 2 min followed by addition of PKA (20 nM) and 
the reaction aliquots were quenched and analyzed by CE over time. Another sample [420 
µL mito buffer containing C12-bn-PKA (9.5 µM), DTT (5 mM), ATP (1 mM), and MgCl2 (1 
mM)] was also performed in parallel in which no photolysis was employed before the 
addition of PKA (20 nM). The reaction aliquots were quenched at 30 and 60 min after the 
PKA addition and photolyzed for 2 min followed by CE analysis. A solution of C12-bn-PKA 
(9.5 µM) in mito buffer containing DTT (1 mM), ATP (1 mM), and MgCl2 (1 mM) was added 
PKA (20 nM) and phosphorylation was monitored over time by quenching followed by 
photolysis and CE analysis. Phosphorylated peptide of C12-bn-PKA was generated 
enzymatically and confirmed by LC-MS. Standard photolyzed products were generated by 
3 min photolysis and confirmed by LC-MS. Phosphorylation rates were calculated from 
the percentages of phospho peak over total peptide and the amount of peptide released 
after photolysis acquired from the photorelease studies. 
Studies of C12-bn-PKA with Liposomes 
  DSPC (18:0 PC,1,2-distearoyl-sn-glycero-3-phosphocholine)/CHOL (cholesterol) 
liposomes (55/45 mol/mol, lipid concentration 60 ± 2.5 mM, mean particle diameter 87.3 
± 0.5 nm) were purchased from Formumax. The liposomes were diluted in HEPES buffer 
(100 mM pH 7.3) containing 10% sucrose to a lipid concentration of 24 mM. To a 20 µL 
solution of the liposome was added C12-bn-PKA (9.5 µM), MgCl2 (1 mM), and ATP (1 mM). 
The solution was incubated at 28 oC for 30 min followed by the addition of PKA (5 nM). 
Reaction was quenched at 3 min and analyzed by capillary electrophoresis.  A parallel 
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sample in which 20 µL of HEPES buffer (100 mM, pH 7.3) was used instead of liposome 
suspension was also performed as the reference.  
Studies with Erythrocyte Ghosts 
Erythrocyte ghosts preparation 
  Ghost buffer: PBS 0.1X and 50 mM Tris pH 7.5. Erythrocyte ghosts were prepared 
by washing erythrocytes with cold PBS 0.1X until centrifugation (5000 g for 5 min) gave a 
white to white-yellow pellet. The pellet was then resuspended in the ghost buffer to a 
concentration corresponding to 40% hematocrit. 
C18-bn-K(5Tam) and erythrocyte ghosts 
  Ghost buffer (100 µL) containing C18-bn-K(5Tam)  was sonicated for 3 min. To that 
solution was added erythrocyte ghosts (100 µL, 40% hematocrit). The final concentration 
of C18-bn-K(5Tam) was 4 µM. The suspension was incubated on ice for 30 min followed 
by centrifugation (5000 g for 5 min). The supernatant was discarded, the pellet washed 
with ghost buffer (200 µL), and then resuspended in 200 µL ghost buffer containing 5 mM 
DTT. Images were acquired before and after of photolysis (3 min) using X-Nite 590 filter. 
C18-bn-K(Tam)--K(Fam), erythrocyte ghosts, and trypsin 
  A 100 µL ghost buffer containing C18-bn-K(Tam)--K(Fam) was sonicated for 1 min. 
To that solution were added erythrocyte ghosts (100 µL, 40% hematocrit). The final 
concentration of C18-bn-K(Tam)--K(Fam) was 4 µM. The suspension was incubated on ice 
for 30 min followed by centrifugation (5000 g for 5 min). The supernatant (supernatant i) 
was collected, the pellet was suspended in cold ghost buffer (200 µL), centrifuged to 
collect supernatant ii, and then suspended in 200 µL ghost buffer containing DTT (5 mM). 
100 µL of the above suspension was photolyzed for 3 min. 80 µL of the photolyzed or non 
photolyzed suspension was transferred to a 384-well plate, equilibrated at 37 oC for 5 min 
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followed by addition of trypsin (10 nM) and the fluorescence change was monitored (λex 
492 nm, λem 525 nm). A well containing 80 µL of ghost buffer (20% hematocrit), DTT (5 
mM), Ac-K(Tam)--K(Fam) (4 µM), and trypsin (10 nM) was prepared as a reference. The 
experiments were performed in triplicate. 
Determination of Peptide Concentration in Supernatants  
  Supernatants [C18-bn-K(Tam)--K(Fam) loading on mitochondria and erythrocyte 
ghosts] were diluted with MeOH (1:1 by volume) and the fluorescence of the solution 
compared to the fluorescence of standard C18-bn-K(Tam)--K(Fam) (4 µMin 200 µL mito 
buffer or ghost buffer diluted with 200 µL MeOH; λex 555 nm, λem 587 nm). Standard 
curves were built showing a linear relationship between fluorescence and concentration 
of C18-bn-K(Tam)--K(Fam) (in 50% MeOH and 50% mito buffer or ghost buffer, when the 
concentration of the peptide < 2 µM). 
Studies with Erythrocyte Lysates 
Erythrocyte Whole Lysate Preparation 
  Erythrocytes were washed twice with PBS 1X. 100 µL of washed erythrocytes were 
diluted in 850 µL of cold deionized water. The mixture was sonicated (3 times, 30 s each). 
105.4 µL of PBS 10X was then added to the mixture followed by two additional cycles of 
30 s sonication to obtain whole lysate. The lysate was kept on ice and was made fresh 
before use each day. 
Inhibition of protease activity in erythrocyte lysate 
  To a 200 µL of erythrocyte lysates preincubated at 37 oC for 5 min (with and 
without different protease inhibitors) was added Ac-K(Tam)--K(Fam) (1 µM) and the 
fluorescence changes monitored (37 oC, λex 492 nm, λem 525 nm) over time. 
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LC-MS Confirmation of Digestion of Ac-K(Tam)--K(Fam) by Erythrocyte Whole Lysates 
  Proteolysis of Ac-K(Tam)--K(Fam) (20 µM, 200 µL total volume) in whole lysate 
was monitored in the plate reader until the fluorescence plateaued. HCl (20 µL, 10 M) and 
MeOH (160 µL) were then added to the reaction mixture followed by filtration by 
centrifugation 14,000 g for 30 min using 3K cutoff filter (Invitrogen). The collected solution 
was then dried and analyzed by LC-MS on the C18 column. 
Confocal Microscopy 
  All microscopy experiments were performed at 37 oC on an Olympus FV1000 
scanning confocal with an IX81 microscope base. A Coherent Genesis CX355-100 STM 355 
nm, 100 mW continuous wave UV laser was coupled to the confocal via an installed UV 
port. Laser and region of photolysis were controlled via Fluoview software. Photolysis was 
performed using the stimulation mode of the Fluoview software with images collected 
before and after stimulation. A photolytic dwell time of 10 μs/pixel in tornado mode was 
employed for the defined region of interest using 5 frames at 355 nm and 1 mW power 
level. All imaging was performed with a 100X objective using 488 nm and 559 nm lasers. 
5-Fam was used to generate photobleaching curve. ImageJ software was employed for 
image analyses. Final fluorescence intensity changes of 5-Fam were corrected for 
photobleaching effect by the formula 
  Ft (corrected) = Ft x fo/ft 
Where Ft were fluorescence value measured at time t, fo and ft were fluorescence values 
of bleaching curve at t = 0 and at t. 
Loading of C18-bn-K(5Tam) and C18-bn-K(Tam)--K(Fam) into erythrocytes 
  Erythrocytes were washed 2 times with PBS 1X, centrifuged at 1,400 g for 10 min. 
The supernatant was discarded to furnish the erythrocytes (100% hematocrit). The C18-
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lipidated peptide (4 µM) was dissolved in H2O (125 µL) containing (2-hydroxypropyl)-β-
cyclodextrin (100 mg/mL). To this solution was added the washed erythrocytes (50 µL). 
The mixture was then incubated on ice for 30 min. Cold deionized H2O was added to the 
mixture until centrifugation at 1000 g for 5 min gave no observable pellet (added 300 µL 
of H2O). The mixture was then incubated on ice for 40 min followed by addition of PBS 
10X (52.7 µL) and incubation on ice for additional 2 h. The mixture was then centrifuged 
at 1400 g for 10 min and most of the supernatant collected (475 µL - loading lysate). 2 µL 
of the remaining erythrocyte suspension was resuspended in of PBS 1X (200 µL) 
containing DTT (5 mM) for confocal imaging. 
Loading of C18-bn-K(Tam)--K(Fam) into erythrocytes with protease inhibitors 
  The procedure was identical to loading of C18-bn-K(Tam)--K(Fam) into 
erythrocytes except, in this case, 125 µL H2O containing (2-hydroxypropyl)-β-cyclodextrin 
(100 mg/mL) also contains EDTA (10 mM), leupeptin (100 µM), and MG-132 (100 µM). 
Syntheses 
Synthesis of Lipidated Photolabile Linker C18-bn-COOH 
 
Scheme 4.1: Synthesis of lipidated photolabile linker C18-bn-COOH. 
  Octadecylamine (270 mg, 1.00 mmol) was dissolved in 5 mL DMF (with a small 
amount of CH2Cl2 to help dissolve the compound). To the above solution was added DIPEA 
(1.65 mL, 10 mmol) and a DMF solution containing Fmoc-nb-COOH (580 mg, 1.11 mmol) 
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and HCTU (463 mg, 1.12 mmol). The reaction was mixed for 30 min and stopped by 
addition of H2O (2 mL). The mixture containing product Fmoc-nb-C18 was added 
piperidine (2 mL, 20 mmol) and mixed for 1 h to deprotect the Fmoc group. The reaction 
mixture containing NH2-nb-C18 was dried under vacuum and redissolved in DMF (5 mL). 
DIPEA (1.65 mL, 10 mmol) was added to the crude solution of NH2-nb-C18 in DMF 
followed by addition of succinic anhydride (1 g, 10 mmol). The mixture was stirred for 4 h 
then extracted with H2O:EtOAc after neutralizing the pH of the aqueous phase to 5 with 
HCl 10 M. The EtOAc extract containing C18-bn-COOH was dried and purified by flash 
chromatography using silica column and CH2Cl2:MeOH= 90:10 with 0.1% TFA. 1H NMR 
(600 MHz, DMSO-d6) δ 12.03 (s, 1 H), 8.57 (d, J = 7.4 Hz, 1 H), 7.83 (t, J = 5.4 Hz, 1 H), 7.47 
(s, 1 H), 7.16 (s,1 H), 5.34 (quin, J = 6.8 – 7.1 Hz, 1 H), 4.00 (t, J = 6.4 Hz, 2 H), 3.91 (s, 3 H), 
3.01 (q, J = 6.2 – 6.6 Hz, 2 H), 2.40-2.32 (comp, 4 H), 2.21 (t, J = 7.4 Hz, 2 H), 1.93 (quin, J = 
6.6 – 7.1 Hz, 2 H), 1.38 (d, J = 6.9 Hz, 3 H), 1.36 (comp, 2H), 1.22 (comp, 30 H), 0.85 (t, J = 
6.9 Hz, 3 H); 13C NMR (600 MHz, DMSO-d6) δ 173.8, 171.2, 170.4, 153.4, 146.2, 139.8, 
135.7, 109.3, 108.2, 68.3, 56.1, 44.2, 40.1, 38.4, 31.6, 31.3, 29.8, 29.1-29.0 (comp), 28.8, 
28.7 (comp), 26.4, 24.8, 22.1, 21.9, 14.0; C35H59N3O8. Exact mass calculated (M) 649.43, 
found (ESI+, m/z) 650.4 (M + H)+, 672.4 (M + Na)+. 
Synthesis of C18-bn-K(5Tam) 
Synthesis of NH2-K(5Tam) 
  To a solution of 5Tam (17.8 mg, 41.3 µmol) in DMF was added HCTU (41.2 µmol) 
and DIPEA (200 µmol) dissolved in DMF. The reaction mixture was incubated at room 
temperature for 2 min to preactivate 5Tam. To a DMF solution containing Fmoc-
Lys(NH3+Cl-)-OH (40.9 mg, 101 µmol) was added DIPEA (200 µmol) followed by addition of 
HCTU-activated 5Tam solution above (final volume ~ 3 mL). The reaction was shaken at 
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room temperature for 30 min followed by the addition of H2O (1 mL) to stop the reaction. 
Piperidine (700 µmol) was then added to the reaction mixture, which was shaken for 30 
min to deprotect the Fmoc group on Lys. DMF and piperidine were removed by 
lyophilization. The crude mixture was then purified by flash chromatography using a C18 
column with a H2O:CH3CN gradient from 0% to 50% of CH3CN in 15 column void volumes 
to afford NH2-K(5Tam). 1H NMR (600 MHz, D2O) δ 8.41 (d, J = 1.7 Hz, 1 H), 8.06 (dd, J = 
7.8, 1.7 Hz, 1 H), 7.52 (d, J = 7.8 Hz, 1 H), 7.13 (d, J = 9.5 Hz, 2 H), 6.81 (dd, J = 9.5, 2.3 Hz, 
2 H), 6.38 (s, 2 H), 3.84 (t, J = 6.1 Hz, 1 H), 3.47 (t, J = 6.9 Hz, 2 H), 3.07 (s, 12 H), 1.99 - 1.89 
(comp, 2 H), 1.72 (quin, J = 7.2 – 7.7 Hz, 2 H), 1.58 – 1.44 (comp, 2 H); C31H35N4O6+ Exact 
mass calculated 559.26; found (ESI+, m/z) 559.2 (M)+, 280.1 (M + H)2+. 
 
Synthesis of C18-bn-K(5Tam) 
  To a 500 µL DMF solution (with a small amount of CH2Cl2 to help dissolve the 
compound) containing C18-bn-COOH (7 mg, 10.77 µmol) was added DIPEA (21 µmol) and 
HCTU (8.5 µmol). The reaction mixture was shaken for 2 min. To a 5 mL DMF solution of 
NH2-K(5Tam) (8.5 µmol) was added DIPEA (85 µmol) followed by addition of HCTU-
activated C18-bn-COOH solution above. The reaction mixture was shaken for 5 min then 
 
Scheme 4.2: Synthesis of C18-bn-K(5Tam). 
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quenched by addition of H2O (1 mL). Solvent and excess reagents were removed under 
vacuum. The crude material was purified by HPLC on the C4 column using H2O:CH3CN with 
0.1% TFA to afford C18-bn-K(5Tam). C66H92N7O13+. Exact mass calculated 1190.67, found 
(ESI+, m/z) 1190.7 (M)+, 595.9 (M + H)2+. 
Synthesis of Protease Fluorescent Substrates Ac-K(Tam)--K(Fam) and C18-bn-K(Tam)--
K(Fam) 
  Solid phase peptide synthesis (SPPS) was performed on a Prelude peptide 
synthesizer from Protein Technology using Fmoc-protected amino acids (amino acids 3 
eq., HCTU 2.95 eq., DIPEA 10 eq. in DMF, double coupling in 20 and 40 min). Fmoc 
deprotection was performed using piperidine (25%) in DMF (3 times, 10 min each). The 
peptide containing a Lys side chain protected with the acid sensitive 4-methyltrityl group 
(Mtt), Boc-K(Fmoc)RRRLAALAAK(Mtt), was synthesized on a NovaSyn TGR resin using  
SPPS. The Fmoc protecting group on the lysine residue was deprotected by piperidine 
(25%) in DMF followed by coupling of 5-Tam fluorophore using 5-Tam (1.5 eq.), HCTU (1.5 
eq.), and DIPEA (10 eq.) in DMF for 4 h. The Mtt was removed with 1% trifluoroacetic acid 
(TFA) in CH2Cl2 followed by coupling 5-Fam using 5-Fam (1.5 eq.), N,N′-
diisopropylcarbodiimide (DIC, 1.7 eq.), and 1-hydroxybenzotriazole (HOBt, 10 eq.) in DMF 
for 2 h. The peptide was then cleaved from the resin with TFA:H2O:Triisopropylsilane in a 
ratio of 95:2.5:2.5, and purified by HPLC using H2O:CH3CN with 0.1% TFA to afford NH2-
K(5Tam)RRRLAALAAK(5Fam)-amide. Solution of pure NH2-K(5Tam)RRRLAALAAK(5Fam)-
amide was acidified with HCl and dried. C100H135N24O22+. Exact mass calculated 2024.02, 
found (ESI+, m/z) 675.3 (M + 2H)3+, 506.6 (M + 3H)4+, 405.6 (M + 4H)5+. 
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Synthesis of Ac-K(Tam)--K(Fam) 
  Dried NH2-K(5Tam)RRRLAALAAK(5Fam)-amide (0.55 µmol) was redissolved in 
DMF (500 µL). To this solution was then added DIPEA (5.5 µmol) and Ac2O (5.5 µmol). The 
reaction mixture was shaken at room temperature for 1 h. H2O (500 µL) was then added 
and the mixture shaken for 30 min. Piperidine (27.5 µmol) was then added and the 
mixture shaken for 30 min. Solvent and excess reagents were removed under vacuum and 
the crude product purified by HPLC using the C18 column to afford pure Ac-K(Tam)--
K(Fam). C102H137N24O23+. Exact mass calculated 2066.03, found (ESI+, m/z) 1033.6 (M + 
H)2+, 689.2 (M + 2H)3+, 517.2 (M + 3H)4+, 414.0 (M + 4H)5+. 
 
Scheme 4.3: Synthesis of protease fluorescent substrates Ac-K(Tam)--K(Fam) and C18-
bn-K(Tam)--K(Fam). 
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Synthesis of C18-bn-K(Tam)--K(Fam) 
  C18-bn-COOH (21.5 mg, 33 µmol), HCTU (12.4 mg, 30 µmol), and DIPEA (10.9 µL, 
66 µmol) were dissolved in minimum amount of DMF (with a small amount of CH2Cl2 to 
help dissolve the compound) and the solution was stirred for 2 min. The HCTU-activated 
C18-bn-COOH was then added to DMF (20 mL) containing NH2-
K(5Tam)RRRLAALAAK(5Fam)-amide (22 µmol) and DIPEA (220 µmol). The reaction 
mixture was shaken at room temperature for 20 min. H2O (0.5 mL) was then added to the 
reaction mixture, which was then shaken for 30 min followed by addition of piperidine 
(110 µL, 1.1 mmol) and 30 min stirring. Solvent and excess reagents were then removed 
under high vacuum and crude product purified by HPLC on the C4 column to afford pure 
C18-bn-K(Tam)--K(Fam). C135H192N27O29+. Exact mass calculated 2655.44, found (ESI+, 
m/z) 1328.3 (M + H)2+, 885.9 (M + 2H)3+, 664.6 (M + 3H)4+, 531.9 (M + 4H)5+. 
Synthesis of 5Tam-K(Chol)-nb-R-AMC 
Synthesis of Fmoc-K(Chol)-OH. 
 
  
 
Scheme 4.4: Synthesis of Fmoc-K(Chol)-OH. 
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To a DMF solution containing Fmoc-Lys(NH3+Cl-)-OH (1.00 g, 2.47 mmol) was added DIPEA 
(10 mmol) followed by the addition of cholesteryl chloroformate  (554 mg, 1.23 mmol). 
The reaction was shaken at room temperature for 2 h followed by the addition of H2O and 
extraction with CH2Cl2. Organic extract was dried and the residue was purified by flash 
chromatography using a silica column and CH2Cl2 95:5 with 0.1% acetic acid to afford 
Fmoc-K(Chol)-OH. C49H68N2O6. Exact mass calculated (M) 780.5, found (ESI+, m/z) 803.5 
(M + Na)+. 
Synthesis of NH2-R(pbf)-AMC 
 
Scheme 4.5: Synthesis of NH2-R(pbf)-AMC. 
  NH2-R(pbf)-AMC was synthesized followed the procedure reported in Pept. Res. 
9(2): 92-6. Briefly, 7-amino-4-methylcoumarine (250 mg, 1.43 mmol) and Fmoc-R(pbf)-OH 
(670 mg, 1.43 mmol) were dissolve in pyridine, which was dried over KOH pellets and 
redistilled right before use. This solution was cooled by dried ice and POCl3 (1.7 mmol) 
was added dropwise under vigorous stirring. Crushed ice was added after 30 min followed 
by extraction with ethyl acetate. The organic phase was washed 3 times with water 
followed by solvent removal. The residue was then redisolved in DMF containing 
piperidine (25%) to deprotect the Fmoc group. The reaction was mixed at room 
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temperature for 30 min followed by solvent removal and purification using C18 flash 
chromatography with H2O:CH3CN gradient to afford NH2-R(pbf)-AMC. C29H37N5O6S. Exact 
mass calculated (M) 583.2, found (ESI+, m/z) 1167.5 (2 M + H)+, 584.2 (M + H)+, 292.6 (M 
+ 2H)2+. 
Synthesis of 5Tam-K(Chol)-nb-R-AMC 
 
 
Scheme 4.6: Synthesis of 5Tam-K(Chol)-nb-R-AMC. 
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  5Tam-K(Chol)-bn-COOH was synthesized on resin using 2-chlorotrityl chloride 
resin (Novabiochem). Briefly, Fmoc-nb-COOH (1.2 eq.) was dissolved in dried CH2Cl2 (with 
the help of a small amount of dried DMF). This solution was then added to the 2-
chlorotrityl chloride resin (1 eq.) followed by the addition of DIPEA (5 eq.). The reaction 
was then shaken at room temperature for 2 h. Fmoc were removed by piperidine (25% in 
DMF, 3 times, 10 min each). Fmoc-K(chol)-OH was coupled using amino acid (3 eq.), HCTU 
(2.95 eq.), and DIPEA (10 eq.) in DMF (with a small amount of CH2Cl2) for 4 h. 5Tam was 
coupled using 5Tam (1.5 eq.), HCTU (1.5 eq.), and DIPEA (10 eq.) in DMF for 4 h. 5Tam-
K(Chol)-bn-COOH  was cleaved off the resin using 2% TFA and 5% TIS in CH2Cl2. Following 
the neutralization of TFA with DIPEA, CH2Cl2 was removed and the residue was purified 
by flash chromatography using C18 column and H2O:MeOH gradient containing 0.1 % TFA 
to afford 5Tam-K(Chol)-bn-COOH. C72H95N6O13+, exact mass calculated (M)+ 1251.7, found 
(ESI+, m/z) 1251.8 (M)+. 
  5Tam-K(Chol)-bn-COOH (1 eq.) was coupled to NH2-R(pbf)-AMC in DMF using 
NH2-R(pbf)-AMC (1.5 eq.), HCTU (1.1 eq.), and DIPEA (10 eq.) for 30 min followed by water 
precipitation and extraction with CH2Cl2. The organic extract was washed with H2O three 
times, dried, and treated with TFA:TIS:H2O = 95:2.5:2.5 for 1 h followed by another cycle 
of water precipitation and extraction with CH2Cl2. The organic phase was washed with 
H2O 3 times, dried and purified on C4 column afforded 5Tam-K(Chol)-bn-R-AMC. 
C88H114N11O15+, exact mass calculated (M)+ 1564.8, found (ESI+, m/z) 783.2 (M + H) 2+. 
Synthesis of 5Tam-K(Stear)-nb-R-AMC 
  5Tam-K(Stear)-nb-COOH was synthesized on resin using 2-chlorotrityl chloride 
resin (Novabiochem, Fmoc-nb-COOH (1.2 eq.) was dissolved in dried CH2Cl2 (with the help 
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of a small amount of dried DMF). This solution was then added to the 2-chlorotrityl 
chloride resin (1 eq.) followed by the addition of DIPEA (5 eq.). The reaction was then 
shaken at room temperature for 2 h. Following Fmoc removal with piperidine (25% in 
DMF, 3 times, 10 min each), Fmoc-K(ivDde)-OH (5 eq.) was coupled using HCTU (4.9 eq.) 
and DIPEA (10 eq.) in DMF for 1 h. 5Tam (1.5 eq.) was coupled using HCTU (1.5 eq.) and 
DIPEA (10 eq.) in DMF for 4 h.  The ivDde protecting group was then removed (2% 
hydrazine in DMF, 5 min, 5 times) and stearic acid (10 eq.) was coupled using HCTU (9.5 
eq.) and DIPEA (20 eq.) for 2 h. 5Tam-K(Stear)-nb-COOH was cleaved off the resin using 
2% TFA and 5% TIS in CH2Cl2. Following the neutralization of TFA with DIPEA, CH2Cl2 was 
removed and the residue was purified by reverse phase chromatography using H2O:MeOH 
gradient containing 0.1 % TFA. 5Tam-K(Stear)-nb-COOH, C62H85N6O12+, exact mass 
calculated (M)+ 1105.6, found (ESI+, m/z) 1105.7 (M)+, 553.5 (M+H)2+. 
  5Tam-K(Stear)-nb-COOH (1 eq.) was coupled to NH2-R(pbf)-AMC (1.5 eq.) in DMF 
using HCTU (1.1 eq.) and DIPEA (10 eq.), for 30 min, followed by water precipitation and 
extraction with CH2Cl2. The organic extract was washed with H2O three times, dried and 
roughly purified by C18 reverse phase flash chromatography using H2O:MeOH with 0.1% 
of TFA solvent system. The formation of 5Tam-K(Stear)-nb-R(pbf)-AMC was confirmed by 
LC-MS. 5Tam-K(Stear)-nb-R(pbf)-AMC, C91H120N11O17S+, exact mass calculated (M)+ 
1670.9, found (ESI+, m/z) 836.0 (M+H)2+. 
  The fraction containing 5Tam-K(Stear)-nb-R(pbf)-AMC was dried and treated with 
TFA:TIS:H2O = 95:2.5:2.5 for 1 h. The reaction was then dried and the residue was purified 
purified on C4 column to yield 5Tam-K(Stear)-nb-R-AMC. C78H105N11O142+, exact mass 
calculated 1419.8, found (ESI+, m/z) 1418.9 (M-H)+, 710.2 (M)2+. 
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Scheme 4.7: Synthesis of 5Tam-K(Stear)-nb-R-AMC. 
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Synthesis of 5Tam-EEK(Stear)-nb-R-AMC and 5Tam-EEK(Chol)-nb-R-AMC 
  5Tam-EEK(Stear)-nb-R-AMC and 5Tam-EEK(Chol)-nb-R-AMC were synthesized 
following procedures similar to that of 5Tam-K(Stear)-nb-R-AMC and 5Tam-K(Chol)-nb-
R-AMC, respectively, except that the two glutamate residues were coupled to the peptide 
before the coupling of 5Tam. Glutamate residues were coupled to the peptide using 
Fmoc-Glu(OtBu)-OH (5 eq.), HCTU (4.9 eq.), DIPEA (10 eq.), 1 h coupling. 5Tam-
EEK(Stear)-nb-R-AMC, C88H117N13O20, exact calculated mass 1675.9, found (ESI+, m/z) 
839.3 (M+2H)2+, 5Tam-EEK(Chol)-nb-R-AMC, C98H127N13O21, exact calculated mass 1821.9, 
found (ESI+, m/z) 912.2 (M+2H)2+. 
Synthesis of C12-bn-PKA 
 
  
Scheme 4.8: Synthesis of C12-bn-PKA. 
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Synthesis of C12-bn-COOH 
  Procedure used to synthesize C18-bn-COOH was applied to synthesized C12-bn-
COOH, in which dodecylamine was used instead of octadecylamine. C12-bn-COOH: 1H 
NMR (400 MHz, DMSO-d6) δ 8.56 (d, J = 7.6 Hz, 1 H), 7.82 (t, J = 5.4 Hz, 1 H), 7.48 (s, 1 H), 
7.17 (s,1 H), 5.35 (quin, J = 6.8 – 7.2 Hz, 1 H), 4.02 (t, J = 6.4 Hz, 2 H), 3.92 (s, 3 H), 3.02 (q, 
J = 6.0 – 6.8 Hz, 2 H), 2.42-2.32 (comp, 4 H), 2.22 (t, J = 7.4 Hz, 2 H), 1.94 (quin, J = 6.0 – 
7.2 Hz, 2 H), 1.38 (d, J = 7.2 Hz, 3 H), 1.36 (comp, 2H), 1.23 (comp, 18 - 20 H), 0.86 (t, J = 
6.8 Hz, 3 H); C29H47N3O8, exact mass calculated (M) 565.34, found (ESI+, m/z) 566.3 (M + 
H)+, 588.3 (M + Na)+. 
Synthesis of C12-bn-PKA 
  Fmoc-K(Mtt)RRRLASLAA, was synthesized on a NovaSyn TGR resin using SSPPS. 
The Fmoc group was deprotected by piperidine (25%) in DMF followed by coupling of C12-
bn-COOH (5 eq.), HCTU (4.9 eq.), and DIPEA (10 eq.) in DMF for 4 h. The Mtt was removed 
with 1% TFA in CH2Cl2 followed by coupling 5Fam using 5Fam (1.5 eq.), N,N′-
diisopropylcarbodiimide (DIC, 1.7 eq.), and 1-hydroxybenzotriazole (HOBt, 10 eq.) in DMF 
for 2 h. The resin was treated with piperidine then dried. The peptide was then cleaved 
from the resin with TFA: H2O:Triisopropylsilane in a ratio of 95:2.5:2.5, and purified by 
HPLC on C18 using H2O:CH3CN with 0.1% TFA to afford C12-bn-PKA. C98H148N24O24, exact 
mass calculated (M) 2045.11, found (ESI+, m/z) 1024.1 (M + 2H)2+, 683.0 (M + 3H)3+, 512.5 
(M + 4H)4+. 
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Synthesis of Mal-anp-K(5Tam)RRRLAALAA-amide 
Fmoc-anp-K(Mtt)RRRLAALAA sequence was synsthesized on resin using Fmoc-protected 
amino acids (amino acids 3 eq., HCTU 2.95 eq., DIPEA 10 eq. in DMF, double coupling in 
20 and 40 min). Fmoc deprotection was performed using piperidine (25%) in DMF (3 
times, 10 min each). The lysine residue is side chain protected with the acid sensitive 4-
methyltrityl group (Mtt). The Mtt group was deprotected with 1% of TFA in CH2Cl2 
followed by coupling of 5Tam fluorophore using 5Tam (1.5 eq.), HCTU (1.5 eq.), and DIPEA 
(10 eq.) in DMF for 4 h. The Fmoc protecting group was then deprotected with piperidine 
(25%) followed by coupling of 4-maleimidobutyric acid (carboxylic acid 5 eq., HCTU 4.9 
eq., DIPEA 10 eq.  in DMF, 1 h coupling). The peptide was then cleaved from the resin with 
TFA:H2O:TIS in a ratio of 95:2.5:2.5 (by volume), and purified by HPLC using H2O:CH3CN 
with 0.1% TFA to yield Mal-anp-K(5Tam)RRRLAALAA-amide. C90H129N26O20+, Exact mass 
calculated (M)+ 1894.0, found (ESI+, m/z) 948.1 (M+H)2+, 632.2 (M+2H)3+, 474.4 (M+3H)4+. 
 
Scheme 4.9: Synthesis of Mal-anp-K(5Tam)RRRLAALAA-amide. 
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Synthesis of Cys-Hex1-Cys and Cys-Hex2-Cys 
  Cys-Hex1-Cys and Cys-Hex2-Cys were synthesized on NovaPEG Rink Amide resin 
and DMF solvent. The first Cys amino acid was coupled to NovaPEG Rink Amide resin (1 
eq.) using Fmoc-Cys(Trt)-OH (8 eq.) 3.5 min-preactivated with HOBt (16 eq.) and DIC (8 
eq.), 1 h coupling. Other amino acids were coupled using amino acid (4 eq.), HCTU (3.92 
eq.), and DIPEA (10 eq.), double coupling for 20 and 40 min. Deprotection was 
accomplished by treatment with piperidine (25%) in DMF for 30 min. Acetylation was 
performed using acetic anhydride (10 eq.) and DIPEA (25 eq.) for 30 min. After the 
acetylation step, the peptides were cleaved off the resin using mixture TFA:TIS:H2O = 
95:2.5:2.5 (by volume). The formation of peptides was confirmed by LC-MS. Crude peptide 
was dried and stored for further synthesis. Cys-Hex1-Cys, C110H200N46O28S2, exact mass 
calculated (M) 2677.5, found (ESI+, m/z) 894.0 (M+3H)3+, 670.8 (M+4H)4+, 536.7 (M+5H)5+, 
447.5 (M+6H)6+. Cys-Hex2-Cys, C98H172N34O28S2, exact mass calculated (M) 2337.3, found 
(ESI+, m/z) 1170.2 M+2H)2+, 780.3 (M+3H)3+. 
Synthesis of P-H1-P and P-H2-P 
  Mal-anp-K(5Tam)RRRLAALAA-amide was dissolved in PBS 1X solution containing 
EDTA (10 mM) to which crude Cys-Hex1-Cys or Cys-Hex2-Cys (dissolved in DMF right 
before the reaction) was slowly added. The reaction was followed by LC-MS until no Mal-
anp-K(5Tam)RRRLAALAA-amide was detected. The reaction mixtures were then purified 
by HPLC [C18 column, CH3CN:H2O gradient containing TFA (0.1%)]. P-H1-P, 
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C290H458N98O68S22+, exact mass calculated (M)2+ 6465.5, found (ESI+, m/z) 1078.7 
(M+4H)6+, 924.7 (M+5H)7+, 809.3 (M+6H)8+, 719.5 (M+7H)9+, 647.7 (M+8H)10+, 588.9 
(M+9H)11+, 539.9 (M+10H)12+. P-H2-P, C278H430N86O68S22+, exact mass calculated (M)2+ 
6125.2, found (ESI+, m/z) 1022.0 (M+4H)6+, 876.2 (M+5H)7+, 766.8 (M+6H)8+, 681.7 
(M+7H)9+, 613.6 (M+8H)10+. 
 
 
 
 
Scheme 4.10: Synthesis of P-H1-P and P-H2-P. 
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CHAPTER 5: ERYTHROCYTES AS CARRIERS FOR LIGHT-ACTIVATABLE THERAPEUTICS 
  Over the past few years, peptides have gained significant attention as drugs.87 The 
ready availability of peptides as initial scaffolds for further modification accelerates the 
process of finding and optimizing peptides as potential drug candidates. Additionally, 
large peptide libraries, which can be conveniently produced both chemically and 
biochemically provide an alternative way to screen for new drugs. Peptides, however, 
possess poor oral availability, mainly due to their poor stability and poor intestinal 
adsorption. Intravenous administration, which delivers peptides directly into blood 
stream, is insufficient since peptides can be degraded by peptidases in plasma and cleared 
from blood stream by renal filtration. The bloodstream half-life of peptides is very short, 
typically a few minutes. 
  Significant effort has been put into extending the circulation time of peptides. 
Peptides have been rendered resistant to proteolytic processing by chemical 
substitution/intramolecular cyclization.87 Confining peptide drugs within liposomes or 
nanoparticles to prevent them from being degraded and cleared before releasing them at 
the site of action is also an appealing approach.88 Finally, both covalent and noncovalent 
conjugation of peptides to macromolecules such as polyethylene glycol or plasma 
proteins to stabilize them and prevent them from renal clearance have also been 
explored.87, 89 These strategies, however, still have some limitations. For instance, making 
peptides resistant to peptidases, on one hand lengthens their circulation time, but on the 
other hand could potentially increase the toxicity since they can now have off-target 
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effects and accumulate in specific organs such as the kidney and liver. Liposome and 
nanoparticle carriers, in addition to toxicity, also potentially trigger immune response. 
In this Chapter, we report the results of an on-going project to stabilize and 
photodeliver peptide therapeutics using erythrocytes as carriers. Sequestration of 
peptide therapeutics to the erythrocyte membranes by lipidation protects them from 
proteolysis. Insertion of a photolabile linker between the lipid anchor and peptide drugs 
furnishes the means to control the release of active drug using light. 
 
Results and Discussion 
Studies of CP-nb-Stear 
  We first investigated if a cell permeable peptide can be kept from entering cells by 
sequestration to the cell membrane of erythrocytes, followed by controlled release with 
Figure 5.1: General strategy of delivery peptide drug using erythrocytes as carriers. 
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light using a photolabile group. This would represent an appealing strategy to selectively 
deliver potent cell-permeable drugs to a specific location.  Based on Dr. Melanie 
Priestman’s observation that the peptide 5Tam-Aoc-GRTGRRFSY-amide was taken up by 
HeLa cells, a lipidated version of this peptide was synthesized, CP-nb-Stear (Figure 5.2). A 
stearoyl moiety was appended to the peptide’s C-terminal to facilitate membrane 
binding. A 2-nitrobenzyl photolabile linker (nb) was inserted between the peptide and 
lipid to furnish a means to release the peptide from the membrane in a light-dependent 
fashion. The fluorophore 5Tam is attached to the peptide’s N-terminal to allow 
degradation detection by fluorescence (Figure 5.2). Photolysis of CP-nb-Stear produced 
peptide 5Tam-Aoc-GRTGRRFYS-amide (Figure 5.2, 5.3). 
 
 
 
Figure 5.2: Structures of cell-permeable peptide 5Tam-Aoc-GRTGRRFSY-amide and its 
photolabile lipidated counterpart CP-nb-Stear.  
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  Though protection from proteolysis was confirmed when CP-nb-Stear was bound 
to erythrocyte membranes (Figure 5.4), significant transfer of the peptide from the 
erythrocyte to HeLa cells in the absence of UV light is also observed (Figure 5.5). This 
observation together with the noticeable residual degradation of the peptide in the 
presence of erythrocyte without light is consistent with the hypothesis that the peptide 
dissociates from membrane-bound state. When the peptide is free in solution, it can 
associate with HeLa cells and/or be processed by proteases in solution. 
Figure 5.3: LC-MS analysis of CP-nb-Stear before (a) and after (b) 2 min photolysis. PBS 1X 
(200 µL) containing CP-nb-Stear (2.1 µM) was photolyzed for 3 min using a Hg-Arc lamp 
with 360 nm bandpass filter. Left: fluorescence traces; right: ESI+ mass data of the peak in 
the left. 
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Study with Phospholipid-Conjugated Peptide 
Construction of Phospholipid-Conjugated Counterpart of 5Tam-Aoc-GRTGRRFSY-amide 
  We investigate if increasing the hydrophobicity of the lipid anchor prevents the 
membrane-bound peptide from transferring between cells and undergoing proteolysis in 
the dark. A phospholipid appended maleimide, Dipal-Mal, was synthesized (Figure 5.6). 
 
Figure 5.4: Degradation of 5Tam-Aoc-GRTGRRFSY-amide (red) and CP-nb-Stear (black) in 
human plasma (5% in PBS 1X) in the presence of erythrocytes as assessed by LC-MS 
coupled to a fluorescence detector. Peptide concentration is 2.5 µM. See Materials and 
Method for details. 
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Figure 5.5: Transfer of erythrocyte-bound CP-nb-Stear to HeLa cells upon incubation in the 
absence of UV light. (a) DIC image, (b) Fluorescence image. 
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The maleimide group provides a convenient way of conjugating the phospholipid to any 
peptide with a free thiol residue (Figure 5.6). 
 
With this strategy of construction, we synthesized peptide CP-nb-Dipal (Figure 
5.7a). Formation of the conjugated peptide was confirmed by LC-MS. Photolysis of CP-nb-
Dipal produced the cell-permeable peptide 5Tam-Aoc-GRTGRRFSY-amide (Figure 5.7). 
  As expected, in the absence of UV light, peptide transfer from erythrocytes to HeLa 
cells was not detected when erythrocytes loaded with CP-nb-Dipal are incubated with 
HeLa cells. Upon photolysis with UV light, the peptide 5Tam-Aoc-GRTGRRFSY-amide is 
cleaved from erythrocyte membrane and readily taken up by HeLa cells (Figure 5.8). 
 
 
Figure 5.6: General strategy of synthesis phospholipid-conjugate peptide. 
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Figure 5.7: Photolysis of CP-nb-Dipal as assessed by LC-MS. Structure of CP-nb-Dipal and 
its photolyzed product (a), LC-MS of CP-nb-Dipal before (i) and after photolysis (ii). CP-nb-
Dipal (1 µM) in water (200 µL) was photolyzed using a Hg-Arc lamp and a 360 nm bandpass 
filter. 
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  Furthermore, CP-nb-Dipal was protected from degradation by trypsin (1 nM) and 
chymotrypsin (5 nM) when bound to erythrocytes, whereas the nonlipidated counterpart 
was completely processed after few mininutes of incubation under the same conditions 
(Figure 5.9). When the concentration of trypsin was increased to 5 nM, detectable 
degradation of the phospholipid-conjugated peptide was observed even in the presence 
of erythrocytes and without UV light. However, under these conditions, the protein layer 
covering erythrocyte membrane might be compromised due to proteolysis. 
 
Figure 5.8: Study of hemoglobin-free erythrocytes loaded with CP-nb-Dipal and HeLa cells 
with and without photolysis. Confocal images of HeLa cells after incubating with 
erythrocytes loaded with CP-nb-Dipal peptide in the presence and absence of UV light. (a,
d) 5Tam fluorescence; b, e) Hoechst 33342 fluorescence; (c, f) overlay. (a, b, c) no UV light; 
d, e, f) 30-minute UV photolysis using a Hg-Arc lamp and a 360 nm bandpass filter. 
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Study with Phospholipid-Conjugated Alpha-Melanocyte-Stimulating Hormone (α-MSH) 
  We also examined protection and activation of alpha-melanocyte-stimulating 
hormone (α-MSH) using the membrane sequestration strategy. There is compelling data 
suggesting that α-MSH will be a potent anti-inflammatory agent.90-93 α-MSH affects 
various pathways regulating inflammatory responses such as NF-κB activation, expression 
of adhesion molecules and chemokine receptors, production of pro-inflammatory 
cytokines and other mediators. The anti-inflammatory effects of alpha-MSH have been 
confirmed in a variety of animal models of inflammation (e.g., vasculitis, fibrosis, uveitis, 
inflammatory bowel disease, rheumatoid arthritis, brain inflammation, etc.).92, 93 The 
peptide, however, has a short half-life in blood circulation due to renal clearance and 
 
Figure 5.9: Degradation of 5Tam-Aoc-GRTGRRFSY-amide (red) and CP-nb-Dipal (black) by 
chymotrypsin and trypsin in the presence of hemoglobin-free erythrocytes. (a)
Chymotrypsin (5 nM), (b) trypsin (1 nM), and (c) trypsin (5 nM). Corresponding peptide
concentration (1.25 µM) in 5% hematocrit.  
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proteolytic degradation.94 Prolylcarboxypeptidase (PRCP) was identified as an enzyme 
which removes α-MSH‘s C-terminal Val residue and inactivates the hormone.95 While 
stabilization of the hormone against peptidase degradation by cyclization and chemical 
modification has been extensively studied,96-98 the physiological consequences of such 
stabilization in vivo remain to be explored. Protection by membrane sequestration and 
release by light could be beneficial since the hormone could be controllably activated at 
a specific site. 
We synthesized 5Fam-labeled lipidated α-MSH, MSH-nb-Dipal (Figure 5.10a) via 
thiol-maleimide conjugation. LC-MS analysis demonstrated the formation of MSH-nb-
Dipal. Photolysis with UV light generated 5Fam-labelled α-MSH from the lipidated 
counterpart (Figure 5.10b). 
Stability of α-MSH and Fluorophore-Labelled α-MSH toward PRCP Enzyme 
  We performed a control experiment to confirm the degradation of α-MSH by PRCP 
enzyme. The recombinant human lysosomal Pro-X carboxypeptidase/PRCP was 
purchased from R&D systems. To our surprise, however, we were unable to confirm 
degradation of the nonlipidated fluorophore-label hormone 5Fam-α-MSH and native α-
MSH, Ac-SYSMEHFRWGKPV-amide (Abcam), by the commercial PRCP (Figure 5.11). One 
explanation for this observation could be due to the difference of enzymes produced from 
different sources. It is also interesting to note that, for the dipeptide N-Carbobenzyloxy-
Pro-Phe, the enzyme only recognizes it as a substrate if the peptide’s C-terminus is a COOH 
group.  The same sequence bearing a methyl ester or an amide group at the C-terminus 
was not hydrolyzed by the enzyme.99  
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Figure 5.10: Photolysis of MSH-nb-Dipal as assessed by LC-MS. Structure of MSH-nb-Dipal 
and its photolyzed product (a), LC-MS of MSH-nb-Dipal before (i) and after 5 min photolysis 
(ii). MSH-nb-Dipal (1 µM) in water (200 µL) was photolyzed using a Hg-Arc lamp with a 360
nm bandpass filter. 
a)
MSH-nb-Dipal
0
2
4
6
8
0 2 4 6 8
Fl
uo
re
sc
en
ce
Time / min
803.0
1,070.0
0
50
100
150
720 920 1120 1320
Re
la
tiv
e 
in
te
ns
ity
m/z
991.25
0
50
100
150
720 920 1120 1320
Re
la
tiv
e 
in
te
ns
ity
m/z
5Fam-α-MSH-amide
0
20
40
60
80
100
0 2 4 6 8
Fl
uo
re
sc
en
ce
Time / min
b) i
ii
 138
 
 
 
Figure 5.11: Stability of 5Fam-labelled and native α-MSH toward PRCP degradation as 
analyzed by LC-MS. (a) 5Fam-α-MSH control, (b) 5Fam-α-MSH after 30 min incubation with 
PRCP (20 nM, 37 oC), (c) Native α-MSH control, (d) 5Fam-α-MSH after 30 min  incubation 
with PRCP (20 nM, 37 oC). Left: fluorescence trace, right: mass spectrum of the peak on the
left trace. (a, b) monitored at (λex - λem) 490nm - 525 nm; (c, d) monitored at 280 nm - 315 
nm.  
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  We also investigated the stability of MSH-nb-Dipal, against proteolysis when it 
was associated with erythrocytes. To our surprise, however, significant degradation was 
observed with trypsin, chymotrypsin, and plasmin even in the presence of erythrocytes 
and no photolysis (Figure 5.12). The peptide C8-K(5Tam)-α-MSH-nb-Dipal (see Scheme 
5.5 page 151) was also synthesized in which a octanoyl group was appended the N-
terminus to further facilitate the peptide-membrane association. Examination with 
chymotrypsin, however, shows that significant degradation of the peptide was still 
detected even in the presence of erythrocytes and absence of UV light. It is interesting to 
note that the thickness of erythrocytes’ glycocalyx has been reported as about 5.9 nm.100 
The lipidated peptide was expected to be embedded within the glycocalyx and protected 
from proteolysis. These unexpected results are under further investigation. 
 
 
Figure 5.12: Degradation of MSH-nb-Dipal by (a) trypsin 5 nM, (b) chymotrypsin 5 nM, and 
(c) plasmin 40 nM in the presence of erythrocytes. Erythrocytes loaded with peptide MSH-
nb-Dipal were incubated with the enzyme or without the enzyme at 37 oC. At t = 1 h (a, 
b), 0.5 h (c) the suspensions were centrifuged and supernatant’s fluorescence measured.
Control: fluorescence of supernatant when all of membrane bound peptide was cleaved.
See Materials and Method for details. 
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Materials and Method 
Reagents were purchased as described before (Chapter 2, 3, 4). 
Hemoglobin-Free Erythrocyte Preparation 
  Peripheral human erythrocytes were washed with L-15 media upon receipt and 
stored in L-15 media containing FBS (10%) at 10% hematocrit. Hemoglobin-free 
erythrocyte ghosts were prepared fresh before all experiments. Briefly, the stored 
erythrocytes (1 mL) were washed with PBS 1X 3 times (1 mL PBS 1X, centrifuged at 2000 
g for 2 min), followed by washes (five times) with PBS 0.1X (1 mL PBS 0.1X, centrifuged at 
14,000 g for 2 min). The hemoglobin-free erythrocytes were then restored and kept in 
PBS 1X (1 mL) for 1 h, followed by three more washes with PBS 1X (1 mL PBS 1X, 
centrifuged at 10,000 g for 2 min) and suspended in PBS 1X (1 mL) for loading and further 
experiments. 
Loading Lipidated Peptides on Hemoglobin-Free Erythrocytes 
  Lipidated peptide stock solution was predissolved in ethanol (10 µL). To this 
solution was then added hemoglobin-free erythrocytes in PBS 1X (1 mL, 10% hematocrit). 
The final peptide concentration was 2.5 µM. The solution was gently shaken at room 
temperature (30 min), followed by centrifugation (10,000 g for 2 min). The pellet was 
resuspended in PBS 1X (1 mL) and transferred to a new tube. The suspension was washed 
two more times with PBS 1X (1 mL, 10,000 g/2 min) and resuspended in PBS 1X (1 mL) to 
make hemoglobin-free peptide-loaded erythrocytes (1 mL, 10% hematocrit). All 
supernatants were collected for fluorescence measurement if needed. 
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Stability of 5Tam-Aoc-GRTGRRFSY-amide in the Presence of Human Plasma and 
Erythrocytes 
  Human plasma (solid form from 1 mL, Sigma) was dissolved in PBS 1X (1 mL). 
Erythrocytes were washed with PBS 1X three times. 
  PBS 1X solution (400 µL) containing 5Tam-Aoc-GRTGRRFSY-amide (final 2.5 µM) 
was preincubated at 37 oC for 10 min, followed by the addition of washed erythrocytes 
(100 µL, 100% hematocrit) and human plasma (25 µL). The mixture was then incubated at 
37 oC. At various time points, aliquots (100 µL) were quenched with HCl (10 µL, 10 M). To 
the quenched solution MeOH (200 µL) and H2O (100 µL) was added, followed by 
ultrafiltration (14,000 g/30 min with 3K Amicon filters, Invitrogen) and the wash was 
repeated one more time with MeOH:H2O (50:50 v:v, 400 µL). Filtrates were collected, 
dried, dissolved in DMSO (200 µL), and analyzed by LC-MS using a C18 column. 
Degradation of 5Tam-Aoc-GRTGRRFSY-amide by Trypsin and Chymotrypsin 
  Hemoglobin-free erythrocytes suspension (500 µL, 10% hematocrit) was added to 
a PBS 1X solution (500 µL) containing 5Tam-Aoc-GRTGRRFSY-amide (2.5 µM). An aliquot 
(100 µL) was quenched with HCl (10 µL, 10 M). The remainder (900 µL) was preincubated 
at 37 oC for 5 min before adding enzyme (chymotrypsin or trypsin at specified 
concentrations) added. At various time points, aliquots (100 µL) were quenched with HCl 
(10 µL, 10 M). MeOH (1 mL) was added to all quenched samples, followed by 
centrifugation at 21000 g/10 min. Supernatants were collected, dried, dissolved in DMSO, 
and analyzed by LC-MS. 
Proteolytic Stability of CP-nb-Dipal in the Presence of Membrane 
  CP-nb-Dipal (0.417 µL, 3 mM) was dissolved in ethanol (5 µL). A suspension of 
hemoglobin-free erythrocytes (500 µL, 10% hematocrit in PBS 1X) was added to the 
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peptide solution. The suspension was then shaken at room temperature for 30 min, 
followed by centrifugation (10,000 g/2 min). The supernatant was discarded and the 
pellet was suspended in PBS 1X (500 µL) and transferred to a new vial. The loaded 
erythrocytes were then washed two more times with PBS 1X (500 µL, 10,000 g for 2 min 
centrifugation) before being suspended in PBS 1X (500 µL) to make lipidated-peptide-
loaded erythrocytes (corresponding to 2.5 µM peptide, 10% hematocrit). 
  PBS 1X (500 µL) was added to the loaded erythrocyte suspension (500 µL 10% 
hematocrit, 2.5 µM peptide). One aliquot (100 µL) was quenched with HCl (10 µL, 10 M), 
another aliquot (100 µL) was transfer to a new vial and incubated at 37 oC for 2 h then 
quenched with HCl 10 µL, 10 M). The remainder (800 µL) was preincubated at 37 oC for 5 
min before adding the enzyme (chymotrypsin or trypsin at specified concentrations). At 
various time points, aliquots (100 µL) were quenched with HCl (10 µL, 10 M). MeOH (1 
mL) was added to all quenched samples were added followed by centrifugation at 21000 
g for 10 min. Supernatants were collected, dried, dissolved in DMSO, and analyzed by LC-
MS. 
Study of α-MSH and 5Fam-labelled α-MSH with PRCP 
  Upon receipt, PRCP stock solution was diluted with cold enzyme dilution buffer 
(Tris.HCl 100 mM, pH 7.5 containing 10% glycerol by weight) to a concentration of 1 µM. 
Diluted enzyme was divided into PCR vials (10 µL each). Few aliquots were tested for 
activity, the remainder was stored in -80 oC for future experiments. 
PBS 1X buffer containing 5Fam-α-MSH or native α-MSH (1.25 µM) was preincubated at 37 
oC for 5 min. An aliquot was taken out as a control and PRCP (20 nM) was added to the 
remainder, followed by incubation at 37 oC for 30 min and analyzed by LC-MS. 
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Degradation was followed by mass and fluorescence (λex - λem = 490 nm - 525 nm for 5Fam-
peptide and 280 nm - 315 nm for native α-MSH). 
Study of MSH-nb-Dipal with Chymotrypsin in the Presence of Erythrocytes 
  Hemoglobin-free erythrocytes were loaded with MSH-nb-Dipal as described 
before (10% hematocrit, 2.5 µM peptide). This suspension was then diluted in PBS 1X to 
5% hematocrit and divided into three vials. One vial (1 mL) was incubated at 37 oC. 
Another vial was treated with chymotrypsin (5 nM), followed by incubation at 37 oC. At t 
= 1 h, aliquots (500 µL) were centrifuged (14,000 g for 10 min), followed by supernatant 
fluorescence assessment (200 µL) in a plate reader (λex - λem = 490 nm - 525 nm). The third 
vial (1 mL) was treated with chymotrypsin (50 nM), followed by incubation at 37 oC for 2 
h. The vial was then centrifuged (14,000 g for 10 min) and supernatant fluorescence was 
measured as control fluorescence (200 µL). 
Study of MSH-nb-Dipal with Trypsin in the Presence of Erythrocytes 
  Hemoglobin-free erythrocytes were loaded with MSH-nb-Dipal as described 
before (10% hematocrit, 2.5 µM peptide). This suspension was then diluted in PBS 1X to 
5% hematocrit and divided into three vials. One vial (1 mL) was incubated at 37 oC. 
Another vial was treated with trypsin (5 nM), followed by incubation at 37 oC. At t = 1 h, 
aliquots (500 µL) were centrifuged (14,000 g for 10 min), followed by supernatant 
fluorescence assessment (200 µL) in a plate reader (λex - λem = 490 nm - 525 nm). To the 
third vial was added chymotrypsin (50 nM) followed by incubation at 37 oC for 2 h. The 
vial was then centrifuged (14,000 g for 10 min) and supernatant fluorescence was 
measured as control fluorescence (200 µL). 
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Study of MSH-nb-Dipal with Plasmin in the Presence of Erythrocytes 
  Erythrocytes (1 mL, 10% hematocrit) were washed three times with PBS 1X, 
followed by resuspension in PBS 1X to 10 % hematocrit. This erythrocyte suspension (1 
mL) was then added to ethanol solution of MSH-nb-Dipal (10 µL, final concentration of 
peptide is 2.5 µM), followed by 30 min of gentle shaking at room temperature. The 
erythrocytes were then centrifuged at 2000 g for 2 min, resuspended in PBS 1X (1 mL) and 
transferred to a new vial, followed by two more wash cycles (1 mL PBS 1X, 2000g for 2 
min). Peptide-loaded erythrocytes were then resuspended to 5% hematocrit in PBS 1X 
and divided into two vials (1 mL each). One vial was incubated at 37 oC, plasmin (40 nM) 
was added to the other vial followed by incubation at 37 oC. At t = 30 min, these vials was 
centrifuged (2000 g for 10 min) and supernatants’ fluorescence measured in a plate 
reader (λex - λem = 490 nm - 525 nm).      
Confocal Microscopy Study of Hemoglobin-Free Erythrocytes Loaded with CP-nb-Dipal 
and HeLa Cells with and without Photolysis  
  HeLa cells were plated on 35 mm glass bottom dishes (MatTeck) the night before 
the experiment. Hemoglobin-free erythrocytes were prepared and loaded with CP-nb-
Dipal (2.5 µM peptide, 10% hematocrit). The loaded erythrocyte were diluted to 5% 
hematocrit with L-15 media (Invitrogen) and then added to dishes containing HeLa cells 
(100 µL). The dishes were then kept on ice without photolysis or photolyzed on ice for 30 
min using a Hg-Arc lamp with a 360 nm bandpass filter. HeLa cells were then washed with 
media, followed by incubation with Hoechst 33342 for 1-5 min. The HeLa cells were then 
washed 6 more times with media and imaged using confocal microscopy with filter 
settings corresponding to Hoechst 33342 and 5Tam fluorophores. 
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Syntheses 
Synthesis of CP-nb-Stear 
 
  Peptide CP-nb-Stear was synthesized on resin using NovaPEG amide resin. Aoc, 
Dap, G, R, T, F, S, and Y residues were coupled using double coupling [Fmoc-Dap(Mtt)-OH 
(chempep), Fmoc building blocks of G, R, T, F, S, and Y residues (3 eq.), HCTU (2.94 eq.), 
DIPEA (10 eq.), coupling for 40 min and then amino acid  (1.5 eq.), HCTU (1.47 eq.), DIPEA 
(7.5 eq.), coupling for 20 min]. Fmoc-nb-OH photolabile linker was coupled using Fmoc-
nb-OH (2.05 eq.), HCTU (2.0 eq.), and DIPEA (7.5 eq.) for 2 h. Before the coupling of Fmoc-
Aoc-OH, the peptide was capped with Ac2O (10 eq.), DIPEA (20 eq.) for 20 min. Fmoc 
deprotection was performed using piperidine (25% in DMF) for 20 min. Before the 
 
Scheme 5.1: Synthesis of CP-nb-Stear. 
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deprotetion of Fmoc group and coupling of 5Tam, the Mtt group was removed by 
TFA:TIS:CH2Cl2 (2:5:93 by v:v:v), the resin was washed with DMF (5 times), DMF with 
DIPEA 100 mM (2 times), then DMF, followed by the stearic acid coupling with stearic acid 
(5 eq.), HCTU (4.9 eq.) for 1 h, twice. 5Tam was coupled using 5Tam (1.7 eq.), HCTU (1.67 
eq.), DIPEA (5 eq.) overnight. The resin was washed by DMF and dried. The peptide was 
leaved by TFA 95%, precipitated by cold ether, dried and purified on a C4 column using 
H2O:CH3CN solvents with 0.1% TFA. CP-nb-Stear, C114H168N26O24, exact mass calculated 
2285.3, found (ESI+, m/z) 1143.1 (M+2H)2+, 762.3 (M+3H)3+, 572.1 (M+4H)4+. 
Synthesis of Dipal-Mal 
 
  1,2-Dipalmitoyl-sn-glycero-3-phosphoethanolamine (1.45 mmol, 1 eq.) was 
dissolved in CH2Cl2 and DMF. 3-Maleimido-propionic acid (1.2 eq.) and HCTU (1. 2 eq.) 
were dissolved in DMF in two separate glass vials. DIPEA (2 eq.) was added to the solution 
of 1,2-dipalmitoyl-sn-glycero-3-phosphoethanolamine immediately followed by the 
addition of the maleimide and HCTU solution. The reaction was shaken at room 
temperature for 30 min followed by addition of HCl (10 M) to pH 4. The reaction mixture 
was then extracted with EtOAc three times. The organic extract was dried and purified by 
 
Scheme 5.2: Synthesis of Dipal-Mal. 
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silica column using CH2Cl2:MeOH (MeOH with 0.5% CH3COOH) as solvents, gradient from 
0% to 50% MeOH. Dipal-Mal: 1H NMR (400 MHz, CDCl3) δ 7.53 (s, 1 H), 6.72 (s, 2 H), 5.19 
(s, 1 H), 4.37 (d, J = 9.5 Hz, 1 H), 4.15-4.11 (m, 1 H), 3.91-3.79 (m, 6 H), 3.41 (bd, 2 H), 2.54 
(t, J = 7 Hz, 2 H), 2.30-2.25 (m, 4 H), 2.01 (s, 4 H), 1.25 (s, 48 H), 0.88 (t, J = 6.8 Hz, 6 H). 
Molecular formula C44H78N2O11P-. 
Synthesis of CP-nb-Dipal 
 
Synthesis of CP-nb-Cys 
  Peptide CP-nb-Cys was synthesized on TGR resin. Briefly, all natural amino acids 
was coupled using double coupling with Fmoc-amino acid (5 eq.), HCTU (4.9 eq.), and 
DIPEA (10 eq.) for 20 and 30 min. Photolabile linker was coupled using Fmoc-nb-OH (3.2 
eq.), HCTU (3.0 eq.), and DIPEA (6.5 eq.) for 59 min, then Fmoc-nb-OH (1.8 eq.), HCTU (1.5 
eq.), and DIPEA (4.5 eq.) for 30 min. Aoc was coupled using Fmoc-Aoc-OH (5 eq.), HCTU 
(4.9 eq.), and DIPEA 10 (eq.) for 59 min. 5Tam was coupled using 5Tam (1.2 eq.), HCTU 
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(1.2 eq.), DIPEA (5 eq.) overnight. Fmoc deprotection was performed using piperidine 
(25% in DMF) for 20 min. After the coupling of 5Tam, the resin was washed by DMF and 
dried. The peptide was cleaved by TFA 95%, precipitated by cold ether, dried and purified 
on a C18 column using H2O:CH3CN solvents with 0.1% TFA. 5Tam-Aoc-RTGRRFSY-nb-Cys-
amide, C96H133N25O23S, exact mass calculated 2036.0 (M), found (ESI+, m/z) 1018.2 
(M+2H)2+, 679.2 (M+3H)3+, 509.7 (M+4H)4+. 
Synthesis of CP-nb-Dipal 
  CP-nb-Cys peptide (3.57 µmol) was dissolved in a minimum amount of MeOH. 
Dipal-Mal (6.17 µmol) was dissolved in CHCl3. The two solutions were then mixed, bubbled 
with argon for 10 sec, sealed and shaken overnight. The reaction was then dried with air 
flow and vacuum and purified by the C4 column using H2O:MeOH (each with 0.1 % TFA) 
as solvents. CP-nb-Dipal, C140H211N27O34PS-, exact mass calculated 2877.5 (M)1-, found 
(ESI+, m/z) 1440.1 (M+3H)2+, 906.3 (M+4H)3+, 720.5 (M+5H)4+. 
Synthesis of MSH-nb-Dipal 
Synthesis of 5Fam- α-MSH-nb-Cys-amide 
  Peptide 5Fam-α-MSH-nb-Cys-amide was synthesized on TGR resin. Briefly, all 
natural amino acids were coupled using double coupling with Fmoc-amino acid (5 eq.), 
HCTU (4.9 eq.), and DIPEA (10 eq.) for 20 and 30 min. Photolabile linker was coupled using 
Fmoc-nb-OH (3.2 eq.), HCTU (3.0 eq.), and DIPEA (6.5 eq.) for 59 min, then Fmoc-nb-OH 
(1.8 eq.), HCTU (1.5 eq.), and DIPEA (4.5 eq.) for 30 min. 5Fam (1.5 eq.) was preactivated 
with HOBt (20 eq.) and DIC (1.7 eq.) for 10 min before being added to the resin. After the 
5Fam coupling reaction was kept at room temperature for 2 h, the resin was washed with 
piperidine (25% in DMF) until no fluorescence was detected in DMF. The resin was dried 
and cleaved by TFA 95%, precipitated by cold ether, dried and purified on a C18 column 
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using H2O:CH3CN solvents with 0.1% TFA. 5Fam-α-MSH-nb-Cys-amide, C112H138N24O30S2, 
exact mass calculated 2363.0 (M), found (ESI+, m/z) 789.0 (M+3H)3+, 592.0 (M+4H)4+. 
Synthesis of MSH-nb-Dipal 
  5Fam-α-MSH-nb-Cys-amide (1 eq.) was dissolved in a minimum amount of MeOH. 
Dipal-Mal (2 eq.) was dissolved in CHCl3. The two solutions were then mixed, bubbled 
with Ar for 10 sec, sealed, and shaken overnight. The reaction was then dried with air flow 
and vacuum and purified on a C4 column using H2O:MeOH as solvents (each with 0.1 % 
TFA). MSH-nb-Dipal, C156H216N26O41PS2-, exact mass calculated 3204.5 (M)1-, found (ESI+, 
m/z) 1070.4 (M+4H)3+, 802.9 (M+5H)4+. 
Synthesis of 5Fam-SYSMEHFRWGKPV-amide (5Fam-α-MSH-amide) 
  A solution of 5Fam-α-MSH-nb-Cys-amide in H2O was irradiated with UV light (from 
a Hg-Arc lamp using a 360 nm bandpass filter) for 30 min. The solution was then dried and 
 
Scheme 5.4: Synthesis of MSH-nb-Dipal. 
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purified by HPLC using a C18 column. 5Fam-α-MSH-amide, C96H117N21O24S, exact mass 
calculated (M) 1979.8, found (ESI+, m/z) 990.9 (M+2H)2+, 661.2 (M+3H)3+, 496.2 (M+4H)4+. 
Synthesis of C8-K(5Tam)-α-MSH-nb-Dipal 
 
Synthesis of C8-K(5Tam)-α-MSH-nb-Cys-amide 
  Octanoyl-K(ivDde)SYSMEHFRWGKPV-nb-Cys-Resin was synthesized on TGR 
resin. Photolabile linker was coupled using Fmoc-nb-COOH (3.2 eq.), HCTU (3.0 eq.), and 
DIPEA (6.5 eq.) for 59 min, then Fmoc-nb-COOH (1.8 eq.), HCTU (1.5 eq.), and DIPEA (4.5 
Scheme 5.5: Synthesis of C8-K(5Tam)-α-MSH-nb-Dipal. 
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eq.) for 30 min. Octanoic acid (10 eq.) was coupled using HCTU (9.5 eq.), and DIPEA (20 
eq.) for 1 h. All other amino acids were coupled using double coupling with Fmoc-amino 
acid (5 eq.), HCTU (4.9 eq.), and DIPEA (10 eq.) for 20 and 30 min. The ivDde protecting 
group was removed by hydrazine (2% in DMF, 5 min, 5 times) and 5Tam was coupled using 
5Tam (1.2 eq.), HCTU (1.2 eq.), DIPEA (5 eq.) overnight. The resin was then dried and 
cleaved by TFA 95%, precipitated by cold ether, dried and purified on a C18 column using 
H2O:CH3CN solvents with 0.1% TFA. C8-K(5Tam)-α-MSH-nb-Cys-amide, C130H175N28O30S2, 
exact mass calculated 2672.3 (M), found (ESI+, m/z) 891.6 (M+3H)3+, 669.1 (M+4H)4+. 
Synthesis of C8-K(5Tam)-α-MSH-nb-Dipal  
  C8-K(5Tam)-α-MSH-nb-Cys-amide (1 eq.) was dissolved in MeOH. Dipal-Mal (2 
eq.) was dissolved in CHCl3. The two solutions were mixed, bubbled with Ar for 10 sec, 
sealed, and shaken overnight. The reaction was then dried with air flow and vacuum and 
purified by the C4 column using H2O:MeOH as solvents (each with 0.1 % TFA). C8-K(5Tam)-
α-MSH-nb-Dipal, C174H253N30O41PS2, exact mass calculated 3513.8 (M), found (ESI+, m/z) 
1172.8 (M+3H)3+, 880.2 (M+4H)4+. 
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SUMMARY 
In this dissertation we describe: 
1. The development of the wavelength-tunable fluorescent reporters for monitoring 
protein kinase A activity. The developed sensors are powerful tools to investigate the roles 
of protein kinase A activity in erythrocyte biochemistry, for example, in Plasmodium 
Falciparum infection and propagation. 
2. The design of light-activatable bioagents based on lipidation and membrane 
sequestration. The strategy provides a way to control the presence of a bioagents 
following a single photolytic event. 
3. The further investigation of the membrane sequestration as a way to deliver 
peptide therapeutics into a specific region of the body. We propose to use erythrocytes 
as carriers and protectors of photoactivatable peptide therapeutics. The delivery of a cell 
permeable peptide, an anti-inflammatory agent, and a blood clotting agent are being 
investigated. The study will provide a powerful strategy toward the treatment of various 
diseases such as rheumatoid arthritis and cancer. 
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